Compositions and methods for enriching methylated polynucleotides
Patent Information
- Application Number
- JP2023532507
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-30
- Filing Date
- 2021-11-30
- Publication Date
- 2024-11-21
- Estimated Expiration
- 2041-11-30
AI Technical Summary
Current methods for analyzing cell-free DNA in liquid biopsies, particularly for cancer detection, are inadequate due to low concentration and heterogeneity, making it difficult to accurately detect nucleobase modifications.
A method involving differential treatment of nucleobases in DNA samples to enhance the detection of cytosine modifications, such as methylation, by partitioning the DNA into subsamples based on methylation levels and sequencing these subsamples to distinguish between different nucleobase modifications, including 5-methylcytosine and 5-hydroxymethylcytosine, using agents like antibodies and enzymes to enrich specific methylation patterns.
This approach provides higher resolution and accuracy in detecting epigenetic modifications, enabling more sensitive and detailed analysis of cell-free DNA for cancer detection, particularly in early stages.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical Field]
[0001] Cross-references to related applications This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 119,520, filed November 30, 2020, which is incorporated herein by reference in its entirety for all purposes.
[0002] Field of Invention This disclosure provides compositions and methods relating to the analysis of DNA, for example, cell-free DNA. In some embodiments, the cell-free DNA is derived from a subject having or suspected of having cancer, and / or the cell-free DNA includes DNA derived from cancer cells. In some embodiments, the DNA is subjected to a procedure that affects a first nucleobase in the DNA so as to be different from a second nucleobase in the DNA, the DNA is partitioned into a first partial sample and a second partial sample, the first partial sample containing DNA having a higher proportion of nucleobase modifications (e.g., cytosine modifications) than the second partial sample, and the DNA is sequenced in a manner that distinguishes the first nucleobase from the second nucleobase. [Background technology]
[0003] Introduction and Overview Cancer is the cause of millions of deaths worldwide every year. Early detection of cancer can lead to improved outcomes, as early-stage cancers tend to be more responsive to treatment.
[0004] Improperly controlled cell growth is a prominent feature of cancer, generally arising from genetic and epigenetic changes, such as the accumulation of epigenetic variations including copy number variations (CNVs), single nucleotide variations (SNVs), gene fusions, insertions and / or deletions (indels), cytosine alterations (e.g., 5-methylcytosine, 5-hydroxymethylcytosine, and other more oxidized forms), as well as the association of DNA with chromatin proteins and transcription factors.
[0005] Biopsy is a conventional approach to detecting or diagnosing cancer, in which cells or tissue are extracted from a potentially cancerous site and analyzed for associated phenotypic and / or genotypic features. A drawback of biopsy is that it is invasive.
[0006] Cancer detection based on the analysis of bodily fluids such as blood ("liquid biopsy") is an interesting alternative method based on the observation that DNA derived from cancer cells is released into bodily fluids. Liquid biopsy is non-invasive (sometimes requiring only blood collection). However, given the low concentration and heterogeneity of cell-free DNA, developing accurate and highly sensitive methods for analyzing liquid biopsy material that provide detailed information about nucleo-based modifications has been challenging. Isolating and processing fractions of cell-free DNA useful for further analysis in the liquid biopsy procedure is a crucial part of these methods. Therefore, improved methods and compositions for analyzing cell-free DNA in liquid biopsies, for example, are needed.
[0007] While we do not wish to be bound by any particular theory, cells in or around cancer or neoplasms may shed more DNA than cells of the same tissue type in healthy subjects. Therefore, the distribution of tissues from which a particular DNA sample originates, such as cell-free DNA (cfDNA), may change during cancer development. Thus, for example, an increase in the level of hypermethylated variable target regions, which show lower methylation in healthy cfDNA than in at least one other tissue type, may be an indicator of the presence of cancer (or, depending on the subject's medical history, recurrence). Similarly, an increase in the level of hypomethylated variable target regions in a sample may be an indicator of the presence of cancer (or, depending on the subject's medical history, recurrence).
[0008] Furthermore, cancer can be indicated by non-array modifications, such as methylation. Examples of methylation changes in cancer include the local gain of DNA methylation in CpG islands at the TSS of genes involved in normal growth control, DNA repair, cell cycle regulation, and / or cell differentiation. This hypermethylation can be associated with abnormal loss of transcriptional ability of the genes involved, and occurs at least as frequently as point mutations and deletions as a cause of altered gene expression.
[0009] Therefore, DNA methylation profiling can be used to detect abnormal methylation in the DNA of a sample. DNA can be, for example, methylated at a particular genomic region (a "differentially methylated region", or "DMR") that is normally hypermethylated or hypomethylated in a given sample type (e.g., cfDNA derived from the bloodstream), but shows an abnormal degree of methylation that correlates with a neoplasm or cancer, due to, for example, an increased contribution of tissue abnormalities to the sample type (e.g., due to increased shedding of DNA in or around a neoplasm or cancer), and / or is altered during development, or is disrupted by a disease, such as cancer or any cancer-related disease. SUMMARY OF THE INVENTION MEANS FOR SOLVING THE PROBLEM
[0010] In some embodiments, DNA methylation involves the addition of a methyl group to a cytosine residue at a CpG site (cytosine-phosphate-guanine site, i.e., cytosine followed by guanine in the 5’→3’ direction of the nucleic acid sequence). In some embodiments, DNA methylation involves, for example, the addition of a methyl group to an adenine residue at N6-methyladenine. In some embodiments, DNA methylation is 5-methylation (modification of the 5th carbon of the 6-carbon ring of cytosine). In some embodiments, 5-methylation involves the addition of a methyl group to the 5C position of a cytosine residue that creates 5-methylcytosine (m5c or 5-mC or 5mC). In some embodiments, methylation includes derivatives of m5c. Examples of derivatives of m5c include, but are not limited to, 5-hydroxymethylcytosine (5-hmC or 5hmC), 5-formylcytosine (5-fC), and 5-carboxylcytosine (5-caryboxylcytosine) (5-caC). In some embodiments, DNA methylation is 3C-methylation (modification of the 3rd carbon of the 6-carbon ring of a cytosine residue). In some embodiments, 3C-methylation involves the addition of a methyl group to the 3C position of a cytosine residue that generates 3-methylcytosine (3mC). Methylation can also occur at non-CpG sites; for example, methylation can occur at CpA, CpT, or CpC sites. DNA methylation can alter the activity of the methylated DNA region. For example, if the DNA in a promoter region is methylated, gene transcription can be suppressed. DNA methylation is important for normal development, and abnormalities in methylation can disrupt epigenetic regulation. Disruptions in epigenetic regulation, such as suppression, can cause diseases such as cancer. Promoter methylation in DNA can indicate cancer.
[0011] This disclosure is based in part on the following understanding: Other processing steps, e.g., distribution based on the degree of methylation, and analysis of nucleobase modifications (including, among other things, cytosine methylation and / or hydroxymethylation) according to sequencing may be beneficial. For example, in an exemplary embodiment, a DNA sample (e.g., a cfDNA sample) is subjected to a procedure that differentially affects a given nucleobase in different forms (e.g., unmodified cytosine and methylated cytosine, or hydroxymethylated cytosine and methylated cytosine), and is then distributed into a plurality of subsamples having different amounts of cytosine methylation (e.g., based on binding to an antibody specific to methylcytosine). Sequencing may then be performed to identify sequences in the plurality of subsamples and / or to identify the location in DNA from a particular subsample where a particular species of nucleobase was present. Such methods in accordance with this disclosure can provide more information about epigenetic modifications in DNA, such as cfDNA, than existing approaches, such as MeDIP-seq, MBD-seq, BS-seq, Ox-BS-seq, TAP-seq, ACE-seq, hmC-seal, and TAB-seq.For example, Schutsky, EK et al. Nondestructive, base-resolution sequencing of 5-hydroxymethylcytosine using a DNA deaminase. Nature Biotech, 2018; doi.10.1038 / nbt.4204 (ACE-Seq);Yu, Miao et al. Base-resolution analysis of 5-hydroxymethylcytosine in the Mammalian Genome. Cell, 2012; 149(6):1368-80 (TAB-Seq);Han, D. A highly sensitive and robust method for genome-wide 5hmC profiling of rare cell populations. Mol Cell. 2016; 63(4):711-719 (5hmC-Seal);Shen, SY et al. Sensitive tumor detection and classification using plasma cell-free DNA methylomes. Nature. 2018; See 563(7732):579-583 (cfMeDIP); Nair, SS et al. Comparison of methyl-DNA immunoprecipitation (MeDIP) and methyl-CpG binding domain (MBD) protein capture for genome-wide DNA. Epigenetics. 2011; 6(1):34-44. Unlike such existing methods, methods according to the present disclosure can provide a combination of information about a first modification, e.g., methylation level, by a distributing step, and additional information about a specific modification and / or its location, by a procedure that differentially affects a given nucleobase in different forms.Examples of such procedures include procedures that differentially affect different nucleobases, comprising various conversion or separation steps using bisulfites, substituted boranes, base-modifying enzymes, or modified base-specific antibodies that distinguish between different species of nucleobase classes. In some embodiments, the methods described herein provide a combination of information about (i) the overall level of molecular modification (e.g., cytosine modification) (e.g., based on its distribution), and (ii) higher-resolution information about the identity and / or location of a particular modification (e.g., based on specific conversions of a particular modified or unmodified nucleobase, or further distributions that distinguish between specific types of modifications, and subsequent sequencing, as discussed in detail herein). The methods of the present invention can also facilitate the identification of misdistributed molecules, for example, when a low-methylated molecule is present in a high-methylated distribution due to incomplete sorting of DNA molecules between partial samples. For example, when DNA is subjected to bisulfite conversion, the presence of unconverted CpG dinucleotides in the sequence data from the molecule indicates methylation, regardless of whether it was incompletely sorted.
[0012] The method of the present invention may further include the step of capturing two sets of target regions from DNA. In some embodiments, these sets of target regions include a sequence-variable target region set and an epigenetic target region set. Each of these sets can provide useful information in determining the likelihood that a sample contains DNA derived from cancer cells. In some embodiments, the capture yield of the sequence-variable target region set is higher than the capture yield of the epigenetic target region set. The difference in capture yield can allow for deeper, and therefore more accurate, sequencing of the sequence-variable target region set and shallower, broader coverage of the epigenetic target region set, for example, during parallel sequencing in the same sequencing cell or in the same pool of material being sequenced.
[0013] Epigenetic target region sets can be analyzed in various ways. For example, if the acceptable level of confidence regarding modifications at a particular location is lower than the acceptable level of confidence regarding precision in the sequence-variable target region set (e.g., the objective is to understand the frequency of different types of modifications at various loci, and not necessarily to understand the exact location of the modifications), the analysis may use methods that do not rely on a high degree of precision in sequencing specific nucleotides within the target. Examples include determining modifications, e.g., the degree of methylation, and / or the distribution and size of fragments from which the fragments may exhibit normal or abnormal chromatin structure in cells from which they are derived. Such analyses can be performed by sequencing and require less data (e.g., the number of sequence reads or the depth of sequencing coverage) than determining the presence or absence of sequence mutations, e.g., base substitutions, insertions, or deletions.
[0014] This disclosure aims to satisfy the need for improved analysis of cell-free DNA and / or to provide other benefits. Accordingly, the following exemplary embodiments are provided.
[0015] Embodiment 1 is a method for analyzing DNA in a sample, a) A step of subjecting the sample to a procedure that affects the first nucleobase in the DNA of the sample in such a way that it is different from the second nucleobase in the DNA of the sample, wherein the first nucleobase is a modified or unmodified nucleobase, the second nucleobase is a modified or unmodified nucleobase different from the first nucleobase, and the first nucleobase and the second nucleobase have the same base pairing specificity; b) A step of distributing the sample into a plurality of partial samples by contacting the DNA with an agent that recognizes a modified nucleobase in the DNA, wherein the plurality includes a first partial sample and a second partial sample, the first partial sample contains DNA having a higher proportion of cytosine modification than the second partial sample, and the modified nucleobase recognized by the agent is a product of the procedure that affects the first nucleobase in the DNA in a way that is different from the modified cytosine or the second nucleobase in the DNA of the sample; and c) A step of sequencing DNA in at least one of the first and second partial samples in a manner that distinguishes the first nucleobase from the second nucleobase. This method includes [something].
[0016] Embodiment 2 is the method of Embodiment 1, wherein step c) includes a step of sequencing at least the DNA in the first partial sample.
[0017] Embodiment 3 is a method according to any one of the prior embodiments, wherein step c) includes the step of sequencing the DNA in the second partial sample.
[0018] Embodiment 4 is a method for analyzing DNA in a sample, a) A step of subjecting the sample to a procedure that affects the first nucleobase in the DNA of the sample in such a way that it differs from the second nucleobase in the DNA of the sample, wherein the first nucleobase is a modified or unmodified nucleobase, the second nucleobase is a modified or unmodified nucleobase different from the first nucleobase, and the first nucleobase and the second nucleobase have the same base pairing specificity; and b) A step of distributing the sample into a plurality of partial samples by contacting the DNA with an agent that recognizes a modified nucleobase in the DNA, wherein the plurality includes a first partial sample and a second partial sample, the first partial sample contains DNA having a higher proportion of cytosine modification than the second partial sample, and the modified nucleobase recognized by the agent is a product of the procedure that affects the first nucleobase in the DNA in a way that is different from the modified cytosine or the second nucleobase in the DNA of the sample; c) A step of capturing at least a set of epigenetic target regions of DNA from the first and second partial samples, thereby providing the captured DNA; and d) A step of sequencing the captured DNA in a manner that distinguishes the first nucleobase from the second nucleobase. This method includes [something].
[0019] Embodiment 5 is a method for analyzing DNA in a sample, a) A step of subjecting the sample to a procedure that affects the first nucleobase in the DNA of the sample in such a way that it differs from the second nucleobase in the DNA of the sample, wherein the first nucleobase is a modified or unmodified nucleobase, the second nucleobase is a modified or unmodified nucleobase different from the first nucleobase, and the first nucleobase and the second nucleobase have the same base pairing specificity; and b) A step of distributing the sample into a plurality of partial samples by contacting the DNA with an agent that recognizes a modified nucleobase in the DNA, wherein the plurality includes a first partial sample and a second partial sample, the first partial sample contains DNA having a higher proportion of cytosine modification than the second partial sample, and the modified nucleobase recognized by the agent is a product of the procedure that affects the first nucleobase in the DNA in a way that is different from the modified cytosine or the second nucleobase in the DNA of the sample; c) A step of capturing a plurality of sets of target regions of DNA from the first and second partial samples, wherein the plurality of sets of target regions include a sequence variable target region set and an epigenetic target region set, thereby providing captured DNA; and d) A step of sequencing the captured DNA in a manner that distinguishes the first nucleobase from the second nucleobase. This method includes [something].
[0020] Embodiment 6 is the method of Embodiment 5, wherein cell-free DNA (cfDNA) molecules corresponding to the sequence variable target region set are captured in the sample with a higher capture yield than cfDNA molecules corresponding to the epigenetic target region set.
[0021] Embodiment 7 is a step in which capturing the plurality of sets of target regions is a step in which the DNA of the first and second partial samples is brought into contact with a set of target-specific probes, The above set of target-specific probes includes target-binding probes specific to sequence-variable target sets and target-binding probes specific to epigenetic target sets. This results in the formation of a complex between the target-specific probe and cfDNA; and The above complex is separated from cfDNA that is not bound to the target-specific probe, thereby providing captured cfDNA corresponding to the sequence variable target set and captured cfDNA corresponding to the epigenetic target set. This is a method according to embodiment 5 or 6, which includes the following:
[0022] Embodiment 8 is the method according to any one of Embodiments 4 to 7, wherein the epigenetic target region set includes a highly methylated variable target region set.
[0023] Embodiment 9 is the method of the immediately preceding embodiment, wherein the set of highly methylated variable target regions includes regions having a higher degree of methylation in at least one type of tissue than the degree of methylation in cell-free DNA derived from a healthy subject.
[0024] Embodiment 10 is the method according to any one of Embodiments 4 to 9, wherein the epigenetic target region set includes a low-methylation variable target region set.
[0025] Embodiment 11 is the method of the immediately preceding embodiment, wherein the set of low-methylation variable target regions includes regions having a lower degree of methylation in at least one type of tissue than the degree of methylation in cell-free DNA derived from a healthy subject.
[0026] Embodiment 12 is a method according to any one of Embodiments 4 to 11, wherein the epigenetic target region set includes a methylation control target region set.
[0027] Embodiment 13 is a method according to any one of Embodiments 4 to 12, wherein the epigenetic target region set includes a fragmentation variable target region set.
[0028] Embodiment 14 is the method according to Embodiment 13, wherein the fragmentation variable target region set includes a transcription start site region.
[0029] Embodiment 15 is the method according to Embodiment 13 or 14, wherein the fragmentation variable target region set includes a CTCF binding region.
[0030] Embodiment 16 is a method according to one of the prior embodiments, wherein the DNA is obtained from the test subject.
[0031] Embodiment 17 is a method according to any one of the prior embodiments, wherein the DNA includes cell-free DNA (cfDNA) obtained from the test subject.
[0032] Embodiment 18 is a method according to any one of Embodiments 1 to 16, wherein the DNA includes DNA obtained from a tissue sample under test.
[0033] Embodiment 19 is the method of the immediately preceding embodiment, wherein the tissue sample is a biopsy, microneedle aspiration, or formalin-fixed paraffin-embedded tissue sample.
[0034] Embodiment 20 is a method of Embodiments 5 to 18, further comprising the step of ligating the barcode-containing adapter to the DNA before capture, wherein the ligation step is performed before or simultaneously with amplification, if necessary.
[0035] Embodiment 21 is a method according to any one of the preceding embodiments, wherein the DNA molecule derived from the first partial sample and the DNA molecule derived from the second partial sample are differentially tagged.
[0036] Embodiment 22 is a method according to any one of the preceding embodiments, wherein the DNA molecule derived from the first partial sample and the DNA molecule derived from the second partial sample are sequenced in the same sequencing cell.
[0037] Embodiment 23 is a method according to any one of the preceding embodiments, wherein the DNA is amplified before the sequencing step, or the method includes a capture step, wherein the DNA is amplified before the capture step.
[0038] Embodiment 24 is a method according to any one of the prior embodiments, wherein the step of distributing the sample into a plurality of partial samples includes a step of distributing based on methylation levels.
[0039] Embodiment 25 is the method of Embodiment 24, wherein the agent that recognizes the modified nucleobase in the DNA is a methyl-binding reagent.
[0040] Embodiment 26 is the method of Embodiment 25, wherein the methyl-binding reagent is an antibody.
[0041] Embodiment 27 is the method according to Embodiment 25 or 26, wherein the methyl-binding reagent specifically recognizes 5-methylcytosine.
[0042] Embodiment 28 is a method according to any one of Embodiments 25 to 27, wherein the methyl-binding reagent is immobilized on a solid support.
[0043] Embodiment 29 is a method according to any one of Embodiments 24 to 28, wherein the step of distributing the above sample into a plurality of partial samples includes immunoprecipitation of methylated DNA.
[0044] Embodiment 30 is a method according to any one of the preceding embodiments, wherein the step of distributing the sample into a plurality of partial samples includes a step of distributing based on binding to a protein, wherein the protein is optionally a methylated protein, an acetylated protein, an unmethylated protein, or an unacetylated protein; and / or optionally the protein is a histone.
[0045] Embodiment 31 is the method of Embodiment 30, wherein the dispensing step includes contacting the DNA of the sample with a binding reagent that is specific to the protein and immobilized on a solid support.
[0046] Embodiment 32 is a method according to any one of the prior embodiments, which includes the step of differentially tagging and pooling the first and second partial samples.
[0047] Embodiment 33 is a method according to any one of the prior embodiments, wherein the plurality of partial samples include a third partial sample containing DNA having cytosine modifications in a higher proportion than the second partial sample but in a lower proportion than the first partial sample.
[0048] Embodiment 34 is the method of Embodiment 33, further comprising the step of differentially tagging the third partial sample.
[0049] Embodiment 35 is the method of Embodiment 34, wherein the first, second, and third partial samples are combined after the first partial sample is subjected to the procedure which affects the first nucleobase in the DNA of the first partial sample in a way that is different from the second nucleobase in the DNA of the first partial sample, and optionally the first, second, and third partial samples are sequenced in the same sequencing cell.
[0050] Embodiment 36 is a method according to any one of the prior embodiments, wherein the procedure to which the sample is provided modifies the base pairing specificity of the first nucleo-base without substantially altering the base pairing specificity of the second nucleo-base.
[0051] Embodiment 37 is a method according to any one of the prior embodiments, wherein the first nucleobase is a modified or unmodified cytosine, and the second nucleobase is a modified or unmodified cytosine.
[0052] Embodiment 38 is a method according to any one of the prior embodiments, wherein the first nucleobase comprises unmodified cytosine (C).
[0053] Embodiment 39 is the method according to any one of the prior embodiments, wherein the second nucleobase comprises 5-methylcytosine (mC).
[0054] Embodiment 40 is a method according to any one of the prior embodiments, wherein the procedure to which the sample is provided includes bisulfite conversion.
[0055] Embodiment 41 is the method according to any one of Embodiments 1 to 38, wherein the first nucleobase comprises mC.
[0056] Embodiment 42 is the method according to any one of the prior embodiments, wherein the second nucleobase comprises 5-hydroxymethylcytosine (hmC).
[0057] Embodiment 43 is the method of Embodiment 42, wherein the procedure for providing the sample includes protection at 5hmC.
[0058] Embodiment 44 is the method of Embodiment 42, wherein the procedure for providing the sample includes Tet-assisted bisulfite conversion.
[0059] Embodiment 45 is the method of Embodiment 42, wherein the procedure to which the sample is provided includes a Tet-assisted conversion using a substituted borane reducing agent, wherein the substituted borane reducing agent is optionally 2-picoline borane, borampyridine, tert-butylamine borane, or ammonia borane.
[0060] Embodiment 46 is the method according to Embodiment 45, wherein the substituted borane reducing agent is 2-picolineborane or borampyridine.
[0061] Embodiment 47 is the method according to any one of Embodiments 41 to 43 or 45 to 46, wherein the second nucleobase described above includes C.
[0062] Embodiment 48 is the method according to any one of Embodiments 41 to 43 or 47, wherein the procedure to which the sample is provided comprises protection of hmC and subsequent Tet-assisted conversion using a substituted borane reducing agent, wherein the substituted borane reducing agent is optionally 2-picoline borane, borampyridine, tert-butylamine borane, or ammonia borane.
[0063] Embodiment 49 is the method of Embodiment 48, wherein the substituted borane reducing agent is 2-picolineborane or borampyridine.
[0064] Embodiment 50 is the method according to any one of Embodiments 38, 39, 41 to 43 or 47, wherein the procedure to which the sample is provided includes protection of hmC and subsequent deamination of mC and / or C.
[0065] Embodiment 51 is the method according to Embodiment 50, wherein the deamination of mC and / or C includes treatment with a DNA deaminase enzyme of the AID / APOBEC family.
[0066] Embodiment 52 is a method according to any one of Embodiments 43 or 47 to 51, wherein the protection of hmC includes glucosylation of hmC.
[0067] Embodiment 53 is the method according to any one of Embodiments 1 to 37, 39, 41, or 47, wherein the procedure to which the sample is provided includes a chemical-assisted conversion using a substituted borane reducing agent, wherein the substituted borane reducing agent is optionally 2-picoline borane, borampyridine, tert-butylamine borane, or ammonia borane.
[0068] Embodiment 54 is the method according to Embodiment 53, wherein the substituted borane reducing agent is 2-picolineborane or borampyridine.
[0069] Embodiment 55 is the method according to any one of Embodiments 1 to 37, 39, 41, 47 or 53 to 54, wherein the first nucleobase contains hmC.
[0070] Embodiment 56 is the method according to any one of Embodiments 1 to 36, wherein the first nucleobase is a modified or unmodified adenine, and the second nucleobase is a modified or unmodified adenine.
[0071] Embodiment 57 is the method according to any one of Embodiments 1 to 36, wherein the first nucleobase is a modified or unmodified guanine, and the second nucleobase is a modified or unmodified guanine.
[0072] Embodiment 58 is the method according to any one of Embodiments 1 to 36, wherein the first nucleobase is modified or unmodified thymine, and the second nucleobase is modified or unmodified thymine.
[0073] Embodiment 59 is a method according to any one of the prior embodiments, wherein the modified nucleobase recognized by the above-mentioned agent is a modified cytosine.
[0074] Embodiment 60 is a method according to any one of the prior embodiments, wherein the modified nucleobase recognized by the above-mentioned agent is methylated cytosine.
[0075] Embodiment 61 is a method according to any one of the prior embodiments, wherein the modified nucleobase recognized by the above-mentioned agent is the converted nucleobase.
[0076] Embodiment 61.01 is a method according to any one of the prior embodiments, further comprising the step of distributing at least one subsample into a plurality of further subsamples.
[0077] Embodiment 61.02 is the method of Embodiment 61.01, wherein the first partial sample is distributed into a plurality of further partial samples.
[0078] Embodiment 61.03 is the method according to Embodiment 61.01 or 61.02, wherein the second partial sample is distributed into a plurality of further partial samples.
[0079] Embodiment 61.04 is the method according to any one of Embodiments 61.01 to 61.03, wherein the sample comprises DNA containing uracil, DNA containing mC, and DNA containing one or more of cytosine 5-methylene sulfonate (CMS), hmC, or 5-glucosylhydroxymethylcytosine (ghmC).
[0080] Embodiment 61.05 is the method of Embodiment 61.04, wherein the sample contains DNA including CMS.
[0081] Embodiment 61.06 is the method according to Embodiment 61.04, wherein the sample contains DNA containing hmC.
[0082] Embodiment 61.07 is the method according to Embodiment 61.04, wherein the sample contains DNA containing ghmC.
[0083] Embodiment 61.08 is the method according to any one of Embodiments 61.01 to 61.07, wherein the step of distributing at least one partial sample into a plurality of further partial samples includes the step of contacting the at least one partial sample with a further agent that recognizes ghmC, hmC, or mC.
[0084] Embodiment 61.09 is the method according to Embodiment 61.08, wherein the further agent described above recognizes ghmC.
[0085] Embodiment 61.10 is the method according to Embodiment 61.08, wherein the further agent described above recognizes hmC.
[0086] Embodiment 61.11 is the method according to Embodiment 61.08, wherein the further agent described above recognizes mC.
[0087] Embodiment 61.12 is the method according to any one of Embodiments 61.01 to 61.07, wherein the further agent is an antibody.
[0088] Embodiment 61.13 is the method according to any one of Embodiments 61.01 to 61.12, wherein the further partial sample comprises a first further partial sample containing DNA having a higher proportion of mC than the second further partial sample.
[0089] Embodiment 61.14 is the method according to any one of Embodiments 61.01 to 61.13, wherein the further partial sample comprises a first further partial sample containing DNA having a higher proportion of mC than the second further partial sample.
[0090] Embodiment 61.15 is the method according to any one of Embodiments 61.01 to 61.14, wherein the first partial sample contains DNA having CMS in a higher proportion than the further partial sample.
[0091] Embodiment 61.16 is the method according to any one of Embodiments 61.01 to 61.15, wherein the first partial sample contains DNA having a higher proportion of hmC or ghmC than the further partial sample.
[0092] Embodiment 62 is a combination comprising first and second populations of captured DNA, wherein the first population comprises or is derived from DNA having cytosine modifications at a higher rate than the second population, and each of the first and second populations comprises a form of a first nucleobase originally present in the DNA having altered base pairing specificity and a second nucleobase not having altered base pairing specificity, wherein the form of the first nucleobase originally present in the DNA before the alteration of base pairing specificity is an altered or unaltered nucleobase, and the second nucleobase is an altered or unaltered nucleobase different from the first nucleobase, and the form of the first nucleobase originally present in the DNA before the alteration of base pairing specificity and the second nucleobase have the same base pairing specificity.
[0093] Embodiment 63 is a combination of Embodiment 62, wherein the first group includes an array tag selected from a first set of one or more array tags, and the second group includes an array tag selected from a second set of one or more array tags, and the second set of array tags is different from the first set of array tags.
[0094] Embodiment 64 is a combination of the above-mentioned array tag and a barcode, as described in Embodiment 63.
[0095] Embodiment 65 is a combination of any one of Embodiments 62 to 64, wherein the cytosine modification is methylation.
[0096] Embodiment 66 is a combination of any one of Embodiments 62 to 65, wherein the first nucleobase is modified or unmodified cytosine and the second nucleobase is modified or unmodified cytosine.
[0097] Embodiment 67 is a combination of any one of Embodiments 62 to 66, wherein the first nucleobase comprises unmodified cytosine (C).
[0098] Embodiment 68 is a combination of any one of Embodiments 62 to 67, wherein the second nucleobase comprises one or both of 5-methylcytosine (mC) and 5-hydroxymethylcytosine (hmC).
[0099] Embodiment 69 is a combination of any one of Embodiments 62 to 68, wherein the first group is subjected to bisulfite conversion.
[0100] Embodiment 70 is a combination of any one of Embodiments 62 to 68, wherein the first nucleobase includes mC.
[0101] Embodiment 71 is a combination of any one of Embodiments 62 to 70, wherein the second nucleo base contains hmC.
[0102] Embodiment 72 is a combination of any one of Embodiments 62 to 71, wherein the first group includes protected hmC.
[0103] Embodiment 73 is a combination of Embodiment 66 or 72, wherein the first group described above is used for Tet-assisted bisulfite conversion.
[0104] Embodiment 74 is a combination of Embodiments 66 or 72, wherein the first group described above is subjected to Tet-assisted conversion using a substituted borane reducing agent, and the substituted borane reducing agent is, if necessary, 2-picoline borane, borampyridine, tert-butylamine borane, or ammonia borane.
[0105] Embodiment 75 is a combination of Embodiment 72 in which the first group described above is subjected to the protection of hmC and subsequent Tet-assisted conversion using a substituted borane reducing agent, wherein the substituted borane reducing agent is optionally 2-picoline borane, borampyridine, tert-butylamine borane, or ammonia borane.
[0106] Embodiment 76 is a combination of any one of Embodiments 72 to 74, 68, 70 to 72, or 74 to 75, wherein the second nucleo base includes C.
[0107] Embodiment 77 is the combination described in Embodiment 72, wherein the first group is subjected to the protection of hmC and the subsequent deamination of mC and / or C.
[0108] Embodiment 78 is a combination of any one of Embodiments 72 to 77, wherein the protected hmC comprises glucosylated hmC.
[0109] Embodiment 79 is a combination of any one of Embodiments 72 to 75, wherein the first nucleo base contains hmC.
[0110] Embodiment 80 is a combination of any one of Embodiments 72 to 75 or 79, wherein the second nucleobase contains mC.
[0111] Embodiment 81 is a combination of any one of Embodiments 72 to 75 or 79 to 80, wherein the second nucleo base includes C.
[0112] Embodiment 82 is a combination of any one of Embodiments 72 to 75 or 79 to 81, wherein the first group described above is subjected to a chemical additive transformation using a substituted borane reducing agent, and the substituted borane reducing agent is, if necessary, 2-picoline borane, borampyridine, tert-butylamine borane, or ammonia borane.
[0113] Embodiment 83 is a combination of any one of Embodiments 72 to 75, wherein the first nucleobase is a modified or unmodified adenine, and the second nucleobase is a modified or unmodified adenine.
[0114] Embodiment 84 is a combination of any one of Embodiments 72 to 75, wherein the first nucleo base is a modified or unmodified guanine and the second nucleo base is a modified or unmodified guanine.
[0115] Embodiment 85 is a combination of any one of Embodiments 72 to 75, wherein the first nucleobase is modified or unmodified thymine, and the second nucleobase is modified or unmodified thymine.
[0116] Embodiment 86 is a combination of any one of Embodiments 72 to 85, wherein the captured DNA includes cfDNA.
[0117] Embodiment 87 is a combination of any one of Embodiments 72 to 86, wherein the captured DNA includes a sequence variable target region and an epigenetic target region, the concentration of the sequence variable target region is higher than the concentration of the epigenetic target region, and the concentrations are standardized with respect to the footprint size of the sequence variable target region and the epigenetic target region.
[0118] Embodiment 88 is a combination of any one of Embodiments 62 to 87, produced according to the method described in any one of Embodiments 1 to 61.16.
[0119] Embodiment 89 is a method according to any one of Embodiments 1 to 61.16, wherein the DNA of the first partial sample and the DNA of the second partial sample are differentially tagged; after differential tagging, a portion of the DNA from the second partial sample is added to the first partial sample or at least a portion thereof to form a pool; and sequence-variable target regions and epigenetic target regions are captured from the pool.
[0120] Embodiment 90 is the method of the immediately preceding embodiment, wherein the pool contains approximately 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or less than or equal to 5% of the DNA of the second partial sample.
[0121] Embodiment 91 is the method according to Embodiment 89, wherein the pool contains about 70-90%, about 75-85%, or about 80% of the DNA of the second partial sample.
[0122] Embodiment 92 is the method according to any one of Embodiments 89 to 91, wherein the pool contains substantially all of the DNA of the first partial sample.
[0123] Embodiment 93 is a method according to any one of Embodiments 89 to 92, wherein the sequence variable target region is captured from a second portion of DNA derived from the second partial sample.
[0124] Embodiment 94 is a method according to any one of Embodiments 1 to 61.16 or 89 to 93, further comprising the step of determining whether the subject has cancer.
[0125] Embodiment 95 is a method of the immediately preceding embodiment, wherein the sequence determination step comprises generating a plurality of sequence determination reads; the method further comprises mapping the plurality of sequence reads to one or more reference sequences to generate mapped sequence reads; and processing the mapped sequence reads corresponding to the sequence variable target region set and the mapped sequence reads corresponding to the epigenetic target region set to determine the likelihood that the subject has cancer.
[0126] Embodiment 96 is a method according to any one of Embodiments 1 to 61.16 or 89 to 95, wherein the subject of the test has been previously diagnosed with cancer and has undergone one or more prior cancer treatments, and optionally the DNA is obtained at one or more pre-selected time points after the one or more prior cancer treatments, and a captured set of DNA molecules is sequenced, thereby generating a set of sequence information.
[0127] Embodiment 97 is a method of the immediately preceding embodiment, further comprising the step of using the above set of sequence information to detect the presence or absence of DNA originating from or derived from tumor cells at a pre-selected time point.
[0128] Embodiment 98 is the method of the immediately preceding embodiment, further comprising the step of determining a cancer recurrence score for the test subject indicating the presence or absence of the DNA originating from or derived from the tumor cells, and optionally further comprising the step of determining a cancer recurrence status based on the cancer recurrence score, wherein if the cancer recurrence score is determined to be at or above a predetermined threshold, the cancer recurrence status of the test subject is determined to be at risk of cancer recurrence, or if the cancer recurrence score is below the predetermined threshold, the cancer recurrence status of the test subject is determined to be at a lower risk of cancer recurrence.
[0129] Embodiment 99 is the method of the immediately preceding embodiment, further comprising the step of comparing the cancer recurrence score of the subject of test with a predetermined cancer recurrence threshold, wherein the subject of test is classified as a candidate for further cancer treatment if the cancer recurrence score exceeds the cancer recurrence threshold, or is not classified as a candidate for further cancer treatment if the cancer recurrence score falls below the cancer recurrence threshold. [Brief explanation of the drawing]
[0130] [Figure 1-1] Figure 1 shows an exemplary workflow according to a particular embodiment of the present disclosure, beginning with a blood sample, from which cfDNA is isolated from the blood sample; the cfDNA is treated with a bisulfite (BS) that converts C to U, and then distributed into low, intermediate, or high methylation subsamples using an antibody specific to methylcytosine; each subsample is subjected to molecular barcoding to identify the DNA derived from the low, intermediate, or high methylation subsample; the samples are pooled, captured, amplified, and sequenced (in any appropriate order). Methods generally similar to this exemplary method, involving bisulfite conversion, indicate, via conversion or its absence, which cytosine positions were or were not uncultivated cytosine relative to mC or hmC. [Figure 1-2] Same as above.
[0131] [Figure 2] Figure 2 is a schematic diagram of an example of a system suitable for use in some embodiments of this disclosure.
[0132] [Figure 3-1] Figures 3A and 3B illustrate an exemplary workflow according to a particular embodiment of the present disclosure. [Figure 3-2] Same as above. [Modes for carrying out the invention]
[0133] Detailed description of a particular embodiment References to certain embodiments of the present invention are made in detail here. While the present invention is described in conjunction with such embodiments, it should be understood that such embodiments are not intended to limit the present invention to those embodiments. In contrast, the present invention is intended to cover all alternatives, modifications, and equivalents that may fall within the scope of the invention as defined by the appended claims.
[0134] Before describing in detail the teachings of the present invention, it should be understood that this disclosure is not limited to any particular composition or processing step and is itself variable. It should be noted that, as used herein and in the appended claims, the singular forms “one (a),” “one (an),” and “the” include plural references unless the context explicitly indicates otherwise. Thus, for example, a reference to “one (a) nucleic acid” includes multiple nucleic acids, and a reference to “one (a) cell” includes multiple cells, and so on.
[0135] Numerical ranges include the digits that define that range. Measured and measurable values are understood to be approximations, taking into account significant figures and measurement errors. Furthermore, the use of “comprise,” “comprises,” “comprising,” “contain,” “contains,” “containing,” “include,” “includes,” and “including” is not intended as limitation. Both the general and detailed statements above should be understood as illustrative and descriptive only, and not as limitations on teaching.
[0136] Unless specifically noted in the above specification, embodiments in the specification that enumerate various components “including” can also be interpreted as “consisting of” or “essentially being made from” the enumerated components; embodiments in the specification that enumerate various components “consisting of” can also be interpreted as “including” or “essentially being made from” the enumerated components; embodiments in the specification that enumerate various components “essentially being made from” can also be interpreted as “consisting of” or “including” the enumerated components (this interchangeability does not apply to the use of these terms in the claims).
[0137] The section headings used herein are for structural purposes only and should be construed as not limiting the subject matter disclosed in any way. In the event of any conflict between any document or other material incorporated by reference and any express content of this specification, including definitions, this specification shall prevail. I. Definition
[0138] "Cell-free DNA," "cfDNA molecules," or simply "cfDNA" include DNA molecules that are naturally present in the subject in extracellular form (e.g., blood, serum, plasma, or other bodily fluids, e.g., lymph, cerebrospinal fluid, urine, or sputum). While cfDNA was previously found in cells (one or more) in large, complex organisms, such as mammals, it has undergone release from cells into the fluids found in organisms and can now be obtained from fluid samples without the need to perform an in vitro cell lysis step. cfDNA molecules can exist as DNA fragments.
[0139] As used herein, “distribution” of nucleic acids, such as DNA molecules, means separating, fractionating, sorting, or enriching a sample or population of nucleic acids into multiple partial samples or subpopulations of nucleic acids based on one or more modifications or features present in different proportions in each of multiple partial samples or subpopulations. Distribution may include physically distributing nucleic acid molecules based on the presence or absence of one or more methylated nucleobases. A sample or population may be distributed into one or more distributed partial samples or subpopulations based on features indicating a genetic or epigenetic change or disease state.
[0140] When used herein, if the fraction of nucleotides having modifications or other features is higher in the first sample or population than in the second population, the modifications or other features are present in a “higher proportion” in the first sample or population of nucleic acids than in the second sample or population. For example, if one-tenth of the nucleotides in the first sample are mC and one-twentieth of the nucleotides in the second sample are mC, then the first sample contains 5-methylated cytosine modifications in a higher proportion than the second sample.
[0141] As used herein, the “originally isolated” form of a sample refers to the composition or chemical structure of the sample at the time of its isolation and before any procedure that alters the chemical structure of the isolated sample is performed. Similarly, “originally present” features in a DNA molecule refer to features present in the “original DNA molecule” or features present in a DNA molecule that “originally contains” those features before the DNA molecule undergoes any procedure that alters the chemical structure of the DNA molecule.
[0142] As used herein, “without substantially altering the base-pairing specificity” of a given nucleobase means that the majority of molecules containing that nucleobase that can be sequenced will have no alteration of the base-pairing specificity of the given nucleobase compared to its base-pairing specificity as it was in the original isolated sample. In some embodiments, 75%, 90%, 95%, or 99% of molecules containing that nucleobase that can be sequenced will have no alteration of the base-pairing specificity compared to its base-pairing specificity as it was in the original isolated sample. As used herein, “altered base-pairing specificity” of a given nucleobase means that the majority of molecules containing that nucleobase that can be sequenced will have base-pairing specificity in that nucleobase compared to its base-pairing specificity in the original isolated sample.
[0143] As used herein, “base pairing specificity” refers to the standard DNA base (A, C, G, or T) to which a given base most preferentially pairs. For example, unmodified cytosine and 5-methylcytosine have the same base pairing specificity (i.e., specificity to G), but uracil has base pairing specificity to A, while cytosine has base pairing specificity to G; therefore, uracil and cytosine have different base pairing specificities. Uracil’s ability to form fluctuating pairs with G is irrelevant, since uracil nevertheless most preferentially pairs with A among the four standard DNA bases.
[0144] As used herein, “combination” including multiple members means, for example, a single composition or a set of adjacent compositions containing these members in separate containers or compartments within a larger container, such as a multiwell plate, tube rack, refrigerator, freezer, incubator, water bath, ice bucket, machine, or other storage configuration.
[0145] The “capture yield” of probe collection for a given target set refers to the amount of nucleic acid corresponding to the target set that the probe collection captures under typical conditions (e.g., an amount compared to another target set, or an absolute amount). An exemplary typical capture condition is incubation of the sample nucleic acid and probe at 65°C for 10–18 hours in a small reaction volume (approximately 20 μL) containing stringent hybridization buffer. Capture yields can be expressed in absolute terms or, for multiple probe collections, in relative terms. When capture yields for multiple sets of target regions are compared, they are standardized with respect to the footprint size of the target region set (e.g., based on per kilobase). Therefore, for example, if the footprint sizes of the first and second target regions are 50kb and 500kb, respectively (giving a normalization factor of 0.1), then when the mass concentration per unit volume of captured DNA corresponding to the first set of target regions is greater than 0.1 times the mass concentration per unit volume of captured DNA corresponding to the second set of target regions, the DNA corresponding to the first set of target regions will be captured in a higher yield than the DNA corresponding to the second set of target regions. As a further example, using the same footprint size, if the captured DNA corresponding to the first set of target regions has a mass concentration per unit volume that is 0.2 times the mass concentration per unit volume of captured DNA corresponding to the second set of target regions, then the DNA corresponding to the first set of target regions will be captured in twice the yield of the DNA corresponding to the second set of target regions.
[0146] "Capturing" one or more target nucleic acids means preferentially isolating or separating one or more target nucleic acids from non-target nucleic acids.
[0147] A "captured set" or "captured" nucleic acid refers to a nucleic acid that has been captured.
[0148] A “target region set” or “set of target regions” refers to multiple genomic loci that are targeted for capture and / or targeted by a set of probes (e.g., via sequence complementarity).
[0149] "Corresponding to a target region set" means that the nucleic acid, for example, cfDNA, originates from a gene locus within the target region set, or specifically binds to one or more probes targeting the target region set.
[0150] In the context of probes or other oligonucleotides and target sequences, "specifically binding" means that, under appropriate hybridization conditions, the oligonucleotide or probe hybridizes to its target sequence or a replica thereof to form a stable probe:target hybrid, while simultaneously minimizing the formation of a stable probe:non-target hybrid. Thus, the probe hybridizes to the target sequence or a replica thereof to a sufficiently higher degree than it would to a non-target sequence, enabling the capture or detection of the target sequence. Appropriate hybridization conditions are well known in the art and can be predicted based on sequence composition or determined using conventional test methods (see, for example, sections 1.90-1.91, 7.37-7.57, 9.47-9.51 and 11.47-11.57 of Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), which is thus incorporated herein by reference, in particular sections 9.50-9.51, 11.12-11.13, 11.45-11.47 and 11.55-11.57).
[0151] A “sequence-variable target region set” refers to a set of target regions that, compared to normal cells, may exhibit sequence changes, such as nucleotide substitutions (i.e., single-nucleotide variations), insertions, deletions, or gene fusions or transpositions, in neoplastic cells (e.g., tumor cells and cancer cells).
[0152] An "epigenetic target region set" refers to a set of target regions that may exhibit sequence-independent changes in neoplastic cells (e.g., tumor cells and cancer cells) compared to normal cells, or in cfDNA derived from cancerous subjects compared to cfDNA derived from healthy subjects. Examples of sequence-independent changes, but not limited to these, include changes in methylation (increase or decrease), nucleosome distribution, cfDNA fragmentation patterns, CCCTC binding factor ("CTCF") binding, transcription start sites, and regulatory protein binding regions. Therefore, epigenetic target region sets, but not limited to these, include high-methylation variable target region sets, low-methylation variable target region sets, and fragmentation variable target region sets, such as CTCF binding sites and transcription start sites. For the purposes of the present invention, loci sensitive to neoplasm-related, tumor-related, or cancer-related localized amplification and / or gene fusions may also be included in the epigenetic target region set, because the detection of copy number changes by sequencing, or by fused sequences mapped to more than one locus in the reference genome, tends to be more similar to the detection of the exemplary epigenetic changes discussed above than the detection of nucleotide substitutions, insertions, or deletions, in that, for example, their detection does not depend on the precision of base calls at one or a few individual locations, and localized amplification and / or gene fusions can be detected at a relatively shallow depth of sequencing.
[0153] Nucleic acids are “tumor-produced” or “circulating tumor DNA” (“ctDNA”) when they originate from tumor cells. Tumor cells are neoplastic cells that originate from a tumor, whether they remain in the tumor or are isolated from the tumor (for example, in the cases of metastatic cancer cells and circulating tumor cells).
[0154] The term "methylation" or "DNA methylation" refers to the addition of a methyl group to a nucleobase in a nucleic acid molecule. In some embodiments, methylation refers to the addition of a methyl group to cytosine at a CpG site (cytosine-phosphate-guanine site (i.e., cytosine and subsequent guanine in the 5'→3' direction of the nucleic acid sequence)). In some embodiments, DNA methylation is, for example, N 6 -In methyladenine, this refers to the addition of a methyl group to adenine. In some embodiments, DNA methylation is 5-methylation (modification of the fifth carbon of the 6-carbocyclic ring of cytosine). In some embodiments, 5-methylation refers to the addition of a methyl group to the 5C position of cytosine, creating 5-methylcytosine (5mC). In some embodiments, methylation includes derivatives of 5mC. Derivatives of 5mC include, but are not limited to, 5-hydroxymethylcytosine (5-hmC), 5-formylcytosine (5-fC), and 5-carboxylcytosine (5-caC). In some embodiments, DNA methylation is 3C methylation (modification of the third carbon of the 6-carbocyclic ring of cytosine). In some embodiments, 3C methylation includes the addition of a methyl group to the 3C position of cytosine, producing 3-methylcytosine (3mC). Methylation can occur even at non-CpG sites; for example, methylation can occur at CpA, CpT, or CpC sites. DNA methylation can alter the activity of methylated DNA regions. For example, if DNA in a promoter region is methylated, gene transcription may be repressed. DNA methylation is important for normal development, and abnormalities in methylation can disrupt epigenetic regulation. Disruption of epigenetic regulation, such as repression, can lead to disease, such as cancer. Promoter methylation in DNA can indicate cancer.
[0155] The term "hypermethylation" refers to an increased level or degree of methylation in a nucleic acid molecule compared to other nucleic acid molecules in a population of nucleic acid molecules (e.g., a sample). In some embodiments, hypermethylated DNA may include DNA molecules containing at least one methylated residue, at least two methylated residues, at least three methylated residues, at least five methylated residues, or at least ten methylated residues.
[0156] The term "hypomethylation" refers to a reduced level or degree of methylation in a nucleic acid molecule compared to other nucleic acid molecules in a population of nucleic acid molecules (e.g., a sample). In some embodiments, hypomethylated DNA includes unmethylated DNA molecules. In some embodiments, hypomethylated DNA may include DNA molecules containing 0 methylated residues, at most 1 methylated residue, at most 2 methylated residues, at most 3 methylated residues, at most 4 methylated residues, or at most 5 methylated residues.
[0157] The term “agents that recognize modified nucleobases in DNA” refers to molecules or reagents that bind to or detect one or more modified nucleobases in DNA. A “modified nucleobase” is a nucleobase that exhibits differences in chemical structure compared to an unmodified nucleobase. In the case of DNA, unmodified nucleobases are adenine, cytosine, guanine, or thymine. In some embodiments, the modified nucleobase is a modified cytosine. In some embodiments, the modified nucleobase is a methylated nucleobase. In some embodiments, the modified cytosine is methylcytosine, e.g., 5-methylcytosine. In such embodiments, the cytosine modification is methyl. Agents that recognize methylcytosine in DNA include, but are not limited to, “methyl-binding reagents” which refer herein to reagents that bind to methylcytosine. Methyl-binding reagents include, but are not limited to, methyl-binding domains (MBDs) and methyl-binding proteins (MBPs), as well as antibodies specific to methylcytosine. In some embodiments, such antibodies bind to 5-methylcytosine in the DNA. In some such embodiments, the DNA may be single-stranded or double-stranded.
[0158] The terms “or any combination thereof (singular)” and “or any combination thereof (plural)” as used herein refer to any and all permutations and combinations of the enumerated terms preceding them. For example, “A, B, C, or any combination thereof” is intended to include at least one of the following: A, B, C, AB, AC, BC, or ABC, and also BA, CA, CB, ACB, CBA, BCA, BAC, or CAB, where the order is important in the particular context. Extending this example, combinations containing repetitions of one or more items or terms, such as BB, AAA, AAB, BBC, AAABCCCC, CBBAAA, CABABB, etc., are explicitly included. A person skilled in the art will understand that, unless otherwise evident from the context, there is typically no limitation regarding the number of items or terms in any combination.
[0159] "Or" is used in an inclusive sense, that is, equivalent to "and / or," unless the context requires otherwise. II. Exemplary Methods A. Procedures to affect the first nucleobase in DNA in a way that makes it different from the second nucleobase in DNA.
[0160] A method disclosed herein includes the step of subjecting DNA to a procedure that affects a first nucleobase in the DNA in such a way that it is different from a second nucleobase in the DNA, wherein the first nucleobase is a modified or unmodified nucleobase, the second nucleobase is a modified or unmodified nucleobase different from the first nucleobase, and the first and second nucleobases have the same base pairing specificity. In some embodiments, the procedure chemically converts the first or second nucleobase such that the base pairing specificity of the converted nucleobase is altered. In some embodiments, if the first nucleobase is modified or unmodified adenine, the second nucleobase is modified or unmodified adenine; if the first nucleobase is modified or unmodified cytosine, the second nucleobase is modified or unmodified cytosine; if the first nucleobase is modified or unmodified guanine, the second nucleobase is modified or unmodified guanine; and if the first nucleobase is modified or unmodified thymine, the second nucleobase is modified or unmodified thymine (in which case the modified and unmodified uracil are incorporated within the modified thymine for the purposes of this step).
[0161] In some embodiments, the first nucleobase is modified or unmodified cytosine, and then the second nucleobase is modified or unmodified cytosine. For example, the first nucleobase may contain unmodified cytosine (C), and the second nucleobase may contain one or more of 5-methylcytosine (mC) and 5-hydroxymethylcytosine (hmC). Alternatively, the second nucleobase may contain C, and the first nucleobase may contain one or more of mC and hmC. Other combinations are also possible, for example, as shown in the above summary and the discussion below, such as when one of the first and second nucleobases contains mC and the other contains hmC.
[0162] In some embodiments, a procedure that affects the first nucleobase in DNA in a way that differs from the second nucleobase in DNA involves bisulfite conversion. Treatment with bisulfite converts unmodified cytosine and certain modified cytosines (e.g., 5-formylcytosine (fC) or 5-carboxylcytosine (caC)) to uracil, but not other modified cytosines (e.g., 5-methylcytosine, 5-hydroxylmethylcytosine (5-hydroxylmethylcystosine)). Thus, when bisulfite conversion is used, the first nucleobase contains or consists of one or more of the unmodified cytosine, 5-formylcytosine, 5-carboxylcytosine, or other cytosine forms affected by the bisulfite, and the second nucleobase may contain one or more of mC and hmC, e.g., mC and optionally hmC. Sequencing of bisulfite-treated DNA identifies locations read as cytosine as mC or hmC locations. Conversely, locations read as T are identified as T or a bisulfite-sensitive form of C, such as unmodified cytosine, 5-formylcytosine, or 5-carboxylcytosine. Therefore, performing bisulfite conversion as described herein facilitates the identification of mC or hmC-containing locations using sequence reading. For an exemplary description of bisulfite conversion, see, for example, Moss et al., Nat Commun. 2018; 9: 5068. An exemplary workflow in which bisulfite conversion is performed is shown in Figure 1.
[0163] In some embodiments, a procedure that affects the first nucleobase in the DNA in a way that distinguishes it from a second nucleobase in the DNA involves oxidative bisulfite (Ox-BS) conversion. This procedure first converts hmC to a bisulfite-sensitive fC, and then performs the bisulfite conversion. Thus, when oxidative bisulfite conversion is used, the first nucleobase contains one or more of the following: unmodified cytosine, fC, caC, hmC, or other cytosine forms affected by bisulfite, and the second nucleobase contains mC. Sequencing of the Ox-BS converted DNA identifies the positions read as cytosine as mC positions. On the other hand, positions read as T are identified as T, hmC, or a bisulfite-sensitive form of C, e.g., unmodified cytosine, fC, or hmC. Therefore, performing the Ox-BS conversion as described herein facilitates the identification of mC-containing positions using sequence reading. For an exemplary description of oxidative bisulfite conversion, see, for example, Booth et al., Science 2012; 336: 934-937.
[0164] In some embodiments, procedures that affect the first nucleobase in DNA in a way that differs from the second nucleobase in DNA include Tet-assisted bisulfite (TAB) conversion. In TAB conversion, hmC is protected from conversion, and mC is oxidized prior to bisulfite treatment, resulting in the position originally occupied by mC being converted to U, while the position originally occupied by hmC remains in the protected form of cytosine. For example, as described in Yu et al., Cell 2012; 149: 1368-80, a β-glucosyltransferase may be used to protect hmC (forming 5-glucosylhydroxymethylcytosine (ghmC)), then a TET protein, e.g., mTet1, may be used to convert mC to caC, and then bisulfite treatment may be used to convert C and caC to U, while ghmC remains unaffected. Therefore, when TAB conversion is used, the first nucleobase contains one or more of the following: unmodified cytosine, fC, caC, mC, or other cytosine forms affected by bisulfites, and the second nucleobase contains hmC. Sequencing of the TAB-converted DNA identifies the locations read as cytosine as hmC locations. On the other hand, locations read as T are identified as T, mC, or bisulfite-sensitive forms of C, such as unmodified cytosine, fC, or caC. Thus, performing TAB conversion as described herein facilitates the identification of hmC-containing locations using sequence readings.
[0165] In some embodiments, the procedure for affecting the first nucleobase in the DNA in a manner distinct from the second nucleobase in the DNA includes a Tet-assisted conversion using a substituted borane reducing agent, which, if necessary, is 2-picoline borane, borampyridine, tert-butylamine borane, or ammonia borane. In the Tet-assisted pic-borane conversion using a substituted borane reducing agent, the TET protein is used to convert mC and hmC to caC without affecting the unmodified C. The caC, and fC if present, are then converted to dihydrouracil (DHU) by treatment with 2-picoline borane (pic-borane) or another substituted borane reducing agent, e.g., borampyridine, tert-butylamine borane, or ammonia borane, also without affecting the unmodified C. See, for example, Liu et al., Nature Biotechnology 2019; 37:424-429 (e.g., Supplementary Figure 1 and Supplementary Note 7). DHU is read as T in sequencing. Therefore, when this type of conversion is used, the first nucleobase contains one or more of mC, fC, caC, or hmC, and the second nucleobase contains unmodified cytosine. Sequencing of the converted DNA identifies the position read as cytosine as the unmodified C position. On the other hand, the position read as T is identified as T, mC, fC, caC, or hmC. Therefore, performing the TAP conversion as described herein facilitates the identification of positions containing unmodified C using sequence reading. This procedure encompasses Tet-assisted pyridineborane sequencing (TAPS), as described in further detail above in Liu et al. 2019.
[0166] Alternatively, protection of hmC (e.g., using βGT) can be combined with Tet-assisted conversion using a substituted borane reducing agent. hmC can be protected as described above via glucosylation using βGT to form ghmC. Treatment with a TET protein, e.g., mTet1, then converts mC to caC, but not C or ghmC. CaC is then converted to DHU by treatment with pic-borane or another substituted borane reducing agent, e.g., borampyridine, tert-butylamine borane, or ammonia borane, without affecting either the original C or ghmC. Thus, when Tet-assisted conversion using a substituted borane reducing agent is used, the first nucleobase contains mC, and the second nucleobase contains one or more of the original cytosine or hmC, e.g., original cytosine and, if necessary, hmC, fC, and / or caC. Sequencing of the converted DNA identifies the position read as cytosine as either hmC or an unmodified C position. Conversely, the position read as T is identified as T, fC, caC, or mC. Therefore, performing the TAPSβ conversion as described herein facilitates the identification of positions containing unmodified C or hmC from positions containing mC using sequence readings. For an illustrative description of this type of conversion, see, for example, Liu et al., Nature Biotechnology 2019; 37:424-429.
[0167] In some embodiments, the procedure for affecting the first nucleobase in DNA in a manner distinct from the second nucleobase in DNA involves a chemically assisted conversion using a substituted borane reducing agent, which may optionally be 2-picoline borane, borampyridine, tert-butylamine borane, or ammonia borane. In the chemically assisted conversion using a substituted borane reducing agent, an oxidizing agent, such as potassium perruthenate (KRuO4) (also suitable for use in ox-BS conversion), is used to specifically oxidize hmC to fC. Treatment with pic-borane or another substituted borane reducing agent, such as borampyridine, tert-butylamine borane, or ammonia borane, converts fC and caC to DHU but does not affect mC or the unmodified C. Therefore, when this type of conversion is used, the first nucleobase contains one or more of hmC, fC, and caC, and the second nucleobase contains one or more of unmodified cytosine or mC, e.g., unmodified cytosine and optionally mC. Sequencing of the converted DNA identifies the position read as cytosine as either an mC or an unmodified C position. On the other hand, the position read as T is identified as T, fC, caC, or hmC. Thus, performing this type of conversion as described herein facilitates the use of sequence reading to distinguish positions containing unmodified C or mC from positions containing hmC. For an illustrative description of this type of conversion, see, for example, Liu et al., Nature Biotechnology 2019; 37:424-429.
[0168] In some embodiments, a procedure that affects the first nucleobase in DNA in a way that distinguishes it from a second nucleobase in DNA involves APOBEC-coupled epigenetic (ACE) conversion. In ACE conversion, a DNA deaminase enzyme from the AID / APOBEC family, e.g., APOBEC3A (A3A), is used to deaminate unmodified cytosine and mC without deaminating hmC, fC, or caC. Thus, when ACE conversion is used, the first nucleobase contains unmodified C and / or mC (e.g., unmodified C and mC as appropriate), and the second nucleobase contains hmC. Sequencing of the ACE-converted DNA identifies the position read as cytosine as an hmC, fC, or caC position, while the position read as T is identified as T, unmodified C, or mC. Therefore, performing ACE conversion as described herein facilitates the identification of hmC-containing positions from mC or unmodified C-containing positions using sequence reading. For an exemplary description of ACE conversion, see, for example, Schutsky et al., Nature Biotechnology 2018; 36: 1083-1090.
[0169] In some embodiments, the procedure for affecting the first nucleobase in DNA in a way that differs from the second nucleobase in DNA includes, for example, the enzymatic transformation of the first nucleobase, similar to that in EM-Seq. See, for example, Vaisvila R, et al. (2019) EM-seq: Detection of DNA methylation at single base resolution from picograms of DNA. bioRxiv; DOI: 10.1101 / 2019.12.20.884692v1, available at www.biorxiv.org / content / 10.1101 / 2019.12.20.884692v1. For example, TET2 and optionally T4-βGT may be used to convert 5mC and 5hmC into substrates that cannot be deaminated by a deaminase (e.g., APOBEC3A), and then the deaminase (e.g., APOBEC3A) may be used to deaminate the unmodified cytosine to convert them to uracil. In some embodiments, 5mC and / or 5hmC are converted to 5caC (e.g., using Tet2), and then the unmodified C is converted to U (e.g., using APOBEC3A). The 5caC-containing DNA (generated from DNA that originally contained 5mC and / or 5hmC) may then be partitioned using, for example, an anti-caC antibody.
[0170] In some embodiments, the first nucleobase is modified or unmodified adenine, and the second nucleobase is modified or unmodified adenine. In some embodiments, the modified adenine is N 6 -methyl adenine (mA). In some embodiments, the modified adenine is N 6 -Methyladenine (mA), N 6 -Hydroxymethyladenine (hmA) or N 6 - One or more of the formyladenine (fA) compounds.
[0171] Techniques including methylated DNA immunoprecipitation (MeDIP) can be used to separate DNA containing modified bases, e.g., mC, mA, caC (which can be produced by oxidation of mC or hmC by Tet2 prior to the enzymatic conversion of unmodified C to U, e.g., using a deaminase, e.g., APOBEC3A), or dihydrouracil from other DNA. See, for example, Kumar et al., Frontiers Genet. 2018; 9: 640; Greer et al., Cell 2015; 161: 868-878. Antibodies specific to mA are described in Sun et al., Bioessays 2015; 37:1155-62. Antibodies against various modified nucleobases, e.g., mC, caC, and thymine / uracil forms, including dihydrouracil or halogenated forms, e.g., 5-bromouracil, are commercially available. Various modified bases can also be detected based on changes in their base pairing specificity. For example, hypoxanthine is a modified form of adenine that can result from deamination and is read as G in sequencing. See, for example, U.S. Patent No. 8,486,630; Brown, Genomes, 2 nd See Ed., John Wiley & Sons, Inc., New York, NY, 2002, chapter 14, "Mutation, Repair, and Recombination." B. Steps for distributing the sample into multiple subsamples; sample characteristics; analysis of epigenetic features.
[0172] In certain embodiments described herein, after a procedure that affects a first nucleobase and a second nucleobase differently, populations of different forms of nucleic acids (e.g., highly methylated DNA and highly methylated DNA) may be physically distributed based on one or more characteristics of the nucleic acids before further analysis, e.g., further differential modification or isolation, tagging, and / or sequencing of the nucleobases. This approach may be used, for example, to determine whether a particular sequence is highly methylated or highly methylated. In some embodiments, the distribution is based on different forms of nucleic acids that were originally present in the sample before being subjected to the procedure that affects the first nucleobase and the second nucleobase differently. In some embodiments, the distribution is based on different forms of nucleic acids in the nucleic acids of the sample produced by the procedure that affects the first nucleobase and the second nucleobase differently.
[0173] Methylation profiling can involve determining methylation patterns across different regions of the genome. For example, molecules can be allocated based on their degree of methylation (e.g., the relative number of methylated nucleobases per molecule), and after sequencing, the sequences of molecules in different allocations can be mapped to a reference genome. This may indicate regions of the genome that are more or less highly methylated compared to other regions. In this method, genomic regions can differ in their degree of methylation, as opposed to individual molecules.
[0174] In some embodiments, combining signals obtained from methylation profiling with signals obtained from somatic cell variations (e.g., SNVs, indels, CNVs, and gene fusions) facilitates cancer detection.
[0175] Nucleic acid molecules in a sample can be fractionated or partitioned based on the methylation status of the nucleic acid molecules. Partitioning nucleic acid molecules in a sample can increase the detection of rare signals. For example, gene variations that are present in highly methylated DNA but are less (or absent) in low-methylated DNA can be more easily detected by partitioning the sample into highly methylated and low-methylated nucleic acid molecules. By analyzing multiple fractions of a sample, multidimensional analysis of a single molecule can be performed, and therefore higher sensitivity can be achieved. Partitioning may involve physically distributing nucleic acid molecules into subsets or groups based on the presence or absence of one or more methylated nucleobases. A sample can be fractionated or partitioned into one or more partitioned sets based on features indicating differential gene expression or disease status. A sample can be fractionated based on features or combinations thereof that provide differences in signaling between normal and diseased states during the analysis of nucleic acids, e.g., cell-free DNA (cfDNA), non-cfDNA, tumor DNA, circulating tumor DNA (ctDNA), and cell-free nucleic acid (cfNA).
[0176] In some embodiments, highly methylated variable epigenetic target regions are analyzed to determine whether they exhibit high methylation features of tumor cells or cell types not typically contributing to the DNA sample being analyzed (e.g., cfDNA), and / or low methylated variable epigenetic target regions are analyzed to determine whether they exhibit low methylation features of tumor cells or cell types not typically contributing to the DNA sample being analyzed (e.g., cfDNA). Furthermore, rare signals can be increased by distributing heterogeneous nucleic acid populations, for example, by enriching a more common, rare nucleic acid molecule in one fraction (or distribution) of the population. For example, gene variations that are present in highly methylated DNA but less (or absent) in low methylated DNA can be more easily detected by distributing the sample into highly methylated and low methylated nucleic acid molecules. By analyzing multiple fractions of the sample, multidimensional analysis of a single gene locus or nucleic acid species in the genome can be performed, and thus higher sensitivity can be achieved.
[0177] In some examples, heterogeneous nucleic acid samples are distributed into two or more distributions (e.g., at least three, four, five, six, or seven distributions). In some embodiments, each distribution is differentially tagged. The tagged distributions can then be pooled together for collective sample preparation and / or sequencing. The distribution-tagging-pooling steps may be performed more than once, and each round of distributions may be performed based on different characteristics (examples provided herein) and tagged using differential tags and distribution means that distinguish them from other distributions.
[0178] Examples of features that may be used for distribution include sequence length, methylation level, nucleosome binding, sequence mismatch, immunoprecipitation, and / or proteins that bind to DNA. The resulting distribution may include one or more of the following nucleic acid forms: single-stranded DNA (ssDNA), double-stranded DNA (dsDNA), shorter DNA fragments, and longer DNA fragments. In some embodiments, a step of distribution based on cytosine modifications (e.g., cytosine methylation) or methylation is commonly performed and may be combined with at least one additional distribution step, which may be based on any of the above-described features or forms of DNA, as needed. In some embodiments, a heterogeneous population of nucleic acids is distributed into nucleic acids with one or more epigenetic modifications and nucleic acids without one or more epigenetic modifications. Examples of epigenetic modifications include the presence or absence of methylation; the level of methylation; the type of methylation (e.g., 5-methylcytosine versus other types of methylation, e.g., adenine methylation and / or cytosine hydroxymethylation); and association with one or more proteins, e.g., histones, and the level of association. Alternatively, a heterogeneous population of nucleic acids may be distributed into nucleic acid molecules associated with nucleosomes and nucleic acid molecules without nucleosomes. Alternatively, a heterogeneous population of nucleic acids may be distributed into single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA). Alternatively, a heterogeneous population of nucleic acids may be distributed based on nucleic acid length (e.g., molecules up to 160 bp and molecules longer than 160 bp).
[0179] In some cases, each distribution (a partial sample enriched with a specific nucleic acid morphology) is differentially tagged, and the distributions are pooled together before sequencing. In other cases, different morphologies are sequenced separately.
[0180] In some embodiments, a population of different nucleic acids is subjected to a procedure that affects a first nucleobase in the DNA in a way that it differs from a second nucleobase in the DNA, where the first nucleobase is a modified or unmodified nucleobase, and the second nucleobase is a modified or unmodified nucleobase different from the first nucleobase, and the first and second nucleobases have the same base pairing specificity. The population is then distributed into two or more different partitions. Each partition is enriched with a different nucleic acid form, where the first partition (also called a partial sample) contains DNA with a higher proportion of cytosine modifications than the second partial sample. Each partition is tagged separately. The tagged nucleic acids are pooled together before sequencing. Sequence readings are obtained and analyzed, including for in silico identification of the first nucleobase in at least one of the first and second partial samples from the second nucleobase. Tags are used to sort reads from different distributions. Analysis to detect genetic variants can be performed at the distribution level and at the whole nucleic acid population level. For example, analysis may include in silico analysis to determine genetic variants in nucleic acids within each distribution, e.g., CNVs, SNVs, indels, and fusions. In some examples, in silico analysis may include determining chromatin structure. For example, sequence reading coverage may be used to determine the positioning of nucleosomes in chromatin. Higher coverage may correlate with higher nucleosome occupancy in genomic regions, while lower coverage may correlate with lower nucleosome occupancy or nucleosome-depleted regions (NDRs).
[0181] The sample may contain modifications that include post-replication alterations to nucleotides, and nucleic acids in which the normally non-covalent binding to one or more proteins is altered.
[0182] In one embodiment, the nucleic acid population is obtained from a serum, plasma, or blood sample derived from a subject suspected of having a neoplasm, tumor, or cancer, or a subject previously diagnosed with a neoplasm, tumor, or cancer. The nucleic acid population includes nucleic acids having varying levels of methylation. Methylation may result from any one or more post-replication or post-transcriptional modifications. Post-replication modifications include, in particular, modifications of cytosine at the 5-position of the nucleobase, e.g., 5-methylcytosine, 5-hydroxymethylcytosine, 5-formylcytosine, and 5-carboxylcytosine. The agent used to distribute the nucleic acid population in the sample may be an affinity agent, e.g., an antibody with desired specificity, a natural binding partner, or a variant thereof (Bock et al., Nat Biotech 28: 1106-1114 (2010); Song et al., Nat Biotech 29: 68-72 (2011)), or an artificial peptide selected, for example by phage display, to have specificity for a given target. In some embodiments, the agent used in the distribution is an agent that recognizes a modified nucleobase. In some embodiments, the modified nucleobase recognized by the agent is a modified cytosine, e.g., methylcytosine (e.g., 5-methylcytosine). In some embodiments, the modified nucleobase recognized by the agent is the product of a procedure that affects a first nucleobase in the DNA in a sample so that it is different from a second nucleobase in the DNA. In some embodiments, the modified nucleobase may be a "converted nucleobase," meaning that its base pairing specificity has been altered by the procedure. For example, a particular procedure may convert an unmethylated or unmodified cytosine to dihydrouracil, or more generally, at least one modified or unmodified form of cytosine may undergo deamination to produce uracil (considered a modified nucleobase in the context of DNA) or a further modified form of uracil. Examples of distributing agents include antibodies that recognize a modified nucleobase, such as a modified cytosine, for example, methylcytosine (e.g., 5-methylcytosine).In some embodiments, the distributor is an antibody that recognizes a modified cytosine other than 5-methylcytosine, such as 5-carboxylcytosine (5caC). Alternative distributors include methyl-binding domains (MBDs), such as MBD2, and methyl-binding proteins (MBPs) as described herein, which include proteins such as MeCP2.
[0183] An additional, non-limiting example of a dispersant is a histone-binding protein that can separate histone-bound nucleic acids from free or unbound nucleic acids. Examples of histone-binding proteins that may be used in the methods disclosed herein include RBBP4, RbAp48, and SANT domain peptides.
[0184] The binding of the distributing agent to a specific nucleic acid, and the distribution of the nucleic acid to a partial sample, may occur to a certain degree, or may occur in an essentially binary manner. In some cases, nucleic acids containing a higher proportion of a particular modification bind to the agent to a higher degree than nucleic acids containing a lower proportion of the modification. Similarly, the distribution may produce partial samples containing higher and lower proportions of nucleic acids containing a particular modification. Alternatively, the distribution may produce partial samples containing essentially all of the modified nucleic acid or no such nucleic acid at all. In all cases, varying levels of modification may be sequentially eluted from the distributing agent.
[0185] In some embodiments, the distribution may include both binary distribution and distribution based on the degree / level of modification. For example, methylated fragments may be distributed by methylated DNA immunoprecipitation (MeDIP), or all methylated fragments may be distributed from unmethylated fragments using a methyl-binding domain protein (e.g., MethylMinder Methylated DNA Enrichment Kit (ThermoFisher Scientific)). Subsequently, additional distribution may include eluting fragments with different levels of methylation by adjusting the salt concentration in the solution containing the methyl-binding domain and the bound fragments. As the salt concentration increases, fragments with higher levels of methylation are eluted.
[0186] In some cases, the final distribution is enriched with nucleic acids having different degrees of modification (over- or under-presentation of modifications). Over- and under-presentation can be defined by the number of modifications produced by the nucleic acid compared to the median number of modifications per strand in the population. For example, if the median number of 5-methylcytosine residues in nucleic acids in a sample is 2, nucleic acids containing more than 2 5-methylcytosine residues are over-presented with this modification, and nucleic acids with 1 or zero 5-methylcytosine residues are under-presented. The effect of affinity separation is to enrich nucleic acids with over-presented modifications in the conjugated phase and nucleic acids with under-presented modifications in the unconjugated phase (i.e., in solution). Nucleic acids in the conjugated phase can be eluted before subsequent processing.
[0187] When using MeDIP or the MethylMiner Methylated DNA Enrichment Kit (ThermoFisher Scientific), various levels of methylation can be separated using sequential elution. For example, a low-methylated distribution (no methylation) can be separated from a methylated distribution by contacting the nucleic acid population with MBD from this kit, which is bound to magnetic beads. The beads are used to separate methylated nucleic acids from unmethylated nucleic acids. Subsequently, one or more elution steps are performed sequentially to elute nucleic acids with different levels of methylation. For example, a first set of methylated nucleic acids can be eluted at a salt concentration of 160 mM or higher, e.g., at least 150 mM, at least 200 mM, 300 mM, 400 mM, 500 mM, 600 mM, 700 mM, 800 mM, 900 mM, 1000 mM, or 2000 mM. After such methylated nucleic acids are eluted, magnetic separation is used again to separate nucleic acids with higher levels of methylation from those with lower levels of methylation. The elution and magnetic separation steps can be repeated to create various partitions, for example, a low-methylated partition (enriched with nucleic acids that do not contain methylation), a methylated partition (enriched with nucleic acids that contain low levels of methylation), and a high-methylated partition (enriched with nucleic acids that contain high levels of methylation).
[0188] In some methods, nucleic acids bound to the agent used for affinity separation-based distribution are subjected to a washing step. The washing step washes away nucleic acids that are weakly bound to the affinity agent. Such nucleic acids may be enriched with nucleic acids that have been modified to a degree close to the mean or median (i.e., an intermediate value between nucleic acids that remain bound to the solid phase and nucleic acids that do not remain bound to the solid phase at the time of initial contact between the sample and the agent).
[0189] Affinity segregation results in at least two, sometimes three or more, distributions of nucleic acids with varying degrees of modification. While these distributions are still separate, nucleic acids from at least one distribution, typically two or three (or more) distributions, are ligated to nucleic acid tags, usually provided as components of an adapter, so that nucleic acids in different distributions receive different tags that identify members of one distribution from those of another. Tags ligated to nucleic acid molecules in the same distribution can be the same or different from each other. However, if they are different, these tags may share a common part of their coding to identify the molecule to which they are ligated as belonging to a particular distribution.
[0190] For further details regarding the partitioning of nucleic acid samples based on characteristics such as methylation, please refer to WO2018 / 119452, which is incorporated herein by reference.
[0191] In some embodiments, nucleic acid molecules may be fractionated into different distributions based on which nucleic acid molecules are bound to a specific protein or fragment thereof and which are not bound to that specific protein or fragment thereof.
[0192] Nucleic acid molecules can be fractionated based on DNA-protein binding. Protein-DNA complexes can be fractionated based on specific properties of the protein. Examples of such properties include various epitopes, modifications (e.g., histone methylation or acetylation), or enzymatic activity. Examples of proteins that can bind to DNA and serve as a basis for fractionation include, but are not limited to, protein A and protein G. Any suitable method can be used to fractionate nucleic acid molecules based on protein-bound regions. Examples of methods used to fractionate nucleic acid molecules based on protein-bound regions include, but are not limited to, SDS-PAGE, chromatin-immunoprecipitation (ChIP), heparin chromatography, and asymmetrical field flow fractionation (AF4).
[0193] In some embodiments, the distribution of the sample into multiple partial samples is carried out by contacting the nucleic acid with an antibody that recognizes a modified nucleobase, which may be a modified cytosine in the DNA, or a product of a procedure that affects the first nucleobase in the DNA in a way that it differs from the second nucleobase in the sample's DNA. In some embodiments, the modified nucleobase is 5mC. In some embodiments, the modified nucleobase is 5caC. In some embodiments, the modified nucleobase is dihydrouracil (DHU). In some embodiments, the antibody that recognizes the modified nucleobase in the DNA is used to distribute single-stranded DNA.
[0194] In some embodiments, partitioning is carried out by contacting the nucleic acid with the methyl-binding domain ("MBD") of a methyl-binding protein ("MBP"). In some such embodiments, the nucleic acid is contacted with the entire MBP. In some embodiments, the MBD is bound to 5-methylcytosine (5mC), and the MBP comprises the MBD and is referred herein interchangeably as a methyl-binding protein or methyl-binding domain protein. In some embodiments, the MBD is coupled to paramagnetic beads, such as Dynabeads® M-280 streptavidin, via a biotin linker. Partitioning into fractions having different degrees of methylation may be carried out by eluting the fractions by increasing the NaCl concentration.
[0195] In some embodiments, the bound DNA is eluted by contacting the antibody or MBD with a protease, such as proteinase K. This can be performed instead of, or in addition to, the elution step using NaCl discussed above.
[0196] Examples of agents that recognize the modified nucleobases intended herein include, but are not limited to, the following: (a) MeCP2 is a protein that preferentially binds to 5-methylcytosine rather than unmodified cytosine. (b) RPL26, PRP8, and the DNA mismatch repair protein MHS6 preferentially bind to 5-hydroxymethylcytosine rather than to unmodified cytosine. (c)FOXK1, FOXK2, FOXP1, FOXP4, and FOXI3 preferably bind to 5-formyl-cytosine more than unmodified cytosine (Iurlaro et al., Genome Biol. 14: R119 (2013)). (d) One or more methylated or modified nucleobases or their conversion products, e.g., antibodies specific to 5mC, 5caC, or DHU.
[0197] Generally, elution is a function of the number of methylated sites per molecule, with molecules having more methylation eluting under increasing salt concentrations. To elute DNA into distinct populations based on the degree of methylation, a series of elution buffers with progressively increasing NaCl concentrations can be used. Salt concentrations can range from approximately 100 nm to approximately 2500 mM NaCl. In one embodiment, the process results in three partitions. The molecules are brought into contact with a solution containing a molecule with a drug that recognizes a modified nucleobase, at a first salt concentration, which can bind to a capture site, e.g., streptavidin. At the first salt concentration, some populations of the molecules are bound to the drug, while others remain unbound. The unbound population can be separated as a "low-methylated" population. For example, the first partition enriched with the low-methylated form of DNA is the partition that remains unbound at lower salt concentrations, e.g., 100 mM or 160 mM. A second partition enriched with intermediate methylated DNA is eluted using an intermediate salt concentration, e.g., between 100 mM and 2000 mM. This is also separated from the sample. A third partition enriched with highly methylated DNA is eluted using a high salt concentration, e.g., at least about 2000 mM.
[0198] In some embodiments, the methods described herein further include a step of distributing at least one partial sample into a plurality of further partial samples. For example, if, after bisulfite conversion, the sample contains uracil-containing DNA, mC-containing DNA, and cytosine 5-methylene sulfonate (CMS)-containing DNA, the method may include a first distribution step in which the DNA of the sample is contacted with an agent that recognizes CMS, and a second distribution step in which the DNA of a second partial sample is contacted with an agent (e.g., an antibody) that recognizes mC. See Figure 3A. Such a sample may be prepared by subjecting the DNA containing mC and hmC to a bisulfite conversion that converts hmC to CMS and unmethylated C to U without affecting 5mC. In such embodiments, a first partial sample, a first further partial sample, and a second further partial sample are provided (where the first further partial sample and the second further partial sample together constitute a second partial sample), the first partial sample containing DNA with a higher proportion of CMS than the further partial sample, and the first further partial sample containing DNA with a higher proportion of mC than the second further partial sample. In such embodiments, sequencing the DNA of one or more (or all) further partial samples is considered equivalent to sequencing the DNA of the second partial sample.
[0199] In another example, if, after T4-βGT glycosylation and bisulfite conversion, the sample contains uracil-containing DNA, mC-containing DNA, and hmC or ghmC-containing DNA, the method may include a first partitioning step in which the DNA of the sample is contacted with an agent (e.g., an antibody) that recognizes hmC and ghmC, and a second partitioning step in which the DNA of a second partial sample is contacted with an agent that recognizes mC. See Figure 3B. Such a sample can be prepared by subjecting DNA containing 5mC and 5hmC to the T4-βGT glycosylation step and subsequent bisulfite conversion. In such embodiments, a first partial sample, a first further partial sample, and a second further partial sample are provided (where the first further partial sample and the second further partial sample together constitute a second partial sample), the first partial sample containing DNA having a higher proportion of hmC or ghmC than the further partial sample, and the first further partial sample containing DNA having a higher proportion of mC than the second further partial sample. In such embodiments, sequencing the DNA of one or more (or all) further partial samples is considered equivalent to sequencing the DNA of the second partial sample. C. Tagging of distribution
[0200] In some embodiments, two or more distributions, for example, each distribution, are differentially tagged. “Tagging” a DNA molecule is the procedure by which a tag is bound to or associated with a DNA molecule. The tag can be a molecule, such as a nucleic acid, that contains information that characterizes the molecule to which the tag is associated. For example, a molecule may have a sample tag (which identifies a molecule in one sample from a molecule in a different sample), a distribution tag (which identifies a molecule in one distribution from a molecule in a different distribution), or a molecular tag / molecular barcode / barcode (which identifies different molecules from each other (in both proprietary and non-proprietary tagging scenarios)). In certain embodiments, the tag may include one or a combination of barcodes. As used herein, the term “barcode” means, depending on the context, a nucleic acid molecule having a particular nucleotide sequence, or the nucleotide sequence itself. A barcode may have, for example, between 10 nucleotides and 100 nucleotides. The collection of barcodes may have degenerate sequences or sequences having a certain Hamming distance, if desired for a particular purpose. Therefore, for example, a molecular barcode may consist of a single barcode or a combination of two barcodes, each attached to a different end of a molecule. Furthermore, or alternatively, different sets of molecular barcodes or molecular tags may be used for different distributions and / or samples, such that the barcodes function as molecular tags through their individual sequences, and based on the set of members they are, they also function to identify the corresponding distribution and / or sample. Tags containing barcodes may be incorporated into an adapter or attached to an adapter in other ways. Among other methods, tags may be incorporated by ligation, overlap extension PCR.
[0201] The tagging strategy can be divided into an exclusive tagging strategy and a non-exclusive tagging strategy. In exclusive tagging, all or substantially all of the molecules in the sample carry different tags, such that reads can be assigned to the original molecules based on the tag information alone. Tags used in such methods are sometimes referred to as "exclusive tags". In non-exclusive tagging, different molecules in the same sample can carry the same tag, such that other information in addition to the tag information is used to assign sequence reads to the original molecules. Such information can include start and stop coordinates, coordinates to which the molecule is mapped, start or stop coordinates alone, etc. Tags used in such methods are sometimes referred to as "non-exclusive tags". Thus, it is not necessary to tag all molecules in the sample exclusively. This is sufficient to tag exclusively the molecules that fall within an identifiable class within the sample. Thus, molecules in different identifiable families can carry the same tag without loss of information about the identity of the tagged molecules.
[0202] In certain embodiments of non-exclusive tagging, the number of different tags used can be sufficient such that there is a very high probability (e.g., at least 99%, at least 99.9%, at least 99.99% or at least 99.999%) that all molecules in a particular group carry different tags. It should be noted that when barcodes are used as tags and the barcodes are attached, e.g., randomly, to both ends of the molecule, combinations of barcodes can together constitute a tag. This number in the item is a function of the number of molecules that come into the call. For example, a class can be all molecules that map to the same start-stop position on a reference genome. A class can be all molecules that map over a particular locus, e.g., a particular base or a particular region (e.g., up to 100 bases, or a gene, or an exon of a gene). In certain embodiments, the number z of different tags used to identify some of the molecules in a class exclusively is 2 * z, 3 * z, 4 * z, 5 * z, 6 * s[[ID=]] z, 7* z, 8 * z, 9 * z, 10 * z, 11 * z, 12 * z, 13 * z, 14 * z, 15 * z, 16 * z, 17 * z, 18 * z, 19 * z, 20 * z or 100 * Any of z (e.g., lower limit) and 100,000 * z, 10,000 * z, 1000 * z or 100 * It can be between any of z (for example, the upper limit).
[0203] For example, in a sample of approximately 5 ng to 30 ng of cell-free DNA, approximately 3,000 molecules are expected to be mapped to specific nucleotide coordinates, with molecules between approximately 3 and 10 having arbitrary start coordinates, sharing the same stop coordinate. Therefore, approximately 50 to 50,000 different tags (e.g., barcode combinations between approximately 6 and 220) may be sufficient to uniquely tag all such molecules. To uniquely tag all 3,000 molecules mapped across nucleotide coordinates, approximately 1 million to 20 million different tags would be required.
[0204] Generally, the assignment of unique or non-unique tag barcodes in a reaction is subject to U.S. Patent Applications No. 20010053519, No. 20030152490, No. 20110160078 and U.S. Patents No. 6,582,908 and No. 7,537,898 and U.S.
[0205] The method and system described in No. 9,598,731 are followed. Tags may be attached to the sample nucleic acid randomly or non-randomly.
[0206] In some embodiments, tagged nucleic acids are sequenced after being packed into a microwell plate. The microwell plate may have 96, 384, or 1536 microwells. In some cases, these are introduced in a expected ratio of unique tags to microwells. For example, unique tags may be packed so that more unique tags than approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, 100, 500, 1000, 5000, 10000, 50,000, 100,000, 500,000, 1,000,000, 10,000,000, 50,000,000 or 1,000,000,000 are packed per genomic sample. In some cases, unique tags may be packed so that approximately 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, 100, 500, 1000, 5000, 100,000, 500,000, 1,000,000, 10,000,000, 500,000, or fewer than 1,000,000,000 unique tags are packed per genome sample. In some cases, the average number of unique tags packed per sample genome is approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, 100, 500, 1000, 5000, 10000, 50,000, 100,000, 500,000, 1,000,000, 10,000,000, 50,000,000, or less than or more than 1,000,000,000 unique tags per genome sample.
[0207] A preferred form uses 20 to 50 different tags (e.g., barcodes) ligated to both ends of the target nucleic acid. For example, 35 different tags (e.g., barcodes) ligated to both ends of the target molecule create 35 × 35 permutations, which is equal to 1225 for 35 tags. Such a number of tags is sufficient for different molecules with the same start and end points to have a high probability (e.g., at least 94%, 99.5%, 99.99%, 99.999%) of receiving different combinations of tags. Other barcode combinations include any number between 10 and 500, e.g., approximately 15 × 15, approximately 35 × 35, approximately 75 × 75, approximately 100 × 100, approximately 250 × 250, and approximately 500 × 500.
[0208] In some cases, the unique tag may be a predetermined, random, or semi-random sequence oligonucleotide. In other cases, multiple barcodes may be used, and the barcodes do not necessarily need to be unique among them. In this example, the barcodes may be ligated to individual molecules such that the combination of the barcode and the sequence it can be ligated creates a unique sequence that can be tracked individually. As described herein, the detection of a non-unique barcode combined with sequence data at the start and end positions of the sequence reading may enable the assignment of a unique identity to a particular molecule. The length or number of base pairs of individual sequence readings may also be used to assign a unique identity to such molecules. Thereafter, as described herein, a fragment derived from a single strand of nucleic acid to which a unique identity has been assigned may enable the subsequent identification of fragments derived from the parent strand.
[0209] Tags may be used to label individual polynucleotide population distributions so as to correlate tags(one or more) to a particular distribution. Alternatively, tags may be used in embodiments of the invention that do not involve a distribution step. In some embodiments, a single tag may be used to label a particular distribution. In some embodiments, multiple different tags may be used to label a particular distribution. In embodiments where multiple different tags are used to label a particular distribution, the set of tags used to label one distribution may be easily differentiated from the set of tags used to label other distributions. In some embodiments, the tag may have additional functions, for example, it may be used to index a sample source, or as a unique molecular identifier (which may be used to improve the quality of sequencing data by differentiating sequencing errors from mutations, as described, for example, Kinde et al., Proc Nat'l Acad Sci USA 108: 9530-9535 (2011), Kou et al., PLoS ONE, 11: e0146638 (2016)), or as a non-unique molecular identifier, as described, for example, U.S. Patent No. 9,598,731. Similarly, in some embodiments, the tag may have additional functions, for example, it may be used to index a sample source, or as a non-unique molecular identifier (which may be used to improve the quality of sequencing data by differentiating sequencing errors from mutations).
[0210] In one embodiment, distribution tagging involves tagging the molecules in each distribution with a distribution tag. After the distributions are recombined (e.g., to reduce the number of sequencing runs required and avoid unnecessary costs) and the molecules are sequenced, the distribution tags identify the source distribution. In another embodiment, different distributions are tagged with different sets of molecular tags, for example, consisting of pairs of barcodes. In this method, each molecular barcode is useful not only for indicating a source distribution but also for identifying the molecules within the distribution. For example, a first set of 35 barcodes may be used to tag the molecules in a first distribution, and a second set of 35 barcodes may be used to tag the molecules in a second distribution.
[0211] In some embodiments, after distribution and tagging with distribution tags, molecules may be pooled for sequencing in a single run. In some embodiments, sample tags are attached to molecules, for example, in a step following the attachment and pooling of distribution tags. Sample tags can facilitate pooling materials generated from multiple samples for sequencing in a single sequencing run.
[0212] Alternatively, in some embodiments, the distribution tags may be correlated with the sample and the distribution. As a simple example, a first tag may indicate a first distribution of a first sample; a second tag may indicate a second distribution of a first sample; a third tag may indicate a first distribution of a second sample; and a fourth tag may indicate a second distribution of a second sample.
[0213] A tag can bind to a molecule that has already been distributed based on one or more features, but the final tagged molecule in the library may no longer possess those features. For example, a single-stranded DNA molecule may be distributed and tagged, but the final tagged molecule in the library is likely to be double-stranded. Similarly, DNA may be subjected to distribution based on different levels of methylation, but the tagged molecules derived from these molecules in the final library are likely to be unmethylated. Therefore, a tag bound to a molecule in the library typically exhibits features of the "parent molecule" from which the final tagged molecule originates, but does not necessarily exhibit features of the tagged molecule itself.
[0214] For example, barcodes 1, 2, 3, 4, etc., are used to tag and label molecules during the first distribution; barcodes A, B, C, D, etc., are used to tag and label molecules during the second distribution; and barcodes a, b, c, d, etc., are used to tag and label molecules during the third distribution. Differentially tagged distributions can be pooled before sequencing. Differentially tagged distributions can be sequenced separately or together in parallel in the same flow cell, for example, in an Illumina sequencer.
[0215] Following sequencing, analysis of reads to detect genetic variants may be performed at the per-distribution level as well as at the whole nucleic acid population level. Tags are used to sort reads from different distributions. Analysis may include in silico analysis to determine genetic and epigenetic variations (one or more of the following, such as methylation and chromatin structure) using sequence information, genomic coordinate length, coverage, and / or copy number. In some embodiments, higher coverage may correlate with higher nucleosome occupancy in genomic regions, while lower coverage may correlate with lower nucleosome occupancy or nucleosome-depleted regions (NDRs).
[0216] The distribution procedure may result in incomplete sorting of DNA molecules between partial samples. For example, a small number of molecules in the second partial sample may be highly modified (e.g., highly methylated), and / or a small number of molecules in the first partial sample may be unmodified or mostly unmodified (e.g., unmethylated or mostly unmethylated). Highly modified molecules in the second partial sample and unmodified or mostly unmodified molecules in the first partial sample are considered nonspecifically distributed. The method described herein includes steps that can reduce technical noise from nonspecifically distributed DNA, for example, by transforming certain bases so that the nonspecifically distributed DNA can be identified after sequencing, and / or by degrading it. Thus, the method described herein can provide improved sensitivity and / or more efficient analysis. D. Alternative methods for analyzing modified nucleic acids
[0217] In some embodiments, the adapter may be attached to the nucleic acid after it has been distributed, while in other embodiments, the adapter may be attached to the nucleic acid before it has been distributed. In some such methods, before distribution, the nucleic acid is subjected to a procedure that affects the first nucleobase in the DNA in such a way that it differs from the second nucleobase in the DNA, where the first nucleobase is a modified or unmodified nucleobase, and the second nucleobase is a modified or unmodified nucleobase that is different from the first nucleobase, and the first and second nucleobases have the same base pairing specificity.
[0218] In some embodiments, after a step of subjecting the sample to a procedure that affects the first nucleobase in the DNA in a manner different from that of a second nucleobase, and a step of distributing the sample into multiple subsamples, a first adapter is added to the nucleic acid by ligation to its 3' end, which may include ligation to single-stranded DNA. The adapter may be used, for example, as a priming site for second-strand synthesis using a universal primer and DNA polymerase. The second adapter may then be ligated to at least the 3' end of the second strand of a double-stranded molecule. In some embodiments, the first adapter contains an affinity tag, e.g., biotin, and the nucleic acid ligated to the first adapter is bound to a solid support (e.g., beads) which may contain a binding partner to the affinity tag, e.g., streptavidin. For further discussion of such procedures, see Gansauge et al., Nature Protocols 8:737-748 (2013). Commercially available kits for sequencing single-stranded nucleic acids and compatible library preparations, such as Swift Biosciences' Accel-NGS® Methyl-Seq DNA Library Kit, are available. In some embodiments, the nucleic acids are amplified after adapter ligation. In some embodiments, the nucleic acids of a partial sample are pooled after adapter ligation; amplification, if used, may be performed before or after the pooling step.
[0219] In some methods, a population of nucleic acids possessing varying degrees of modification (e.g., 0, 1, 2, 3, 4, 5 or more methyl groups per nucleic acid molecule) is brought into contact with an adapter before fractionation of the population, depending on the degree of modification. The adapter binds to either one or both ends of the nucleic acid molecules in the population.
[0220] Preferably, the adapter (whether added before or after distribution) contains a sufficient number of different tags to produce a low probability of a number of tag combinations, for example, 95, 99, or 99.9% of two nucleic acids having the same start and stop sites receive the same combination of tags. The adapter may contain the same or different primer binding sites, whether it has the same or different tags, but preferably the adapter contains the same primer binding site.
[0221] In some embodiments, after adapter binding, the nucleic acids are brought into contact with a drug that preferentially binds to nucleic acids containing the modification (e.g., such drugs previously described). The nucleic acids are then distributed into at least two partial samples, each containing a different degree of modification from the drug. For example, if the drug has affinity for nucleic acids containing the modification, nucleic acids that over-present the modification (compared to the median presentation in the population) will preferentially bind to the drug, while nucleic acids that under-present the modification will not bind to the drug or will elute more readily from it. The nucleic acids are then amplified from a primer that binds to the primer binding site in the adapter. After amplification, the different distributions may be subjected to further processing steps, which typically include further (e.g., clonal) amplification and parallel but separate sequence analysis. Sequence data from the different distributions may then be compared.
[0222] In another embodiment, the partition scheme may be carried out using the following exemplary procedure: The nucleic acid is subjected to a procedure that affects a first nucleobase in the DNA in such a way that it differs from a second nucleobase in the DNA, where the first nucleobase is a modified or unmodified nucleobase, and the second nucleobase is a modified or unmodified nucleobase different from the first nucleobase, and the first and second nucleobases have the same base pairing specificity. The nucleic acid is ligated at both ends to a Y-type adapter containing a primer binding site and a tag. The molecule is amplified. The amplified molecule is then fractionated by contact with an antibody that preferentially binds to 5-methylcytosine to produce two partitions. One partition contains the original molecule lacking methylation and the amplified copy with lost methylation. The other partition contains the original DNA molecule with methylation. The two partitions are then processed and sequenced separately, with further amplification of the methylated partition. Next, the sequence data of the two distributions can be compared. In this example, tags are not used to distinguish between methylated and unmethylated DNA, but are used to distinguish between different molecules within these distributions, so that it is possible to determine whether readings with the same start and stop points are based on the same molecule or different molecules.
[0223] This disclosure provides further methods for analyzing a population of nucleic acids in which at least a portion of the nucleic acid contains one or more modified cytosine residues, e.g., 5-methylcytosine and any other modifications previously described. In these methods, the nucleic acid molecule is subjected to a procedure that affects a first nucleobase in the DNA so that it differs from a second nucleobase in the DNA, wherein the first nucleobase contains a cytosine modified at position 5, and the second nucleobase contains an unmodified cytosine. This procedure may be a bisulfite treatment or another procedure that converts the unmodified cytosine to uracil. The nucleic acid subjected to the procedure is then distributed, and the partial sample of nucleic acid is then brought into contact with an adapter containing one or more cytosine residues modified at position 5C, e.g., 5-methylcytosine. Preferably, all cytosine residues in such adapter are also modified, or all such cytosines in the primer-binding region of the adapter are modified. The adapter binds to both ends of the nucleic acid molecule in the population. Preferably, the adapter contains a sufficient number of different tags to produce a low probability of a given number of tag combinations, for example, 95, 99, or 99.9% of two nucleic acids having the same start and stop sites receive the same tag combination. The primer binding sites in such an adapter may be the same or different, but are preferably the same. After binding to the adapter, the nucleic acid is amplified from the primers that bind to the primer binding sites of the adapter. The amplified nucleic acid is split into first and second aliquots. The first aliquot is assayed for sequence data with or without further processing. Thus, the sequence data for the molecules in the first aliquot is determined independently of the initial methylation state of the nucleic acid molecules. Only the nucleic acid molecules originally ligated to the adapter are amplified here (separate from their amplification product) because these nucleic acids retain cytosine in the primer binding sites of the adapter, while the amplification product loses methylation of these cytosine residues and undergoes conversion to uracil in bisulfite treatment. Thus, only the original molecules in the population, which are at least partially methylated, undergo amplification. After amplification, these nucleic acids are subjected to sequence analysis.A comparison of sequences determined from the first and second aliquots can, in particular, indicate which cytosines in the nucleic acid population were subjected to methylation.
[0224] Such analysis may be carried out using the following exemplary procedure. After distribution, the methylated DNA is ligated at both ends to a Y-type adapter containing a primer binding site and a tag. After the adapter is ligated, the DNA molecule is amplified. The amplified product is split into two aliquots for sequencing with or without conversion. The aliquot not subjected to conversion may be subjected to sequencing analysis with or without further processing. The other aliquot is subjected to a procedure that affects the first nucleobase in the DNA so that it differs from the second nucleobase in the DNA, with the first nucleobase containing cytosine modified at position 5 and the second nucleobase containing unmodified cytosine. This procedure may be bisulfite treatment or another procedure that converts the unmodified cytosine to uracil. When contacted with a primer specific to the original primer binding site, only the primer binding site protected by the cytosine modification can support amplification. Therefore, only the original molecule, and not copies from the first amplification, is subjected to further amplification. The further amplified molecules are then subjected to sequence analysis. The sequences from the two aliquots can then be compared. Similar to the separation scheme discussed above, the nucleic acid tag in the adapter is not used to distinguish between methylated and unmethylated DNA, but it is used to distinguish nucleic acid molecules within the same distribution. E. Enrichment / capture steps; amplification; adapter; barcode
[0225] In some embodiments, the methods disclosed herein include the step of capturing one or more sets of target regions of DNA, for example, cfDNA. Capture may be carried out using any suitable approach known in the art.
[0226] In some embodiments, the capture step includes contacting the DNA to be captured with a set of target-specific probes. The set of target-specific probes may have any of the features described herein for a set of target-specific probes, including but not limited to the embodiments shown above and the following sections relating to probes. The capture step may be performed on one or more partial samples prepared during the methods disclosed herein. In some embodiments, DNA is captured from at least a first or second partial sample, e.g., at least a first and a second partial sample. In some embodiments, the partial samples are differentially tagged (e.g., as described herein) and then pooled before being captured.
[0227] The capture step can be carried out using conditions appropriate for specific nucleic acid hybridization, which generally depend to some extent on the characteristics of the probe, such as its length and base composition. Those skilled in the art are familiar with appropriate conditions, taking into account the general knowledge in the art regarding nucleic acid hybridization. In some embodiments, a complex is formed between the target-specific probe and DNA.
[0228] In some embodiments, the methods described herein include a step of capturing multiple sets of target regions of cfDNA obtained from a test subject. The target regions include epigenetic target regions that may exhibit differences in methylation levels and / or fragmentation patterns depending on whether they originate from a tumor or healthy cells. The target regions also include sequence-variable target regions that may exhibit differences in sequence depending on whether they originate from a tumor or healthy cells. The capturing step generates a captured set of cfDNA molecules, and cfDNA molecules corresponding to the sequence-variable target region set are captured in a higher capture yield in the captured set of cfDNA molecules than cfDNA molecules corresponding to the epigenetic target region set. For further discussion of the capturing step, capture yield, and related embodiments, see WO2020 / 160414, which is incorporated herein by reference for all purposes.
[0229] In some embodiments, the method described herein includes the step of contacting cfDNA obtained from a test subject with a set of target-specific probes, the set of target-specific probes being configured to capture cfDNA corresponding to a sequence-variable target region set with a higher capture yield than cfDNA corresponding to an epigenetic target region set.
[0230] Since deeper sequencing depths may be required to analyze sequence-variable target regions with sufficient confidence or accuracy than those required for analyzing epigenetic target regions, capturing cfDNA corresponding to a set of sequence-variable target regions at a higher capture yield than the cfDNA corresponding to a set of epigenetic target regions may be beneficial. The volume of data required to determine fragmentation patterns (e.g., to test for disruption of transcription start sites or CTCF binding sites) or fragment abundance (e.g., in highly methylated and hypomethylated partitions) is generally smaller than the volume of data required to determine the presence or absence of cancer-related sequence mutations. Capturing target region sets at different yields may facilitate sequencing target regions to different depths of sequencing in the same sequencing run (e.g., using a pooled mixture and / or in the same sequencing cell).
[0231] In various embodiments, these methods further include, in accordance with the discussion herein, a step of sequencing the captured cfDNA to different degrees of sequencing depth for, for example, an epigenetic target region set and a sequence variable target region set.
[0232] In some embodiments, the complex of a target-specific probe and DNA is separated from the DNA that is not bound to the target-specific probe. For example, if the target-specific probe is covalently or acovalently bound to a solid support, a washing or aspiration step may be used to separate the unbound material. Alternatively, if the complex has chromatographic properties distinct from the unbound material (for example, if the probe contains a ligand that binds to a chromatography resin), chromatography may be used.
[0233] As will be discussed in detail elsewhere in this specification, a set of target-specific probes may include multiple sets, for example, probes for a set of sequence-variable target regions and probes for a set of epigenetic target regions. In some such embodiments, the capture step is performed simultaneously in the same container using probes for the sequence-variable target regions and probes for the epigenetic target regions, for example, the probes for the sequence-variable target regions and probes for the epigenetic target regions are in the same composition. This approach provides a relatively efficient workflow. In some embodiments, the concentration of probes for the sequence-variable target regions is higher than the concentration of probes for the epigenetic target regions.
[0234] Alternatively, the capture step may be performed using a sequence-variable target region probe set in a first container and an epigenetic target region probe set in a second container, or the contact step may be performed using a sequence-variable target region probe set at a first time point and in the first container, and using an epigenetic target region probe set at a second time point before or after the first time point. This approach allows for the preparation of separate first and second compositions containing captured DNA corresponding to the sequence-variable target region set and captured DNA corresponding to the epigenetic target region set. These compositions may be processed separately as desired (e.g., to fractionate based on methylation as described elsewhere herein) and may be recombined in appropriate proportions to provide material for further processing and analysis, e.g., sequencing.
[0235] In some embodiments, DNA is amplified. In some embodiments, amplification is performed before the capture step. In some embodiments, amplification is performed after the capture step.
[0236] In some embodiments, the adapter is contained within the DNA. This can be carried out in parallel with the amplification procedure, for example, by providing the adapter in the 5' portion of the primer, as described above. Alternatively, the adapter may be added by other approaches, such as ligation.
[0237] In some embodiments, a tag, which may or may contain a barcode, is included in the DNA. The tag can facilitate the identification of the nucleic acid's origin. For example, a barcode may be used to allow the identification of the origin (e.g., the target) from which the DNA originated after pooling multiple samples for parallel sequencing. This can be carried out in parallel with the amplification procedure, for example, by providing the barcode in the 5' portion of the primer, as described above. In some embodiments, the adapter and tag / barcode are provided by the same primer or primer set. For example, the barcode may be located on the 3' side of the adapter and on the 5' side of the target hybridization portion of the primer. Alternatively, the barcode may be added by other approaches, for example, by ligation together with the adapter in the same ligation substrate, if necessary.
[0238] Additional details relating to amplification, tagging, and barcodes, which can be combined to the extent possible using any of the embodiments described above or in the Introduction and Overview sections, are discussed in the following "General Features of the Method" section. F. Captured Set
[0239] In some embodiments, a captured set of DNA (e.g., cfDNA) is provided. With respect to the disclosed method, the captured set of DNA may be provided, for example, by performing a capture step after a distribution step, as described herein. The captured set may include DNA corresponding to a sequence variable target region set, an epigenetic target region set, or a combination thereof. In some embodiments, the amount of captured sequence variable target region DNA is greater than the amount of captured epigenetic target region DNA, when standardized with respect to differences in the size (footprint size) of the targeted region.
[0240] In some embodiments, the first set of target regions is captured from a first partial sample containing at least epigenetic target regions. The epigenetic target regions captured from the first partial sample may include hypermethylated variable target regions. In some embodiments, the hypermethylated variable target regions are CpG-containing regions in cfDNA derived from a healthy subject that are unmethylated or have low methylation (e.g., below-average methylation compared to bulk cfDNA). In some embodiments, the hypermethylated variable target regions are regions in healthy cfDNA that exhibit lower methylation than in at least one other tissue type. While we do not wish to be bound by any particular theory, cancer cells may shed more DNA into the bloodstream than healthy cells of the same tissue type. Therefore, the distribution of tissues from which cfDNA originates may change during cancer development. Thus, an increase in the level of hypermethylated variable target regions in the first partial sample may be an indicator of the presence of cancer (or, depending on the subject's medical history, recurrence).
[0241] In some embodiments, a second set of target regions is captured from a second partial sample containing at least an epigenetic target region. The epigenetic target region may include a hypomethylated variable target region. In some embodiments, the hypomethylated variable target region is a CpG-containing region in cfDNA derived from a healthy subject that is methylated or highly methylated (e.g., above-average methylation compared to bulk cfDNA). In some embodiments, the hypomethylated variable target region is a region in healthy cfDNA that exhibits higher methylation than in at least one other tissue type. While we do not wish to be bound by any particular theory, cancer cells may shed more DNA into the bloodstream than healthy cells of the same tissue type. Therefore, the distribution of tissues from which cfDNA originates may change during cancer development. Thus, an increase in the level of hypomethylated variable target regions in a second partial sample may be an indicator of the presence of cancer (or, depending on the subject's medical history, recurrence).
[0242] Alternatively, a first and second captured set may be provided, each containing DNA corresponding to a sequence-variable target region set and DNA corresponding to an epigenetic target region set, respectively. The first and second captured sets may be combined to provide a combined captured set.
[0243] In some embodiments, including the combined captured sets discussed above, the captured set containing DNA corresponding to the sequence variable target region set and DNA corresponding to the epigenetic target region set is at a higher concentration than the DNA corresponding to the epigenetic target region set, for example, 1.1 to 1.2 times higher, 1.2 to 1.4 times higher, 1.4 to 1.6 times higher, 1.6 to 1.8 times higher, 1.8 to 2.0 times higher, 2.0 to 2.2 times higher, and 2.2 to 2.4 times higher. 2.4 to 2.6 times higher concentration, 2.6 to 2.8 times higher concentration, 2.8 to 3.0 times higher concentration, 3.0 to 3.5 times higher concentration, 3.5 to 4.0 times, 4.0 to 4.5 times higher concentration, 4.5 to 5.0 times higher concentration, 5.0 to 5.5 times higher concentration, 5.5 to 6.0 times higher concentration, 6.0 to 6.5 times higher concentration, 6.5 to 7.0 times higher, 7.0 to 7.5 times higher concentration, 7.5 to 8.0 times higher concentration, 8.0 to 8.5 times higher concentration, 8.5 to 9.0 times higher concentration, 9.0 to 9.5 times higher concentration, 9.5 to 10.0 times higher concentration, 10 to 11 times higher concentration, 11 to 12 times higher concentration Concentrations may exist at 12-13 times higher, 13-14 times higher, 14-15 times higher, 15-16 times higher, 16-17 times higher, 17-18 times higher, 18-19 times higher, 19-20 times higher, 20-30 times higher, 30-40 times higher, 40-50 times higher, 50-60 times higher, 60-70 times higher, 70-80 times higher, 80-90 times higher, or 90-100 times higher. The degree of variation in concentration is the main cause of standardization regarding the footprint size of the target area, as discussed in the definition section. 1. Epigenetic target region set
[0244] The epigenetic target region set may include one or more types of target regions that are likely to differentiate DNA from neoplastic (e.g., tumor or cancer) cells from healthy cells, e.g., DNA from non-neoplastic circulating cells. Exemplary types of such regions are discussed in detail herein. The epigenetic target region set may also include one or more control regions, as described herein, for example.
[0245] In some embodiments, the epigenetic target region set has a footprint of at least 100 kbp, for example, at least 200 kbp, at least 300 kbp, or at least 400 kbp. In some embodiments, the epigenetic target region set has a footprint in the range of 100 to 20 Mbp, for example, 100 to 200 kbp, 200 to 300 kbp, 300 to 400 kbp, 400 to 500 kbp, 500 to 600 kbp, 600 to 700 kbp, 700 to 800 kbp, 800 to 900 kbp, 900 to 1,000 kbp, 1 to 1.5 Mbp, 1.5 to 2 Mbp, 2 to 3 Mbp, 3 to 4 Mbp, 4 to 5 Mbp, 5 to 6 Mbp, 6 to 7 Mbp, 7 to 8 Mbp, 8 to 9 Mbp, 9 to 10 Mbp, or 10 to 20 Mbp. In some embodiments, the epigenetic target region set has a footprint of at least 20 Mbp. a. Highly methylated variable target region
[0246] In some embodiments, the epigenetic target region set includes one or more hypermethylated variable target regions. Generally, a hypermethylated variable target region refers to a region where, for example, an increase in the observed level of methylation in a cfDNA sample indicates an increased likelihood that the sample (e.g., of cfDNA) contains DNA produced by neoplastic cells, e.g., tumor or cancer cells. For example, hypermethylation of promoters of tumor suppressor genes has been repeatedly observed. See, for example, Kang et al., Genome Biol. 18:53 (2017) and the references cited therein. In another example, as discussed above, a hypermethylated variable target region may include a region where the methylation in cancerous tissue is not necessarily different from that of DNA from healthy tissue of the same type, but the methylation is different (e.g., has more methylation) compared to typical cfDNA in a healthy subject. For example, if the presence of cancer results in increased cell death, e.g., apoptosis, of cells of the tissue type corresponding to cancer, such cancer may be detected using at least some of such hypermethylated variable target regions.
[0247] A comprehensive discussion of methylation-variable target regions in colorectal cancer is provided in Lam et al., Biochim Biophys Acta. 1866:106-20 (2016). These include VIM, SEPT9, ITGA4, OSM4, GATA4, and NDRG4. An exemplary set of hypermethylation-variable target regions based on colorectal cancer (CRC) studies is provided in Table 1. Many of these genes are likely to have cancer-related associations beyond colorectal cancer; for example, TP53 is widely recognized as a critically important tumor suppressor, and hypermethylation-based inactivation of this gene may be a common oncogenic mechanism. Table 1. Exemplary hypermethylated target regions based on CRC studies [Table 1-1] [Table 1-2]
[0248] In some embodiments, the highly methylated variable target region comprises several gene loci listed in Table 1, e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the gene loci listed in Table 1. For example, for each gene locus included as a target region, there may be one or more probes having a hybridization site that binds between the gene's transcription start site and the stop codon (the last stop codon for genes that are alternatively spliced), or within the gene's promoter region. In some embodiments, one or more probes bind within 300 bp, e.g., 200 or 100 bp, of the gene's transcription start site in Table 1.
[0249] Methylation-variable target regions in various types of lung cancer are, for example, described in: Ooki et al., Clin. Cancer Res. 23:7141-52 (2017); Belinksy, Annu. Rev. Physiol. 77:453-74 (2015); Hulbert et al., Clin. Cancer Res. 23:1998-2005 (2017); Shi et al., BMC Genomics 18:901 (2017); Schneider et al., BMC Cancer. 11:102 (2011); Lissa et al., Transl Lung Cancer Res 5(5):492-504 (2016); Skvortsova et al., Br. J. Cancer. 94(10):1492-1495 (2006); Kim et al., Cancer Res. 61:3419-3424 (2001);Furonaka et al., Pathology International 55:303-309 (2005);Gomes et al., Rev. Port. Pneumol. 20:20-30 (2014);Kim et al., Oncogene. 20:1765-70 (2001);Hopkins-Donaldson et al., Cell Death Differ. 10:356-64 (2003);Kikuchi et al., Clin. Cancer Res. 11:2954-61 (2005);Heller et al., Oncogene 25:959-968 (2006);Licchesi et al., Carcinogenesis. 29:895-904 (2008);Guo et al., Clin. Cancer Res. 10:7917-24 (2004);Palmisano et al., This is discussed in detail in Cancer Res. 63:4620-4625 (2003) and Toyooka et al., Cancer Res. 61:4556-4560, (2001).
[0250] A representative set of hypermethylation-variable target regions based on lung cancer research is provided in Table 2. Many of these genes are likely to have cancer-related associations beyond lung cancer; for example, Casp8 (caspase 8) is a key enzyme in programmed cell death, and hypermethylation-based inactivation of this gene may be a common oncogenic mechanism not limited to lung cancer. Furthermore, several genes appear in both Tables 1 and 2, demonstrating their universality. Table 2. Exemplary hypermethylation target regions based on lung cancer research. [Table 2]
[0251] Any of the above embodiments relating to the target regions identified in Table 2 may be combined with any of the above embodiments relating to the target regions identified in Table 1. In some embodiments, the highly methylated variable target region comprises a plurality of loci listed in Table 1 or Table 2, for example, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the loci listed in Table 1 or Table 2.
[0252] Additional hypermethylation target regions can be obtained, for example, from the Cancer Genome Atlas. Kang et al., Genome Biology 18:53 (2017) describe the construction of a stochastic method called CancerLocator using hypermethylation target regions derived from breast, colon, kidney, liver, and lung cancers. In some embodiments, the hypermethylation target regions may be specific to one or more types of cancer. Thus, in some embodiments, the hypermethylation target regions include one, two, three, four, or five subsets of hypermethylation target regions that collectively exhibit hypermethylation in one, two, three, four, or five of the breast, colon, kidney, liver, and lung cancers.
[0253] In some embodiments, when different epigenetic target regions are captured from the first and second partial samples, the epigenetic target region captured from the first partial sample includes a highly methylated variable target region. b. Low-methylation variable target regions
[0254] Global hypomethylation is a phenomenon commonly observed in various cancers. See, for example, Hon et al., Genome Res. 22:246-258 (2012) (breast cancer); Ehrlich, Epigenomics 1:239-259 (2009) (a review article focusing on the observation of hypomethylation in colon, ovarian, prostate, leukemia, hepatocyte, and cervical cancer). For example, regions, such as repeating elements, such as LINE1 elements, Alu elements, centromere tandem repeats, pericinochore tandem repeats, and satellite DNA, as well as intergenetic regions that are normally methylated in healthy cells, may show reduced methylation in tumor cells. Therefore, in some embodiments, a set of epigenetic target regions may include hypomethylated variable target regions, in which case the decrease in the observed level of methylation indicates an increased possibility that the sample (e.g., of cfDNA) contains DNA produced by neoplastic cells, e.g., tumor or cancer cells. In another example, as discussed above, hypomethylated variable target regions may include regions whose methylation in cancerous tissue is not necessarily different from that of healthy tissue DNA of the same type, but whose methylation is different (e.g., less methylated) compared to typical cfDNA in healthy subjects. For example, if the presence of cancer results in increased cell death, e.g., apoptosis, of cells of the tissue type corresponding to the cancer, such cancer may be detected using at least some of these hypomethylated variable target regions.
[0255] In some embodiments, the hypomethylated variable target regions include repetitive elements and / or intergenic regions. In some embodiments, the repetitive elements include 1, 2, 3, 4, or 5 of LINE1 elements, Alu elements, centromeric tandem repeats, pericentromeric tandem repeats, and / or satellite DNA.
[0256] Exemplary specific genomic regions showing cancer-related hypomethylation include nucleotides 8403565 - 8953708 and 151104701 - 151106035 of human chromosome 1. In some embodiments, the hypomethylated variable target regions overlap with or include one or both of these regions.
[0257] In some embodiments, when different epigenetic target regions are captured from the first and second partial samples, the epigenetic target regions captured from the second partial sample include hypomethylated variable target regions. In some embodiments, the epigenetic target regions captured from the second partial sample include hypomethylated variable target regions, and the epigenetic target regions captured from the first partial sample include hypermethylated variable target regions. c.CTCF binding region
[0258] CTCF is a DNA-binding protein that contributes to chromatin organization and often co-localizes with cohesin. Disruptions of CTCF binding sites have been reported in various different cancers. See, e.g., Katainen et al., Nature Genetics, doi:10.1038 / ng.3335, published online June 8, 2015; Guo et al., Nat. Commun. 9:1520 (2018). CTCF binding gives rise to recognizable patterns in cfDNA that can be detected, for example, by sequencing via fragment length analysis. Details regarding sequence-based fragment length analysis are provided in Snyder et al., Cell 164:57-68 (2016); WO2018 / 009723; and US20170211143A1, each of which is hereby incorporated by reference herein.
[0259] Thus, disruption of CTCF binding gives rise to variations in the fragmentation pattern of cfDNA. Accordingly, CTCF binding sites are one type of fragmentation variable target region.
[0260] There are many known CTCF binding sites. See, e.g., CTCFBSDB (CTCF Binding Site Database) available on the Internet at insulatordb.uthsc.edu / ; Cuddapah et al., Genome Res. 19:24-32 (2009); Martin et al., Nat. Struct. Mol. Biol. 18:708-14 (2011); Rhee et al., Cell. 147:1408-19 (2011). Each of these is incorporated by reference. Exemplary CTCF binding sites are present at nucleotides 56014955-56016161 on chromosome 8 and nucleotides 95359169-95360473 on chromosome 13.
[0261] Therefore, in some embodiments, the epigenetic target region set includes CTCF-binding regions. In some embodiments, the CTCF-binding regions include at least 10, 20, 50, 100, 200, or 500 CTCF-binding regions, or 10-20, 20-50, 50-100, 100-200, 200-500, or 500-1000 CTCF-binding regions, such as those described above or in one or more of the papers by Cuddapah et al., Martin et al., or Rhee et al. cited above.
[0262] In some embodiments, at least a portion of the CTCF site may be methylated or unmethylated, and the methylation status correlates with whether the cell is a cancer cell. In some embodiments, the epigenetic target region set includes regions at least 100 bp, at least 200 bp, at least 300 bp, at least 400 bp, at least 500 bp, at least 750 bp, and at least 1000 bp upstream and downstream of the CTCF binding site. d. Transcription initiation site
[0263] Transcription start sites can also exhibit disorder in neoplastic cells. For example, while hematopoietic lineages substantially contribute to cfDNA in healthy individuals, nucleosome organization at various transcription start sites in healthy cells may differ from nucleosome organization at those transcription start sites in neoplastic cells. This results in different cfDNA patterns that can be detected by sequencing, as commonly discussed in Snyder et al., Cell 164:57-68 (2016);WO2018 / 009723; and US20170211143A1. In another example, transcription start sites may not necessarily be epigenetically different in cancerous tissue compared to DNA from healthy tissue of the same type, but they may be epigenetically different (e.g., with respect to nucleosome organization) compared to typical cfDNA in healthy subjects. For example, if the presence of cancer results in increased cell death, e.g., apoptosis, in cells of the tissue type corresponding to cancer, such cancer can be detected using at least some of these differences in transcription start sites.
[0264] Therefore, disruption of the transcription start site also leads to variations in the fragmentation pattern of cfDNA. Thus, the transcription start site is also a type of fragmentation-variable target region.
[0265] Human transcription start sites are available online at dbtss.hgc.jp and are thus accessible from the DBTSS (Database of Human Transcription Start Sites) described in Yamashita et al., Nucleic Acids Res. 34 (Database issue): D86-D89 (2006), which is incorporated herein by reference.
[0266] Therefore, in some embodiments, the epigenetic target region set includes transcription start sites. In some embodiments, the transcription start sites include at least 10, 20, 50, 100, 200, or 500 transcription start sites, or 10-20, 20-50, 50-100, 100-200, 200-500, or 500-1000 transcription start sites, such as those listed in DBTSS. In some embodiments, at least a portion of the transcription start sites may be methylated or unmethylated, and the methylation status correlates with whether the cell is a cancer cell. In some embodiments, the epigenetic target region set includes regions at least 100 bp, at least 200 bp, at least 300 bp, at least 400 bp, at least 500 bp, at least 750 bp, and at least 1000 bp upstream and downstream of the transcription start site. e. Localized amplification
[0267] Localized amplification is a somatic mutation, but these can be detected by sequencing based on read frequency in a manner similar to approaches for detecting certain epigenetic changes, such as changes in methylation. Therefore, regions that may exhibit localized amplification in cancer may be included in a set of epigenetic target regions and may include one or more of AR, BRAF, CCND1, CCND2, CCNE1, CDK4, CDK6, EGFR, ERBB2, FGFR1, FGFR2, KIT, KRAS, MET, MYC, PDGFRA, PIK3CA, and RAF1. For example, in some embodiments, the set of epigenetic target regions includes at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 of the above targets. f. Methylation control region
[0268] To facilitate data validation, it may be useful to include control regions. In some embodiments, the epigenetic target region set includes a control region that is expected to be methylated or unmethylated in essentially all samples, regardless of whether the DNA originates from cancer cells or normal cells. In some embodiments, the epigenetic target region set includes a hypomethylated control region that is expected to be hypomethylated in essentially all samples. In some embodiments, the epigenetic target region set includes a hypermethylated control region that is expected to be hypermethylated in essentially all samples. 2. Variable-array target region set
[0269] In some embodiments, the sequence-variable target region set includes multiple regions known to undergo somatic mutation in cancer.
[0270] In some embodiments, a sequence-variable target region set targets multiple different genes or genomic regions ("Panel") selected such that a determined proportion of subjects with cancer exhibit a genetic variant or tumor marker in one or more different genes or genomic regions within the Panel. The Panel may be selected to limit the region to be sequenced to a fixed number of base pairs. The Panel may be selected to sequence a desired amount of DNA by adjusting the affinity and / or amount of the probe, for example, as described elsewhere herein. The Panel may be further selected to achieve a desired sequence reading depth. The Panel may be selected to achieve a desired sequence reading depth or sequence reading coverage for a given amount of base pairs to be sequenced. The Panel may be selected to achieve theoretical sensitivity, theoretical specificity, and / or theoretical precision for detecting one or more genetic variants in a sample.
[0271] Probes for detecting a panel of regions may include probes for detecting target genomic regions (hotspot regions) as well as nucleosome recognition probes (e.g., KRAS codons 12 and 13), and may be designed to optimize capture based on analysis of cfDNA coverage and fragment size variations influenced by nucleosome binding patterns and GC sequence composition. Regions used herein may also include non-hotspot regions optimized based on nucleosome location and GC model.
[0272] Examples of enumerations of target genomic locations can be found in Tables 3 and 4. In some embodiments, the sequence-variable target region set used in the methods of this disclosure includes at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65 or 70 of the genes in Table 3. In some embodiments, the sequence-variable target region set used in the methods of this disclosure includes at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65 or 70 of the SNVs in Table 3. In some embodiments, the sequence-variable target region set used in the methods of this disclosure includes at least 1, at least 2, at least 3, at least 4, at least 5 or 6 of the fusions in Table 3. In some embodiments, the sequence-variable target region set used in the methods of this disclosure includes at least one, at least two, or at least three portions of the indels in Table 3. In some embodiments, the sequence-variable target region set used in the methods of this disclosure includes at least five, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, or 73 portions of the genes in Table 4. In some embodiments, the sequence-variable target region set used in the methods of this disclosure includes at least five, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, or 73 of the SNVs in Table 4. In some embodiments, the sequence-variable target region set used in the methods of this disclosure includes at least one, at least two, at least three, at least four, at least five, or 6 of the fusions in Table 4.In some embodiments, the set of array-variable target regions used in the methods of the present disclosure includes at least a portion of at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, or 18 of the indels of Table 4. Each of these genomic positions of interest can be identified as a backbone region or a hotspot region for a given panel. An example of an enumeration of hotspot genomic positions of interest can be found in Table 5. In some embodiments, the set of array-variable target regions used in the methods of the present disclosure includes at least a portion of at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 of the genes of Table 5. Each hotspot genomic region is listed with several features including the associated gene, the chromosome on which it is present, the start and stop positions of the genome indicating the locus, the length of the locus in base pairs, the exons covered by the gene, and important features that a given genomic region of interest might attempt to capture (e.g., type of mutation). Table 3
Table 3
Table 4
Table 5-1
Table 5-2
Table 5-3
[0273] Furthermore, or separately, suitable target region sets are available from the literature. For example, Gale et al., PLoS One 13: e0194630 (2018), which is thus incorporated herein by reference, describes a panel of 35 cancer-related gene targets that may be used as part or all of a sequence-variable target region set. These 35 targets are AKT1, ALK, BRAF, CCND1, CDK2A, CTNNB1, EGFR, ERBB2, ESR1, FGFR1, FGFR2, FGFR3, FOXL2, GATA3, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, KIT, KRAS, MED12, MET, MYC, NFE2L2, NRAS, PDGFRA, PIK3CA, PPP2R1A, PTEN, RET, STK11, TP53, and U2AF1.
[0274] In some embodiments, the sequence-variable target region set includes at least 10, 20, 30, or 35 cancer-related genes, such as target regions derived from the cancer-related genes listed above.
[0275] In some embodiments, the sequence-variable target region set has a footprint of at least 50 kbp, for example, at least 100 kbp, at least 200 kbp, at least 300 kbp, or at least 400 kbp. In some embodiments, the sequence-variable target region set has a footprint in the range of 100 to 2000 kbp, for example, 100 to 200 kbp, 200 to 300 kbp, 300 to 400 kbp, 400 to 500 kbp, 500 to 600 kbp, 600 to 700 kbp, 700 to 800 kbp, 800 to 900 kbp, 900 to 1,000 kbp, 1 to 1.5 Mbp, or 1.5 to 2 Mbp. In some embodiments, the sequence-variable target region set has a footprint of at least 2 Mbp. G. Subject
[0276] In some embodiments, DNA (e.g., cfDNA) is obtained from a subject having cancer. In some embodiments, DNA (e.g., cfDNA) is obtained from a subject suspected of having cancer. In some embodiments, DNA (e.g., cfDNA) is obtained from a subject having a tumor. In some embodiments, DNA (e.g., cfDNA) is obtained from a subject suspected of having a tumor. In some embodiments, DNA (e.g., cfDNA) is obtained from a subject having a neoplasm. In some embodiments, DNA (e.g., cfDNA) is obtained from a subject suspected of having a neoplasm. In some embodiments, DNA (e.g., cfDNA) is obtained from a subject in remission from a tumor, cancer, or neoplasm (e.g., after chemotherapy, surgical resection, radiation, or a combination thereof). In any of the embodiments described above, the cancer, tumor, or neoplasm, or suspected cancer, tumor, or neoplasm, may be of the lung, colon, rectum, kidney, breast, prostate, or liver. In some embodiments, the cancer, tumor, or neoplasm, or suspected cancer, tumor, or neoplasm, may be of the lung. In some embodiments, the cancer, tumor, or neoplasm, or suspected cancer, tumor, or neoplasm, is of the colon or rectum. In some embodiments, the cancer, tumor, or neoplasm, or suspected cancer, tumor, or neoplasm, is of the breast. In some embodiments, the cancer, tumor, or neoplasm, or suspected cancer, tumor, or neoplasm, is of the prostate. In any of the embodiments described above, the subject may be a human subject. H. Pool the DNA from the first and second partial samples or from those partial samples.
[0277] In some embodiments, these methods include a step of preparing a pool containing at least a portion of the DNA from a second partial sample (also called a low-methylated partition) and at least a portion of the DNA from a first partial sample (also called a high-methylated partition). Target regions, for example, containing epigenetic target regions and / or sequence-variable target regions, may be captured from the pool. The step of capturing a set of target regions from at least a portion of the partial samples, as described elsewhere in this specification, encompasses a capture step performed on a pool containing DNA from the first and second partial samples. The step of amplifying the DNA in the pool may be performed before the step of capturing target regions from the pool. The capture step may have any of the features described elsewhere in this specification for the capture step.
[0278] In some embodiments, sequence-variable target regions are captured from a second portion of a second partial sample. The second portion of the second partial sample may contain some, most, substantially all, or all of the DNA from the second partial sample that was not included in the pool. Regions captured from the pool and regions captured from the second partial sample may be combined and analyzed in parallel.
[0279] Epigenetic target regions may exhibit differences in methylation levels and / or fragmentation patterns, depending on whether they originate from tumors or healthy cells, or what type of tissue they originate from, as discussed elsewhere herein. Sequence-variable target regions may exhibit differences in sequence, depending on whether they originate from tumors or healthy cells.
[0280] Analysis of epigenetic target regions from hypomethylated distributions may, in some applications, be less informative than analysis of sequence-variable target regions from highly methylated and hypomethylated distributions, as well as epigenetic target regions from highly methylated distributions. Therefore, in methods where sequence-variable target regions and epigenetic target regions are captured, the latter may be captured to a lower degree than one or more of the sequence-variable target regions from highly methylated and hypomethylated distributions, as well as epigenetic target regions from highly methylated distributions. For example, sequence-variable target regions may be captured from portions of hypomethylated distributions that are not pooled with highly methylated distributions, and a pool may be prepared that has some (e.g., most, substantially all, or all) DNA from highly methylated distributions and no or only some (e.g., a small amount) DNA from hypomethylated distributions. Such an approach can reduce or eliminate sequencing of epigenetic target regions from hypomethylated distributions, thereby reducing the amount of sequencing data sufficient for further analysis.
[0281] In some embodiments, including a small number of low-methylated DNA distributions in the pool facilitates the quantification of one or more epigenetic features (e.g., methylation or other epigenetic features discussed in detail elsewhere herein) on a relative basis.
[0282] In some embodiments, the pool may contain a small percentage of the DNA from the hypomethylated distribution, e.g., less than about 50% of the DNA from the hypomethylated distribution, e.g., less than 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5%, or equal to such percentages. In some embodiments, the pool contains about 5% to 25% of the DNA from the hypomethylated distribution. In some embodiments, the pool contains about 10% to 20% of the DNA from the hypomethylated distribution. In some embodiments, the pool contains about 10% of the DNA from the hypomethylated distribution. In some embodiments, the pool contains about 15% of the DNA from the hypomethylated distribution. In some embodiments, the pool contains about 20% of the DNA from the hypomethylated distribution.
[0283] In some embodiments, the pool contains a portion of the highly methylated distribution, which may be at least about 50% of the DNA of the highly methylated distribution. For example, the pool may contain at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the DNA of the highly methylated distribution. In some embodiments, the pool contains 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100% of the DNA of the highly methylated distribution. In some embodiments, the second pool contains all or substantially all of the highly methylated distribution.
[0284] In some embodiments, these methods include the step of preparing a first pool containing at least a portion of the DNA of the low-methylated distribution. In some embodiments, these methods include the step of preparing a second pool containing at least a portion of the DNA of the high-methylated distribution. In some embodiments, the first pool further contains a portion of the DNA of the high-methylated distribution. In some embodiments, the second pool further contains a portion of the DNA of the low-methylated distribution. In some embodiments, the first pool contains the majority of the DNA of the low-methylated distribution and, optionally, a small amount of the DNA of the high-methylated distribution. In some embodiments, the second pool contains the majority of the DNA of the high-methylated distribution and a small amount of the DNA of the low-methylated distribution. In some embodiments involving an intermediately methylated distribution, the second pool contains at least a portion of the DNA of the intermediately methylated distribution, for example, the majority of the DNA of the intermediately methylated distribution. In some embodiments, the first pool contains the majority of the DNA of the low-methylated distribution, and the second pool contains the majority of the DNA of the high-methylated distribution and the majority of the DNA of the intermediately methylated distribution.
[0285] In some embodiments, these methods include a step of capturing at least a first set of target regions from a first pool, for example, the first pool being as shown in any of the embodiments above. In some embodiments, the first set includes sequence-variable target regions. In some embodiments, the first set includes hypomethylation-variable target regions and / or fragmentation-variable target regions. In some embodiments, the first set includes sequence-variable target regions and fragmentation-variable target regions. In some embodiments, the first set includes sequence-variable target regions, hypomethylation-variable target regions and fragmentation-variable target regions. The step of amplifying the DNA in the first pool may be performed before this capture step. In some embodiments, the step of capturing a first set of target regions from the first pool includes a step of contacting the DNA in the first pool with a first set of target-specific probes. In some embodiments, the first set of target-specific probes includes target-binding probes specific to sequence-variable target regions. In some embodiments, the first set of target-specific probes includes target-binding probes specific to sequence-variable target regions, hypomethylation-variable target regions and / or fragmentation-variable target regions.
[0286] In some embodiments, these methods include a step of capturing a second set or multiple sets of target regions from a second pool, for example, the first pool being as shown in any of the embodiments above. In some embodiments, the second multiple includes epigenetic target regions, e.g., highly methylated variable target regions and / or fragmentation variable target regions. In some embodiments, the second multiple includes sequence variable target regions and epigenetic target regions, e.g., highly methylated variable target regions and / or fragmentation variable target regions. The step of amplifying the DNA in the second pool may be performed before this capture step. In some embodiments, the step of capturing a second multiple set of target regions from the second pool includes a step of contacting the DNA in the first pool with a second set of target-specific probes, the second set of target-specific probes including target-binding probes specific to sequence variable target regions and target-binding probes specific to epigenetic target regions. In some embodiments, the first set of target regions and the second set of target regions are not identical. For example, the first set of target regions may include one or more target regions that are not present in the second set of target regions. Or, furthermore, the second set of target regions may include one or more target regions that are not present in the first set of target regions. In some embodiments, at least one hypermethylation-variable target region is captured from the second pool but not from the first pool. In some embodiments, multiple hypermethylation-variable target regions are captured from the second pool but not from the first pool. In some embodiments, the first set of target regions includes sequence-variable target regions, and / or the second set of target regions includes epigenetic target regions. In some embodiments, the first set of target regions includes sequence-variable target regions and fragmentation-variable target regions; the second set of target regions includes epigenetic target regions, e.g., hypermethylation-variable target regions and fragmentation-variable target regions.In some embodiments, the first set of target regions includes sequence-variable target regions, fragmentation-variable target regions, and low-methylation-variable target regions; the second set of target regions includes epigenetic target regions, such as high-methylation-variable target regions and fragmentation-variable target regions.
[0287] In some embodiments, the first pool comprises the majority of the DNA for the low-methylated distribution and a portion (e.g., about half) of the DNA for the high-methylated distribution, and the second pool comprises a portion (e.g., about half) of the DNA for the high-methylated distribution. In some such embodiments, the first set of target regions comprises sequence-variable target regions, and / or the second set of target regions comprises epigenetic target regions. The sequence-variable target regions and / or epigenetic target regions may be as shown in any of the embodiments described elsewhere herein. I. Sequence determination
[0288] Generally, sample nucleic acids adjacent to an adapter can be subjected to sequencing with or without prior amplification. Sequencing methods include, for example, Sanger sequencing, high-throughput sequencing, pyrosequencing, synthesis sequencing, single-molecule sequencing, nanopore sequencing, semiconductor sequencing, ligation sequencing, hybridization sequencing, digital gene expression (Helicos), next-generation sequencing (NGS), synthetic single-molecule sequencing (SMSS) (Helicos), massively parallel sequencing, clonal single-molecule array (Solexa), shotgun sequencing, Ion Torrent, Oxford Nanopore, Roche Genia, Maxim-Gilbert sequencing, primer walking, and sequencing using PacBio, SOLiD, Ion Torrent, or Nanopore platforms. Sequencing reactions can be carried out in various sample processing units, which may be multiple lanes, multiple channels, multiple wells, or other means of processing multiple sample sets substantially simultaneously. Sample processing units may also include multiple sample chambers capable of processing multiple runs simultaneously.
[0289] The sequencing reaction may be performed on one or more forms of nucleic acids, of which at least one is known to contain markers for cancer or other diseases. The sequencing reaction may also be performed on any nucleic acid fragment present in the sample. In some embodiments, genome sequence coverage may be 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9%, or less than 100%. In some embodiments, the sequencing reaction may provide sequence coverage of at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, or 80% of the genome. Sequence coverage may be performed on at least 5, 10, 20, 70, 100, 200, or 500 different genes, or at most 5000, 2500, 1000, 500, or 100 different genes.
[0290] Simultaneous sequencing reactions can be performed using multiple sequencing. In some cases, cell-free nucleic acids can be sequenced in at least 1,000, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 50,000, and 100,000 sequencing reactions. In other cases, cell-free nucleic acids can be sequenced in fewer than 1,000, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 50,000, and 100,000 sequencing reactions. Sequencing reactions can be performed sequentially or simultaneously. Subsequent data analysis can be performed on all or some of the sequencing reactions. In some cases, data analysis may be performed on sequencing reactions with at least 1,000, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 50,000, and 100,000 sequences. In other cases, data analysis may be performed on sequencing reactions with fewer than 1,000, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 50,000, and 100,000 sequences. An example read depth is 1,000 to 50,000 reads per locus (base pair). 1. Differential depth of sequence determination
[0291] In some embodiments, nucleic acids corresponding to sequence-variable target region sets are sequenced to a deeper sequencing depth than nucleic acids corresponding to epigenetic target region sets. For example, the sequencing depth for nucleic acids corresponding to sequence variant target region sets may be at least 1.25 times, 1.5 times, 1.75 times, 2 times, 2.25 times, 2.5 times, 2.75 times, 3 times, 3.5 times, 4 times, 4.5 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 11 times, 12 times, 13 times, 14 times, or 15 times deeper than the sequencing depth for nucleic acids corresponding to epigenetic target region sets, or 1.2 The sequencing depth may be 5 to 1.5 times, 1.5 to 1.75 times, 1.75 to 2 times, 2 to 2.25 times, 2.25 to 2.5 times, 2.5 to 2.75 times, 2.75 to 3 times, 3 to 3.5 times, 3.5 to 4 times, 4 to 4.5 times, 4.5 to 5 times, 5 to 5.5 times, 5.5 to 6 times, 6 to 7 times, 7 to 8 times, 8 to 9 times, 9 to 10 times, 10 to 11 times, 11 to 12 times, 13 to 14 times, 14 to 15 times, or 15 to 100 times deeper. In some embodiments, the sequencing depth is at least 2 times deeper. In some embodiments, the sequencing depth is at least 5 times deeper. In some embodiments, the sequencing depth is at least 10 times deeper. In some embodiments, the sequencing depth is 4 to 10 times deeper. In some embodiments, the sequencing depth is 4 to 100 times deeper. Each of these embodiments refers to the extent to which the nucleic acids corresponding to the sequence-variable target region set are sequenced to a deeper sequencing depth than the nucleic acids corresponding to the epigenetic target region set.
[0292] In some embodiments, the captured cfDNA corresponding to the sequence variable target region set and the captured cfDNA corresponding to the epigenetic target region set are sequenced in parallel, for example, in the same sequencing cell (e.g., a flow cell of an Illumina sequencer), and / or in the same composition which may be a pooled composition resulting from recombining separately captured sets, or a composition obtained by capturing the cfDNA corresponding to the sequence variable target region set and the captured cfDNA corresponding to the epigenetic target region set in the same container. J.Analysis
[0293] In some embodiments, the methods described herein include the step of identifying the presence of DNA produced by a tumor (or neoplastic cells or cancer cells).
[0294] The methods of the present invention may be used to diagnose a condition in a subject, particularly the presence of cancer; to characterize a condition (e.g., to stage cancer or determine cancer heterogeneity); to monitor the condition's response to treatment; and to determine the prognostic risk of developing a condition or a subsequent course of the condition. This disclosure may also be useful in determining the effectiveness of a particular treatment option. A successful treatment option may increase the amount of copy number variation or rare mutations detected in the subject's blood, as a successful treatment can lead to more cancer deaths and DNA shedding. In other cases, this may not occur. In another case, perhaps a particular treatment option can be correlated over time with the genetic profile of the cancer. This correlation may be useful in selecting a treatment.
[0295] Furthermore, if the cancer is observed to be in remission after treatment, the method of the present invention may be used to monitor residual disease or disease recurrence.
[0296] The types and number of cancers that may be detected may include blood cancers, brain cancers, lung cancers, skin cancers, nasal cancers, throat cancers, liver cancers, bone cancers, lymphomas, pancreatic cancers, skin cancers, intestinal cancers, rectal cancers, thyroid cancers, bladder cancers, kidney cancers, oral cancers, gastric cancers, solid tumors, heterogeneous tumors, and homogeneous tumors. Cancer type and / or stage may be detected from genetic variations, including mutations, rare mutations, indels, copy number variations, transversions, translocations, inversions, deletions, aneuploidy, partial aneuploidy, polyploidy, chromosomal instability, chromosomal structural alterations, gene fusions, chromosome fusions, gene truncations, gene amplifications, gene duplications, chromosomal damage, DNA damage, abnormal changes in the chemical modification of nucleic acids, abnormal changes in epigenetic patterns, and abnormal changes in 5-methylcytosine of nucleic acids.
[0297] Genetic data can also be used to characterize specific forms of cancer. Cancers are often heterogeneous in both composition and staging. Genetic profile data can enable the characterization of specific subtypes of cancer, which may be important in the diagnosis or treatment of that particular subtype. This information can also provide subjects or practitioners with clues about the prognosis of a particular type of cancer, enabling either the subject or practitioner to adapt treatment options as the disease progresses. Some cancers may progress, becoming more aggressive and genetically unstable. Other cancers may remain benign, inactive, or dormant. The systems and methods of this disclosure may be useful in determining disease progression.
[0298] Furthermore, the methods of this disclosure may be used to characterize heterogeneity of an abnormal condition in a subject. Such methods may include, for example, a step of generating a genetic profile of extracellular polynucleotides derived from the subject, the genetic profile including multiple data resulting from the analysis of copy number variations and rare mutations. In some embodiments, the abnormal condition is cancer. In some embodiments, the abnormal condition may result in a heterogeneous genomic population. In the example of cancer, it is known that some tumors contain tumor cells at different stages of cancer. In other examples, the heterogeneity may include multiple lesions of the disease. Again, in the example of cancer, multiple tumor lesions may be present, perhaps in this case one or more lesions being the result of metastasis spreading from the primary site.
[0299] The methods of the present invention can be used to generate or profile a fingerprint or set of data, which is the sum of genetic information derived from different cells in heterogeneous diseases. This set of data may include, alone or in combination, analyses of copy number variations, epigenetic variations, and mutations.
[0300] The methods of the present invention may be used to diagnose, prognose, monitor, or observe cancer or other diseases. In some embodiments, the methods herein do not involve diagnosing, prognosing, or monitoring a fetus, and therefore do not relate to non-invasive prenatal testing. In other embodiments, these methodologies may be used in pregnant subjects to diagnose, prognose, monitor, or observe cancer or other diseases in prenatal subjects whose DNA and other polynucleotides can co-circulate with maternal molecules.
[0301] An exemplary method for molecular tag identification of a distributed library via NGS, which includes the step of subjecting the sample to a procedure that affects the first nucleobase in the DNA so that it is different from the second nucleobase in the sample's DNA, is as follows: 1. The extracted DNA sample (e.g., plasma DNA extracted from a human sample, as required for target capture as described herein) is subjected to any of the procedures described herein that affect the first nucleobase in the DNA in a manner different from the second nucleobase in the DNA. 2. Physical distribution of DNA samples using methyl-binding antibodies to protect all distributions from processes for downstream processing. 3. Parallel application of differential molecular tags and adapter sequences enabling NGS to each partition. For example, highly methylated, residually methylated ("wash"), and hypomethylated partitions are ligated with NGS-adapters along with molecular tags. 4. Recombine all molecularly tagged partitions and subsequently amplify them using adapter-specific DNA primer sequences. 5. Capture / hybridization of a recombined and amplified total library that targets the desired genomic region (e.g., cancer-specific genetic variants and differentially methylated regions). 6. Add sample tags and re-amplify the captured DNA library. Different samples are pooled and assayed in multiple sequences on an NGS instrument. 7. Bioinformatics analysis of NGS data, in which molecular tags are used to identify unique molecules and for the deconvolution of the sample into differentially MBD-distributed molecules. This analysis can yield information about relevant 5-methylcytosine for genomic regions, in parallel with standard gene sequencing / variant detection.
[0302] In some embodiments of the methods described herein, including but not limited to those described above, the molecular tag consists of a procedure that affects the first nucleobase in the DNA in a way that is different from the second nucleobase in the DNA, for example, a nucleotide that is not modified by any of the procedures described herein (e.g., if the procedure is a bisulfite conversion or any other conversion that does not affect mC, mC together with A, T, and G; if the procedure is a conversion that does not affect hmC, hmC together with A, T, and G; etc.). In some embodiments of the methods described herein, including but not limited to those described above, the molecular tag does not contain a nucleotide that is modified by any of the procedures described herein, including a procedure that affects the first nucleobase in the DNA in a way that is different from the second nucleobase in the DNA (e.g., if the procedure is a bisulfite conversion or any other conversion that affects C, the tag does not contain unmodified C; if the procedure is a conversion that affects mC, the tag does not contain mC; if the procedure is a conversion that affects hmC, the tag does not contain hmC; etc.). Generally, procedures that affect the first nucleobase in the DNA in a way that distinguishes it from the second nucleobase in the DNA may be performed before the step of parallel application of differential molecular tags and adapter sequences that enable NGS to each partition. K. Exemplary Workflow
[0303] Exemplary workflows for distribution and library preparation are provided herein. A description of steps (e.g., performed before distribution) for subjecting a sample to procedures that affect the first nucleobase in the DNA to be different from the second nucleobase in the sample's DNA is provided above and in the examples. In some embodiments, some or all features of the distribution and library preparation workflows may be used in combination. 1.Distribution
[0304] In some embodiments, a monoclonal antibody against 5-methylcytidine (5mC) is used to purify methylated DNA. The DNA is denatured, for example, at 95°C to obtain single-stranded DNA fragments. Washing after incubation with protein G coupled to standard beads or magnetic beads, and with the anti-5mC antibody, is used to immunoprecipitate the antibody-bound DNA. Such DNA can then be eluted. The partitions may contain unprecipitated DNA, and one or more partitions may be eluted from the beads.
[0305] In some embodiments, sample DNA (e.g., between 5 ng and 200 ng) is mixed with methyl-binding domain (MBD) buffer and magnetic beads conjugated with MBD protein, and incubated overnight. Methylated DNA (highly methylated DNA) binds to the MBD protein on the magnetic beads during this incubation. Unmethylated DNA (lowly methylated DNA) or less methylated DNA (intermediately methylated) is removed by washing from the beads with a buffer containing progressively increasing concentrations of salt. For example, one, two, or more fractions containing unmethylated, lowly methylated, and / or intermediately methylated DNA may be obtained from such washing. Finally, a high-salt buffer is used to elute strongly methylated DNA (highly methylated DNA) from the MBD protein. In some embodiments, these washings result in three partitions of DNA with progressively increasing levels of methylation (lowly methylated partition, intermediately methylated fraction, and highly methylated partition).
[0306] In some embodiments, the DNA is desalted and concentrated in the preparation for the enzymatic step of library preparation. 2. Library preparation
[0307] In some embodiments (e.g., after enriching the DNA during distribution), the distributed DNA is made ligable by, for example, extending the terminal overhangs of the DNA molecules, adding adenosine residues to the 3' end of the fragments, and phosphorylating the 5' end of each DNA fragment. DNA ligase and adapters are added to ligate each distributed DNA molecule with the adapter at each end. These adapters contain distribution tags (e.g., non-random, non-unique barcodes) that are identifiable from the distribution tags in adapters used in other distributions. Two, three (or more) distributions are then pooled together and amplified (e.g., by PCR using primers specific to the adapters).
[0308] After PCR, the amplified DNA may be purified and enriched before enrichment. The amplified DNA is brought into contact with a collection of probes described herein that target a specific region of interest (which may be, for example, biotinylated RNA probes). The mixture is incubated, for example, in a salt buffer, for example, overnight. The probes are captured (for example, using streptavidin magnetic beads) and separated from the uncaptured amplified DNA by, for example, a series of salt washes, thereby enriching the sample. After enrichment, the enriched sample is amplified by PCR. In some embodiments, the PCR primers contain a sample tag, thereby incorporating the sample tag into the DNA molecule. In some embodiments, DNA from different samples is pooled together and then multiplexed using, for example, an Illumina NovaSeq sequencer. III. Additional features of a particular disclosed method A. Sample
[0309] A sample may be any biological sample isolated from the subject. A sample may be a body sample. Samples may include body tissues, such as known or suspected solid tumors, whole blood, platelets, serum, plasma, feces, red blood cells, white blood cells or leucocytes, endothelial cells, tissue biopsies, cerebrospinal fluid, synovial fluid, lymph, ascites, interstitial or extracellular fluid, fluid in the intercellular space including gingival crevicular exudate, bone marrow, pleural fluid, cerebrospinal fluid, saliva, mucus, sputum, semen, sweat, and urine. Preferably, the sample is a body fluid, in particular blood and its fractions, as well as urine. The sample may be in the form originally isolated from the subject, or it may have been subjected to further processing to remove or add components, such as cells, or to enrich one component with another. Therefore, preferred body fluids for analysis are plasma or serum containing cell-free nucleic acids. The sample may be isolated from or obtained from the subject and transported to the site of sample analysis. Samples may be stored and shipped at a preferred temperature, e.g., room temperature, 4°C, -20°C, and / or -80°C. Samples may be isolated from or obtained from the subject at the site of sample analysis. Subjects may be humans, mammals, animals, companion animals, service animals, or pets. Subjects may have cancer. Subjects may not have cancer or detectable cancer symptoms. Subjects may have been treated with one or more cancer treatments, e.g., chemotherapy, antibodies, vaccines, or biologics. Subjects may be in remission. Subjects may or may not be diagnosed as susceptible to cancer or any cancer-related genetic mutation / disorder.
[0310] The volume of plasma may depend on the desired reading depth for the region to be sequenced. Exemplary volumes are 0.4–40 ml, 5–20 ml, and 10–20 ml. For example, the volume could be 0.5 mL, 1 mL, 5 mL, 10 mL, 20 mL, 30 mL, or 40 mL. The volume of the sampled plasma could be 5–20 mL.
[0311] The sample may contain various amounts of nucleic acids, including the genome equivalent. For example, a sample of about 30 ng of DNA may contain about 10,000 (10 4 In the case of haploid human genome equivalents and cfDNA, approximately 200 billion (2 × 10⁻¹⁶). 11 It may contain ) individual polynucleotide molecules. Similarly, a sample of about 100 ng of DNA may contain about 30,000 haploid human genome equivalents, and in the case of cfDNA, about 600 billion individual molecules.
[0312] The sample may contain nucleic acids from different sources, for example, from cells and cell-free cells of the same subject, or from cells and cell-free cells of different subjects. The sample may contain nucleic acids that carry mutations. For example, the sample may contain DNA that carries germline mutations and / or somatic mutations. Germline mutations refer to mutations present in the germline DNA of the subject. Somatic mutations refer to mutations originating from somatic cells of the subject, for example, cancer cells. The sample may contain DNA that carries cancer-related mutations (e.g., cancer-related somatic mutations). The sample may contain epigenetic variants (i.e., chemical or protein modifications), which are associated with the presence of genetic variants, for example, cancer-related mutations. In some embodiments, the sample contains epigenetic variants associated with the presence of genetic variants, and the sample does not contain those genetic variants.
[0313] Exemplary amounts of cell-free nucleic acids in the sample before amplification range from approximately 1 fg to approximately 1 μg, for example, 1 pg to 200 ng, 1 ng to 100 ng, and 10 ng to 1000 ng. For example, the amount could be up to approximately 600 ng, up to approximately 500 ng, up to approximately 400 ng, up to approximately 300 ng, up to approximately 200 ng, up to approximately 100 ng, up to approximately 50 ng, or up to approximately 20 ng of cell-free nucleic acid molecules. The amount could be at least 1 fg, at least 10 fg, at least 100 fg, at least 1 pg, at least 10 pg, at least 100 pg, at least 1 ng, at least 10 ng, at least 100 ng, at least 150 ng, or at least 200 ng of cell-free nucleic acid molecules. The amount may be up to 1 femtogram (fg), 10 fg, 100 fg, 1 picogram (pg), 10 pg, 100 pg, 1 ng, 10 ng, 100 ng, 150 ng, or 200 ng of cell-free nucleic acid molecules. The method may include obtaining 1 femtogram (fg) to 200 ng.
[0314] Cell-free nucleic acids are nucleic acids that are neither contained within cells nor otherwise bound to cells, or in other words, nucleic acids that remain in a sample after intact cells have been removed. Cell-free nucleic acids include DNA, RNA, and hybrids thereof, which may contain genomic DNA, mitochondrial DNA, siRNA, miRNA, circulating RNA (cRNA), tRNA, rRNA, nucleolar small RNA (snoRNA), Piwi-interacting RNA (piRNA), long non-coding RNA (long ncRNA), or fragments of any of these. Cell-free nucleic acids may be double-stranded, single-stranded, or hybrids thereof. Cell-free nucleic acids may be released into body fluids via secretion or cell death processes, such as cell necrosis and apoptosis. Some cell-free nucleic acids, such as circulating tumor DNA (ctDNA), are released into body fluids from cancer cells. Others are released from healthy cells. In some embodiments, cfDNA is cell-free embryonic DNA (cffDNA). In some embodiments, cell-free nucleic acids are produced by tumor cells. In some embodiments, cell-free nucleic acids are produced by a mixture of tumor cells and non-tumor cells.
[0315] Cell-free nucleic acids exhibit an exemplary size distribution of approximately 100–500 nucleotides, with molecules of 110–230 nucleotides accounting for about 90% of the molecules, the mode being approximately 168 nucleotides, and a second smaller peak in the range of 240–440 nucleotides.
[0316] Cell-free nucleic acids can be isolated from body fluids via a fractionation or partitioning step, in which the cell-free nucleic acids found in solution are separated from intact cells and other insoluble components of the body fluid. Partitioning may involve techniques such as centrifugation or filtration. Alternatively, cells in the body fluid may be lysed, and cell-free and cellular nucleic acids may be processed together. Generally, after buffer addition and washing steps, nucleic acids may be precipitated with alcohol. Further cleansing steps, such as silica-based columns, may be used to remove impurities or salts. Nonspecific bulk carrier nucleic acids for bisulfite sequencing, hybridization, and / or ligation, such as C1 DNA, DNA, or proteins, may be added through the reaction in certain aspects of the procedure, e.g., to optimize yield.
[0317] After such processing, the sample may contain various forms of nucleic acids, including double-stranded DNA, single-stranded DNA, and single-stranded RNA. In some embodiments, single-stranded DNA and RNA may be converted to double-stranded forms, which are then included in subsequent processing and analysis steps.
[0318] Double-stranded DNA molecules in a sample, and single-stranded nucleic acid molecules converted to double-stranded DNA molecules, can be ligated to an adapter at either one or both ends. Typically, double-stranded molecules are blunt-ended by treatment with a polymerase having 5'-3' polymerase and 3'-5' exonuclease (or proofreading function) in the presence of all four standard nucleotides. Klenow large fragment and T4 polymerase are examples of suitable polymerases. The blunt-ended DNA molecules can be ligated with an adapter that is at least partially double-stranded (e.g., a Y-type or bell-type adapter). Alternatively, complementary nucleotides can be added to the blunt ends of the sample nucleic acid and the adapter to facilitate ligation. Both blunt-end ligation and sticky-end ligation are contemplated herein. In blunt-end ligation, both the nucleic acid molecule and the adapter tag have blunt ends. In sticky-end ligation, typically the nucleic acid molecule has an "A" overhang, and the adapter has a "T" overhang. B. Amplification
[0319] The sample nucleic acid adjacent to the adapter can be amplified by PCR and other amplification methods. Amplification is typically primed by a primer that binds to the primer binding site in the adapter adjacent to the DNA molecule being amplified. Amplification methods may include denaturation, annealing, and extension cycles resulting from thermocycling, or they may be isothermal in transcription-mediated amplification. Other amplification methods include ligase chain reaction, strand displacement amplification, nucleic acid sequence-based amplification, and auto-persistent sequence-based replication.
[0320] In some embodiments, the method of the present invention performs dsDNA ligation with a T-tailed adapter and a C-tailed adapter, resulting in amplification of at least 50, 60, 70, or 80% of the double-stranded nucleic acid before ligation to the adapter. Preferably, the method of the present invention increases the amount or number of amplified molecules by at least 10, 15, or 20% compared to a control method performed with a T-tailed adapter alone. C. Bait set; capture section
[0321] As discussed above, nucleic acids in a sample may be subjected to a capture step in which molecules having a target sequence are captured for subsequent analysis. Target capture may involve the use of a bait set containing an oligonucleotide bait labeled with a capture moiety, e.g., biotin or other examples noted below. The probe may have a sequence selected to tile across a region, e.g., a panel of genes. In some embodiments, the bait set may have higher and lower capture yields for a set of target regions, e.g., a sequence-variable target region set and an epigenetic target region set, as discussed elsewhere herein. Such a bait set is combined with the sample under conditions that allow hybridization of the target molecule with the bait. The captured molecules are then isolated using a capture moiety, e.g., a biotin capture moiety with bead-based streptavidin. Such a method is further described, for example, in U.S. Patent No. 9,850,523, issued December 26, 2017, which is thus incorporated herein by reference.
[0322] The capture portion includes, but is not limited to, biotin, avidin, streptavidin, nucleic acids containing a specific nucleotide sequence, haptens recognized by antibodies, and magnetically attractable particles. The extraction portion may be a binding pair, e.g., a member of a biotin / streptavidin or hapten / antibody. In some embodiments, the capture portion bound to the analyte is captured by its binding pair bound to an isolateable portion, e.g., a magnetically attractable particle, or a larger particle that can be settled via centrifugation. The capture portion may be any type of molecule that enables affinity separation of nucleic acids possessing the capture portion from nucleic acids lacking the capture portion. Exemplary capture portions include biotin, which enables affinity separation by binding to streptavidin linked to or linkable to a solid phase, or oligonucleotides, which enable affinity separation by binding to complementary oligonucleotides linked to or linkable to a solid phase. D. Collection of target-specific probes
[0323] In some embodiments, target-specific probe collection is used in the method described herein. In some embodiments, target-specific probe collection includes target-binding probes specific to sequence-variable target region sets and target-binding probes specific to epigenetic target region sets. In some embodiments, the capture yield of target-binding probes specific to sequence-variable target region sets is higher (e.g., at least twice as high) than the capture yield of target-binding probes specific to epigenetic target region sets. In some embodiments, target-specific probe collection is configured to have a capture yield specific to sequence-variable target region sets that is higher (e.g., at least twice as high) than its capture yield specific to epigenetic target region sets.
[0324] In some embodiments, the capture yield of target-binding probes specific to sequence-variable target region sets is at least 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 times higher than the capture yield of target-binding probes specific to epigenetic target region sets. In some embodiments, the capture yield of target-binding probes specific to sequence-variable target region sets is 1.25 to 1.5, 1.5 to 1.75, 1.75 to 2, 2 to 2.25, 2.25 to 2.5, 2.5 to 2.75, 2.75 to 3, 3 to 3.5, 3.5 to 4, 4 to 4.5, 4.5 to 5, 5 to 5.5, 5.5 to 6, 6 to 7, 7 to 8, 8 to 9, 9 to 10, 10 to 11, 11 to 12, 13 to 14, or 14 to 15 times higher than the capture yield of target-binding probes specific to epigenetic target region sets.
[0325] In some embodiments, the collection of target-specific probes is configured to have a capture yield specific to a sequence-variable target region set that is at least 1.25 times, 1.5 times, 1.75 times, 2 times, 2.25 times, 2.5 times, 2.75 times, 3 times, 3.5 times, 4 times, 4.5 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 11 times, 12 times, 13 times, 14 times, or 15 times higher than its capture yield for an epigenetic target region set. In some embodiments, the collection of target-specific probes is configured to have a capture yield specific to sequence-variable target region sets that is 1.25 to 1.5, 1.5 to 1.75, 1.75 to 2, 2 to 2.25, 2.25 to 2.5, 2.5 to 2.75, 2.75 to 3, 3 to 3.5, 3.5 to 4, 4 to 4.5, 4.5 to 5, 5 to 5.5, 5.5 to 6, 6 to 7, 7 to 8, 8 to 9, 9 to 10, 10 to 11, 11 to 12, 13 to 14, or 14 to 15 times higher than its capture yield specific to epigenetic target region sets.
[0326] Probe collection can be configured to provide higher capture yields for sequence-variable target region sets in various ways, including varying concentrations, lengths, and / or chemistry (e.g., affecting affinity), as well as combinations thereof. Affinity can be modulated by adjusting probe length and / or including nucleotide modifications, as discussed below.
[0327] In some embodiments, target-specific probes specific to sequence-variable target region sets are present at higher concentrations than target-specific probes specific to epigenetic target region sets. In some embodiments, the concentration of target-binding probes specific to sequence-variable target region sets is at least 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 times higher than the concentration of target-binding probes specific to epigenetic target region sets. In some embodiments, the concentration of target-binding probes specific to sequence-variable target region sets is 1.25 to 1.5, 1.5 to 1.75, 1.75 to 2, 2 to 2.25, 2.25 to 2.5, 2.5 to 2.75, 2.75 to 3, 3 to 3.5, 3.5 to 4, 4 to 4.5, 4.5 to 5, 5 to 5.5, 5.5 to 6, 6 to 7, 7 to 8, 8 to 9, 9 to 10, 10 to 11, 11 to 12, 13 to 14, or 14 to 15 times higher than the concentration of target-binding probes specific to epigenetic target region sets. In such embodiments, concentration may refer to the average mass concentration per volume of the individual probes in each set.
[0328] In some embodiments, target-specific probes specific to sequence-variable target region sets have a higher affinity for those targets than target-specific probes specific to epigenetic target region sets. Affinity can be modulated in any way known to those skilled in the art, including by using different probe chemistry. For example, certain nucleotide modifications, such as cytosine 5-methylation (in the context of certain sequences), modifications providing a heteroatom at the 2' sugar position, and LNA nucleotides, can increase the stability of double-stranded nucleic acids, indicating that oligonucleotides having such modifications have a relatively high affinity for their complementary sequences. See, for example, Severin et al., Nucleic Acids Res. 39: 8740-8751 (2011); Freier et al., Nucleic Acids Res. 25: 4429-4443 (1997); and U.S. Patent No. 9,738,894. Furthermore, longer sequence lengths generally provide increased affinity. Other nucleotide modifications, such as the substitution of guanine with nucleo-based hypoxanthine, reduce affinity by decreasing the amount of hydrogen bonding between the oligonucleotide and its complementary sequence. In some embodiments, target-specific probes specific to sequence-variable target region sets have modifications that increase their affinity for those targets. In some embodiments, or / or further, target-specific probes specific to epigenetic target region sets have modifications that decrease their affinity for those targets. In some embodiments, target-specific probes specific to sequence-variable target region sets have a longer average length and / or a higher average melting temperature than target-specific probes specific to epigenetic target region sets. These embodiments can be combined with each other and / or with differences in concentration discussed above to achieve a desired multiplier difference in capture yield, e.g., any multiplier difference or range described above.
[0329] In some embodiments, the target-specific probe includes a capture portion. The capture portion may be any of the capture portions described herein, for example, biotin. In some embodiments, the target-specific probe is coupled to a solid support, for example, covalently or non-covalently, via the interaction of binding pairs of the capture portions. In some embodiments, the solid support is a bead, for example, a magnetic bead.
[0330] In some embodiments, target-specific probes specific to a sequence-variable target region set and / or target-specific probes specific to an epigenetic target region set are probes comprising the bait set discussed above, e.g., capture regions and sequences selected to tile across a panel of genes.
[0331] In some embodiments, the target-specific probe is provided in a single composition. The single composition may be a solution (liquid or frozen). Alternatively, the single composition may be a lyophilized product.
[0332] Alternatively, target-specific probes may be provided as a plurality of compositions, for example, comprising a first composition containing a probe specific to a set of epigenetic target regions and a second composition containing a probe specific to a set of sequence-variable target regions. These probes may be mixed into a combined probe composition in proportions appropriate to provide any of the aforementioned multiplier differences in concentration and / or capture yield. Alternatively, they may be used in separate capture procedures (e.g., using aliquots of the sample or sequentially using the same sample) to provide the first and second compositions, respectively, containing captured epigenetic target regions and sequence-variable target regions. 1. Probes specific to epigenetic target regions
[0333] Probes to epigenetic target region sets may include probes specific to one or more types of target regions that are likely to differentiate DNA from neoplastic (e.g., tumor or cancer) cells from healthy cells, e.g., non-neoplastic circulating cells. Exemplary types of such regions are discussed in detail herein, for example, in the section above relating to the captured set. Probes to epigenetic target region sets may also include probes to one or more control regions, for example, as described herein.
[0334] In some embodiments, the probe to the epigenetic target region set has a footprint of at least 100 kbp, for example, at least 200 kbp, at least 300 kbp, or at least 400 kbp. In some embodiments, the epigenetic target region set has a footprint in the range of 100 to 20 Mbp, for example, 100 to 200 kbp, 200 to 300 kbp, 300 to 400 kbp, 400 to 500 kbp, 500 to 600 kbp, 600 to 700 kbp, 700 to 800 kbp, 800 to 900 kbp, 900 to 1,000 kbp, 1 to 1.5 Mbp, 1.5 to 2 Mbp, 2 to 3 Mbp, 3 to 4 Mbp, 4 to 5 Mbp, 5 to 6 Mbp, 6 to 7 Mbp, 7 to 8 Mbp, 8 to 9 Mbp, 9 to 10 Mbp, or 10 to 20 Mbp. In some embodiments, the epigenetic target region set has a footprint of at least 20 Mbp. a. Highly methylated variable target region
[0335] In some embodiments, the probes for a set of epigenetic target regions include probes specific to one or more highly methylated variable target regions. The highly methylated variable target regions may be any of those listed above. For example, in some embodiments, the highly methylated variable target region-specific probes include probes specific to a plurality of loci listed in Table 1, e.g., probes specific to at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the loci listed in Table 1. In some embodiments, the highly methylated variable target region-specific probes include probes specific to a plurality of loci listed in Table 2, e.g., probes specific to at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the loci listed in Table 2. In some embodiments, probes specific to highly methylated variable target regions include probes specific to a plurality of loci listed in Table 1 or Table 2, e.g., probes specific to at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the loci listed in Table 1 or Table 2. In some embodiments, for each locus included as a target region, there may be one or more probes having a hybridization site that binds between the transcription start site of the gene and the stop codon (or the last stop codon for genes that are alternatively spliced). In some embodiments, one or more probes bind within 300 bp of the listed locations, e.g., within 200 or 100 bp. In some embodiments, the probes have hybridization sites that overlap with the locations listed above. In some embodiments, probes specific to hypermethylation target regions include probes specific to one, two, three, four, or five subsets of hypermethylation target regions that collectively exhibit hypermethylation in one, two, three, four, or five of breast, colon, kidney, liver, and lung cancers. b. Low-methylation variable target regions
[0336] In some embodiments, probes for a set of epigenetic target regions include probes specific to one or more hypomethylated variable target regions. The hypomethylated variable target regions may be any of those shown above. For example, probes specific to one or more hypomethylated variable target regions may include regions that may show reduced methylation in tumor cells, such as repeat elements, e.g., LINE1 elements, Alu elements, centromere tandem repeats, perikichore tandem repeats, and satellite DNA, as well as probes for intergenetic regions that are normally methylated in healthy cells.
[0337] In some embodiments, probes specific to low-methylation variable target regions include probes specific to repeat elements and / or intergenetic regions. In some embodiments, probes specific to repeat elements include probes specific to one, two, three, four, or five of the following: LINE1 elements, Alu elements, centromere tandem repeats, pericinator tandem repeats, and / or satellite DNA.
[0338] Exemplary probes specific to genomic regions exhibiting cancer-related hypomethylation include probes specific to human chromosome 1 nucleotides 8403565–8953708 and / or 151104701–151106035. In some embodiments, probes specific to hypomethylation variable target regions include probes specific to regions that overlap with or contain human chromosome 1 nucleotides 8403565–8953708 and / or 151104701–151106035. c.CTCF binding region
[0339] In some embodiments, probes for epigenetic target region sets include probes specific to CTCF binding regions. In some embodiments, CTCF binding region-specific probes include probes specific to at least 10, 20, 50, 100, 200, or 500 CTCF binding regions, or 10-20, 20-50, 50-100, 100-200, 200-500, or 500-1000 CTCF binding regions, such as those described above, or in one or more of the CTCFBSDB or Cuddapah et al., Martin et al., or Rhee et al. papers cited above. In some embodiments, probes for epigenetic target region sets include regions at least 100 bp, at least 200 bp, at least 300 bp, at least 400 bp, at least 500 bp, at least 750 bp, or at least 1000 bp upstream and downstream of the CTCF binding site. d. Transcription initiation site
[0340] In some embodiments, probes for epigenetic target region sets include probes specific to transcription start sites. In some embodiments, transcription start site-specific probes include probes specific to at least 10, 20, 50, 100, 200, or 500 transcription start sites, or 10-20, 20-50, 50-100, 100-200, 200-500, or 500-1000 transcription start sites, such as those listed in DBTSS. In some embodiments, probes for epigenetic target region sets include probes for sequences at least 100 bp, at least 200 bp, at least 300 bp, at least 400 bp, at least 500 bp, at least 750 bp, or at least 1000 bp upstream and downstream of transcription start sites. e. Localized amplification
[0341] As noted above, localized amplification is a somatic mutation, but these can be detected by sequencing based on read frequency in a manner similar to approaches for detecting certain epigenetic changes, such as changes in methylation. Therefore, regions that may exhibit localized amplification in cancer may be included in a set of epigenetic target regions, as discussed above. In some embodiments, probes specific to a set of epigenetic target regions include probes specific to localized amplification. In some embodiments, probes specific to localized amplification include probes specific to one or more of AR, BRAF, CCND1, CCND2, CCNE1, CDK4, CDK6, EGFR, ERBB2, FGFR1, FGFR2, KIT, KRAS, MET, MYC, PDGFRA, PIK3CA, and RAF1. For example, in some embodiments, probes specific to localized amplification include probes specific to one or more of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 of the targets described above. f. Control area
[0342] To facilitate data validation, it may be useful to include a control region. In some embodiments, the probes specific to the epigenetic target region set include a probe specific to a methylated control region, which is expected to be methylated in essentially all samples. In some embodiments, the probes specific to the epigenetic target region set include a probe specific to a hypomethylated control region, which is expected to be hypomethylated in essentially all samples. 2. Probes specific to sequence-variable target regions
[0343] Probes for sequences-variable target region sets may include probes specific to multiple regions known to undergo somatic mutation in cancer. Probes may be specific to any sequence-variable target region set described herein. Exemplary sequences-variable target region sets are discussed in detail herein, for example, in the section above relating to captured sets.
[0344] In some embodiments, the sequence-variable target region probe set has a footprint of at least 0.5kb, for example, at least 1kb, at least 2kb, at least 5kb, at least 10kb, at least 20kb, at least 30kb, or at least 40kb. In some embodiments, the epigenetic target region probe set has a footprint in the range of 0.5 to 100kb, for example, 0.5 to 2kb, 2 to 10kb, 10 to 20kb, 20 to 30kb, 30 to 40kb, 40 to 50kb, 50 to 60kb, 60 to 70kb, 70 to 80kb, 80 to 90kb, and 90 to 100kb. In some embodiments, the sequence-variable target region probe set has a footprint of at least 50kbp, for example, at least 100kbp, at least 200kbp, at least 300kbp, or at least 400kbp. In some embodiments, the sequence-variable target region probe set has a footprint in the range of 100-2000 kbp, for example, 100-200 kbp, 200-300 kbp, 300-400 kbp, 400-500 kbp, 500-600 kbp, 600-700 kbp, 700-800 kbp, 800-900 kbp, 900-1,000 kbp, 1-1.5 Mbp, or 1.5-2 Mbp. In some embodiments, the sequence-variable target region set has a footprint of at least 2 Mbp.
[0345] In some embodiments, the probes specific to the sequence variable target region set include probes specific to at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65 or 70 of the genes in Table 3. In some embodiments, the probes specific to the sequence variable target region set include probes specific to at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65 or 70 of the SNVs in Table 3. In some embodiments, the probes specific to the sequence variable target region set include probes specific to at least 1, at least 2, at least 3, at least 4, at least 5 or 6 of the fusions in Table 3. In some embodiments, the probes specific to the sequence variable target region set include probes specific to at least 1, at least 2 or 3 of the indels in Table 3. In some embodiments, the probes specific to the sequence variable target region set include probes specific to at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70 or 73 of the genes in Table 4. In some embodiments, the probes specific to the sequence variable target region set include probes specific to at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70 or 73 of the SNVs in Table 4. In some embodiments, the probes specific to the sequence variable target region set include probes specific to at least 1, at least 2, at least 3, at least 4, at least 5 or 6 of the fusions in Table 4.In some embodiments, probes specific to a sequence variable target region set include probes specific to at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, or 18 indels in Table 4. In some embodiments, probes specific to a sequence variable target region set include probes specific to at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 genes in Table 5.
[0346] In some embodiments, probes specific to a sequence-variable target region set include probes specific to target regions derived from at least 10, 20, 30, or 35 cancer-related genes, such as AKT1, ALK, BRAF, CCND1, CDK2A, CTNNB1, EGFR, ERBB2, ESR1, FGFR1, FGFR2, FGFR3, FOXL2, GATA3, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, KIT, KRAS, MED12, MET, MYC, NFE2L2, NRAS, PDGFRA, PIK3CA, PPP2R1A, PTEN, RET, STK11, TP53, and U2AF1. E. Compositions containing captured DNA
[0347] A combination comprising first and second populations of captured DNA is provided herein. The first population may contain, or may be derived from, DNA having nucleobase modifications, such as cytosine modifications, at a higher rate than the second population. The first population may include a form of the first nucleobase originally present in the DNA having altered base pairing specificity, and a second nucleobase not having altered base pairing specificity, wherein the form of the first nucleobase originally present in the DNA before the alteration of base pairing specificity is a modified or unmodified nucleobase, and the second nucleobase is a modified or unmodified nucleobase different from the first nucleobase, and the form of the first nucleobase originally present in the DNA before the alteration of base pairing specificity and the second nucleobase have the same base pairing specificity. The second population does not include a form of the first nucleobase originally present in the DNA having altered base pairing specificity. In some embodiments, the nucleobase modification present in a higher proportion in the first population is a cytosine modification. In some such embodiments, the cytosine modification is a cytosine methylation. In some embodiments, the first nucleobase is a modified or unmodified cytosine, and the second nucleobase is a modified or unmodified cytosine. The first and second nucleobases may be any of those discussed herein. In some embodiments, the modified nucleobase present in a higher proportion in the first population is a form of the nucleobase that is originally present in the DNA. In some embodiments, the modified nucleobase present in a higher proportion in the first population is a form of the nucleobase produced by a procedure that affects the first and second nucleobases differently.
[0348] In some embodiments, the first group includes array tags selected from a first set of one or more array tags, and the second group includes array tags selected from a second set of one or more array tags, wherein the second set of array tags is different from the first set of array tags. The array tags may include barcodes.
[0349] In some embodiments, the first group includes protected hmC, for example, glucosylated hmC.
[0350] In some embodiments, the first group is subjected to one of the conversion procedures discussed herein, such as bisulfite conversion, Ox-BS conversion, TAB conversion, ACE conversion, TAP conversion, TAPSβ conversion, or CAP conversion. In some embodiments, the first group is subjected to the protection of hmC and subsequent deamination of mC and / or C.
[0351] In some embodiments of the combination, the first population contains or is derived from DNA having a higher proportion of cytosine modifications than the second population, and the first population comprises first and second subpopulations, the first nucleobase being a modified or unmodified nucleobase, the second nucleobase being a modified or unmodified nucleobase different from the first nucleobase, and the first and second nucleobases having the same base pairing specificity. In some embodiments, the second population does not contain the first nucleobase. In some embodiments, the first nucleobase is modified or unmodified cytosine, the second nucleobase is modified or unmodified cytosine, and the modified cytosine is mC or hmC, as is necessary. In some embodiments, the first nucleobase is modified or unmodified adenine, and the second nucleobase is modified or unmodified adenine, and if necessary, the modified adenine is mA.
[0352] In some embodiments, the first nucleobase (e.g., modified cytosine) is biotinylated. In some embodiments, the first nucleobase (e.g., modified cytosine) is the product of hysgene cycloaddition to β-6-azido-glucosyl-5-hydroxymethylcytosine, which includes an affinity label (e.g., biotin).
[0353] In any of the combinations described herein, the captured DNA may include cfDNA.
[0354] The captured DNA may have any of the features described herein with respect to the captured set, for example, including a concentration of DNA corresponding to a sequence variable target region set (standardized with respect to footprint size as discussed above) that is higher than the concentration of DNA corresponding to the epigenetic target region set. In some embodiments, the DNA of the captured set includes sequence tags that may be attached to the DNA as described herein. Generally, including sequence tags results in DNA molecules that differ from their naturally occurring untagged forms.
[0355] The combination may further include the probe sets or sequencing primers described herein, each of which may differ from naturally occurring nucleic acid molecules. For example, the probe sets described herein may include capture moieties, and the sequencing primers may include labels that do not exist in nature. F. Computer System
[0356] The methods of the present disclosure may be carried out using or with the assistance of a computer system. For example, such a method is a step of subjecting a sample to a procedure that affects a first nucleobase in the DNA in such a way that it is different from a second nucleobase in the DNA of the sample, wherein the first nucleobase is a modified or unmodified nucleobase, the second nucleobase is a modified or unmodified nucleobase different from the first nucleobase, and the first and second nucleobases have the same base pairing specificity; the sample is made to a first partial test by contacting the DNA with an agent that recognizes the modified nucleobase in the DNA. The steps may include: distributing a sample and a second partial sample into a plurality of partial samples, wherein the first partial sample contains DNA having a higher proportion of cytosine modifications than the second partial sample, and the modified nucleobase recognized by the drug is the product of a procedure that affects the first nucleobase in the DNA in a manner different from the modified cytosine or the second nucleobase in the sample's DNA; and sequencing the DNA in at least one of the first and second partial samples in a manner that distinguishes the first nucleobase from the second nucleobase.
[0357] Figure 2 shows a computer system 201 programmed or otherwise configured to perform the methods of this disclosure. The computer system 201 can configure sample preparation, sequencing, and / or analysis in various embodiments. In some examples, the computer system 201 is configured to perform sample preparation and sample analysis, including nucleic acid sequencing, in accordance with, for example, one of the methods disclosed herein.
[0358] The computer system 201 includes a central processing unit (CPU, also referred to herein as "processor" and "computer processor") 205, which may be a single-core or multi-core processor, or multiple processors for parallel processing. The computer system 201 also includes memory or memory locations 210 (e.g., random-access memory, read-only memory, flash memory), electronic storage devices 215 (e.g., hard disks), a communication interface 220 for communicating with one or more other systems (e.g., a network adapter), and peripheral devices 225, e.g., a cache, other memory, data storage, and / or an electronic display adapter. The memory 210, storage devices 215, interface 220, and peripheral devices 225 communicate with the CPU 205 via a communication network or bus (solid line), e.g., a motherboard. The storage device 215 may be a data storage device (or data repository) for storing data. The computer system 201 may be operably connected to a computer network 230 with the help of the communication interface 220. The computer network 230 may be the Internet, the Internet and / or an extranet, or an intranet and / or extranet communicating with the Internet. In some cases, the computer network 230 may be a telecommunications and / or data network. The computer network 230 may include one or more computer servers that can enable distributed computing, such as cloud computing. In some cases, the computer network 230 may run a peer-to-peer network that, with the help of computer system 0, can enable devices connected to computer system 201 to act as clients or servers.
[0359] The CPU 205 can execute a sequence of machine-readable instructions that can be embodied in a program or software. These instructions can be stored in a memory location, for example, memory 210. Examples of operations performed by the CPU 205 include fetching, decoding, executing, and writing back.
[0360] The storage device 215 can store files, such as drivers, libraries, and saved programs. The storage device 215 can store user-generated programs, recorded sessions, and output associated with programs. The storage device 215 can store user data, such as user preferences and user programs. In some cases, the computer system 201 may include one or more additional data storage devices located on remote servers that communicate with the computer system 201 externally, for example, via an intranet or the internet. Data can be transferred from one location to another, for example, using a communication network or physical data transfer (e.g., using a hard drive, thumb drive, or other data storage mechanism).
[0361] Computer system 201 can communicate with one or more remote computer systems via network 230. In an embodiment, computer system 201 can communicate with a user's (e.g., operator's) remote computer system. Examples of remote computer systems include personal computers (e.g., portable PCs), slate or tablet PCs (e.g., Apple® iPad®, Samsung® Galaxy Tab), telephones, smartphones (e.g., Apple® iPhone®, Android®-enabled devices, Blackberry®), or personal digital assistants. Users can access computer system 201 via network 230.
[0362] The methods described herein may be executed by machine-executable code (e.g., a computer processor) stored on an electronic storage location of a computer system 201, for example, on memory 210 or an electronic storage device 215. The machine-executable or machine-readable code may be provided in the form of software. During use, the code may be executed by the processor 205. In some cases, the code may be retrieved from the storage device 215 and stored on memory 210 for immediate access by the processor 205. In some situations, the electronic storage device 215 may be omitted, and the machine-executable instructions are stored on memory 210.
[0363] In some embodiments, the present disclosure provides a step of subjecting a sample to a procedure, when performed by at least one electronic processor, in which a first nucleobase in the DNA of the sample is affected in such a way that it differs from a second nucleobase in the DNA, wherein the first nucleobase is a modified or unmodified nucleobase, the second nucleobase is a modified or unmodified nucleobase different from the first nucleobase, and the first and second nucleobases have the same base pairing specificity; and distributing the sample into a plurality of partial samples by contacting the DNA with an agent that recognizes the modified nucleobase in the DNA. The present invention provides a non-temporary computer-readable medium, which includes a computer-executable instruction for performing at least a portion of a method comprising: a step in which multiple portions include a first partial sample and a second partial sample, the first partial sample containing DNA having a higher proportion of cytosine modifications than the second partial sample, and the modified nucleobase recognized by a drug is the product of a procedure that affects the first nucleobase in the DNA in such a way that it is different from the modified cytosine or the second nucleobase in the DNA of the sample; and a step in which DNA in at least one of the first and second partial samples is sequenced in such a way that the first nucleobase is distinguished from the second nucleobase.
[0364] The code may be pre-compiled and configured for use with a machine having a processor adapted to run the code, or it may be compiled during runtime. The code may be provided in a programming language that can be chosen to enable execution of the code in a pre-compiled or as-compiled form.
[0365] Embodiments of the systems and methods provided herein, for example, computer system 201, can be embodied in programming. Various embodiments of the technology can be considered "products" or "manufactured goods" in the form of machine (or processor) executable code and / or related data, typically carried on or embodied in a certain type of machine-readable medium. Machine-executable code can be stored on electronic storage devices, such as memory (e.g., read-only memory, random-access memory, flash memory) or hard disks. "Storage" media may include any or all of the tangible memory of a computer, processor, etc., or related modules thereof, such as various semiconductor memories, tape drives, disk drives, etc., which can at any time provide non-temporary storage for software programming.
[0366] All or part of the software may be communicated from time to time over the Internet or various other telecommunication networks. Such communication may enable the loading of software, for example, from one computer or processor to another, or from a management server or host computer to an application server computer platform. Thus, other types of media that may hold software elements include optical waves, radio waves and electromagnetic waves, such as those used across physical interfaces between local devices, over wired and optical fixed telephone network lines, and through various air-links. Physical elements that carry such waves, such as wired or wireless links, optical links, etc., may also be considered media that hold software. As used herein, unless limited to non-temporary tangible “storage” media, terms such as computer or machine-readable media refer to any medium involved in providing instructions to a processor for execution.
[0367] Therefore, machine-readable media, such as computer executable code, can take many forms, including but not limited to tangible storage media, carrier media, or physical transmission media. Non-volatile storage media include, for example, optical or magnetic disks, which can be used to run databases, as shown in the drawings, and any storage devices in any computer. Volatile storage media include dynamic memory, for example, the main memory of such a computer platform. Tangible transmission media include coaxial cables; copper wires and optical fibers, which include wires including buses in computer systems. Carrier media can take the form of electrical or electromagnetic signals, or sound or light waves, for example, those generated during radio frequency (RF) and infrared (IR) data communications. Therefore, common forms of computer-readable media include, for example, floppy disks, flexible disks, hard disks, magnetic tapes, any other magnetic media, CD-ROMs, DVDs or DVD-ROMs, any other optical media, punch cards, paper tapes, any other physical storage media having a pattern of holes, RAM, ROMs, PROMs and EPROMs, FLASH®-EPROMs, any other memory chips or cartridges, carriers carrying data or instructions, cables or links carrying such carriers, or any other media from which a computer can read programming code and / or data. Many of these forms of computer-readable media may be involved in transporting one or more sequences of one or more instructions to a processor for execution.
[0368] The computer system 201 may include, or communicate with, an electronic display containing a user interface (UI) for providing one or more results of sample analysis. Examples of UIs include, but are not limited to, graphical user interfaces (GUIs) and web-based user interfaces.
[0369] For further details regarding computer systems and networks, databases, and computer program products, see, for example, Peterson, Computer Networks: A Systems Approach, Morgan Kaufmann, 5th Ed. (2011), Kurose, Computer Networking: A Top-Down Approach, Pearson, 7 th Ed. (2016), Elmasri, Fundamentals of Database Systems, Addison Wesley, 6th Ed. (2010), Coronel, Database Systems: Design, Implementation, & Management, Cengage Learning, 11 th They are also provided in Tucker, Programming Languages, McGraw-Hill Science / Engineering / Math, 2nd Ed. (2006), and Rhoton, Cloud Computing Architected: Solution Design Handbook, Recursive Press (2011), each of which is thus incorporated herein by reference in its entirety. G. Application 1. Cancer and other diseases
[0370] The methods of the present invention may be used to diagnose a condition in a subject, particularly the presence of cancer; to characterize a condition (e.g., to stage cancer or determine cancer heterogeneity); to monitor the condition's response to treatment; and to determine the prognostic risk of developing a condition or a subsequent course of the condition. This disclosure may also be useful in determining the effectiveness of a particular treatment option. A successful treatment option may increase the amount of copy number variation or rare mutations detected in the subject's blood, as a successful treatment can lead to more cancer deaths and DNA shedding. In other cases, this may not occur. In another case, perhaps a particular treatment option can be correlated over time with the genetic profile of the cancer. This correlation may be useful in selecting a treatment.
[0371] Furthermore, if the cancer is observed to be in remission after treatment, the method of the present invention may be used to monitor residual disease or disease recurrence.
[0372] In some embodiments, the methods and systems disclosed herein may be used to identify customized or targeted therapies for treating a given disease or condition in a patient, based on the classification of nucleic acid variants as being of somatic or germline origin. Typically, the disease considered is a certain type of cancer. Non-specific examples of such cancers include biliary tract cancer, bladder cancer, transitional cell carcinoma, urothelial carcinoma, brain cancer, glioma, astrocytoma, breast cancer, metaplastic carcinoma, cervical cancer, cervical squamous cell carcinoma, rectal cancer, colorectal cancer, colon cancer, hereditary nonpolyposis colorectal cancer, colorectal adenocarcinoma, gastrointestinal stromal tumor (GIST), endometrial cancer, endometrial stromal sarcoma, esophageal cancer, esophageal squamous cell carcinoma, esophageal adenocarcinoma, ocular melanoma, uveal melanoma, gallbladder cancer, gallbladder adenocarcinoma, renal cell carcinoma, clear cell renal cell carcinoma, transitional cell carcinoma, urothelial carcinoma, Wilms' tumor, leukemia, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), and chronic myelomonocytic leukemia. These include (CMML), liver cancer, hepatoma, hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, lung cancer, non-small cell lung cancer (NSCLC), mesothelioma, B-cell lymphoma, non-Hodgkin lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, T-cell lymphoma, non-Hodgkin lymphoma, progenitor T-lymphoblastic lymphoma / leukemia, peripheral T-cell lymphoma, multiple myeloma, nasopharyngeal cancer (NPC), neuroblastoma, oropharyngeal cancer, oral squamous cell carcinoma, osteosarcoma, ovarian cancer, pancreatic cancer, pancreatic ductal adenocarcinoma, pseudopapillary neoplasm, acinar cell carcinoma, prostate cancer, prostate adenocarcinoma, skin cancer, melanoma, malignant melanoma, cutaneous melanoma, small intestine cancer, stomach cancer, gastrointestinal stromal tumor (GIST), uterine cancer, or uterine sarcoma. The type and / or stage of cancer may be detected from genetic variations, including mutations, rare mutations, indels, copy number variations, transversions, translocations, inversions, deletions, aneuploidy, partial aneuploidy, polyploidy, chromosomal instability, chromosomal structural alterations, gene fusions, chromosome fusions, gene truncations, gene amplification, gene duplication, chromosomal damage, DNA damage, abnormal changes in the chemical modification of nucleic acids, abnormal changes in epigenetic patterns, and abnormal changes in 5-methylcytosine of nucleic acids.
[0373] Genetic data can also be used to characterize specific forms of cancer. Cancers are often heterogeneous in both composition and staging. Genetic profile data can enable the characterization of specific subtypes of cancer, which may be important in the diagnosis or treatment of that particular subtype. This information can also provide subjects or practitioners with clues about the prognosis of a particular type of cancer, enabling either the subject or practitioner to adapt treatment options as the disease progresses. Some cancers may progress, becoming more aggressive and genetically unstable. Other cancers may remain benign, inactive, or dormant. The systems and methods of this disclosure may be useful in determining disease progression.
[0374] Furthermore, the methods of this disclosure may be used to characterize heterogeneity of an abnormal condition in a subject. Such methods may include, for example, a step of generating a genetic profile of extracellular polynucleotides derived from the subject, the genetic profile including multiple data resulting from the analysis of copy number variations and rare mutations. In some embodiments, the abnormal condition is cancer. In some embodiments, the abnormal condition may result in a heterogeneous genomic population. In the example of cancer, it is known that some tumors contain tumor cells at different stages of cancer. In other examples, the heterogeneity may include multiple lesions of the disease. Again, in the example of cancer, multiple tumor lesions may be present, perhaps in this case one or more lesions being the result of metastasis spreading from the primary site.
[0375] The methods of the present invention can be used to generate or profile a fingerprint or set of data, which is the sum of genetic information derived from different cells in heterogeneous diseases. This set of data may include, alone or in combination, analyses of copy number variations, epigenetic variations, and mutations.
[0376] The methods of the present invention may be used to diagnose, prognose, monitor, or observe cancer or other diseases. In some embodiments, the methods herein do not involve diagnosing, prognosing, or monitoring a fetus, and therefore do not relate to non-invasive prenatal testing. In other embodiments, these methodologies may be used in pregnant subjects to diagnose, prognose, monitor, or observe cancer or other diseases in prenatal subjects whose DNA and other polynucleotides can co-circulate with maternal molecules.
[0377] Other gene-based diseases, disorders, or conditions that may be evaluated as needed using the methods and systems disclosed herein include, but are not limited to, achondroplasia, alpha-1 antitrypsin deficiency, antiphospholipid syndrome, autism, autosomal dominant polycystic kidney disease, Charcot-Marie-Tooth (CMT), cat-like meowing, Crohn's disease, cystic fibrosis, Darkham's disease, Down syndrome, Duane syndrome, Duchenne muscular dystrophy, factor V Leiden thrombotic diathesis, familial hypercholesterolemia, familial Mediterranean fever, fragile X syndrome, Gaucher disease, hemochromatosis, hemophilia, holoprosencephaly, Huntington's disease, Klinefelter syndrome, Marfan syndrome, myotonic dystrophy, neurofibromatosis, Noonan syndrome, osteogenesis imperfecta, Parkinson's disease, phenylketonuria, and Poland syndrome. Examples of anomalies include porphyria, progeria, retinitis pigmentosa, severe combined immunodeficiency (SCID), sickle cell disease, spinal muscular atrophy, Tay-Sachs syndrome, thalassemia, trimethylaminuria, Turner syndrome, palatinofacial syndrome, WAGR syndrome, and Wilson's disease.
[0378] In some embodiments, the method described herein includes the step of using a set of sequence information obtained as described herein to detect the presence or absence of DNA originating from or derived from tumor cells at a pre-selected time point after a previous cancer treatment of a subject previously diagnosed with cancer. The method may further include the step of determining a cancer recurrence score for the subject of test, indicating the presence or absence of DNA originating from or derived from tumor cells.
[0379] Once a cancer recurrence score is determined, it may be further used to determine the cancer recurrence status. A cancer recurrence status may be, for example, a state of risk for cancer recurrence if the cancer recurrence score exceeds a predetermined threshold. Alternatively, a cancer recurrence status may be a state of low or less risk for cancer recurrence if the cancer recurrence score exceeds a predetermined threshold. In certain embodiments, a cancer recurrence score equal to a predetermined threshold may result in a cancer recurrence status that is either a state of risk for cancer recurrence or a state of low or less risk for cancer recurrence.
[0380] In some embodiments, the cancer recurrence score is compared to a predetermined cancer recurrence threshold, and if the cancer recurrence score is above the cancer recurrence threshold, the subject is classified as a candidate for further cancer treatment, or if the cancer recurrence score is below the cancer recurrence threshold, the subject is not classified as a candidate for treatment. In certain embodiments, a cancer recurrence score equal to the cancer recurrence threshold may result in classification as either a candidate for further cancer treatment or not a candidate for treatment.
[0381] The methods discussed above may further include any suitability features (single or multiple) set out elsewhere in this Spec, including in the section concerning methods for determining the risk of cancer recurrence in study subjects and / or classifying study subjects as candidates for subsequent cancer treatment. 2. Methods for determining the risk of cancer recurrence in study subjects and / or classifying study subjects as candidates for subsequent cancer treatment.
[0382] In some embodiments, the methods provided herein are for determining the risk of cancer recurrence in a test subject. In some embodiments, the methods provided herein are for classifying a test subject as a candidate for subsequent cancer treatment.
[0383] Any such method may include the step of collecting DNA (e.g., originating from or derived from tumor cells) from a test subject diagnosed with cancer at one or more pre-selected time points after one or more prior cancer treatments to the test subject. The subject may be any of the subjects described herein. The DNA may be cfDNA. The DNA may be obtained from a tissue sample.
[0384] Any such method may include a step of capturing multiple sets of target regions from DNA derived from a subject, the multiple sets of target regions including sequence-variable target regions and epigenetic target regions, thereby producing a captured set of DNA molecules. The capture step may be carried out according to any of the embodiments described elsewhere in this specification.
[0385] In any of these methods, prior cancer treatment may include surgery, administration of therapeutic compositions, and / or chemotherapy.
[0386] One of these methods involves a step of sequencing the captured DNA molecule, thereby producing a set of sequence information. Captured DNA molecules of a sequence-variable target region set can be sequenced to a deeper sequencing depth than captured DNA molecules of an epigenetic target region set.
[0387] Any such method may include the step of using a set of sequence information to detect the presence or absence of DNA originating from or derived from tumor cells at a pre-selected point in time. The detection of the presence or absence of DNA originating from or derived from tumor cells may be carried out according to any embodiment described elsewhere herein.
[0388] A method for determining the risk of cancer recurrence in a test subject may include the step of determining a cancer recurrence score for the test subject, indicating the presence or absence or amount of DNA originating from or derived from tumor cells. The cancer recurrence score may further be used to determine the cancer recurrence status. The cancer recurrence status may be, for example, a state of risk of cancer recurrence if the cancer recurrence score is above a predetermined threshold. The cancer recurrence status may be, for example, a state of low or less risk of cancer recurrence if the cancer recurrence score is above a predetermined threshold. In certain embodiments, a cancer recurrence score equal to a predetermined threshold may result in a cancer recurrence status that is either a state of risk of cancer recurrence or a state of low or less risk of cancer recurrence.
[0389] A method for classifying a subject as a candidate for further cancer treatment may include a step of comparing the subject's cancer recurrence score to a predetermined cancer recurrence threshold, thereby classifying the subject as a candidate for further cancer treatment if the cancer recurrence score is above the cancer recurrence threshold, or not as a candidate for treatment if the cancer recurrence score is below the cancer recurrence threshold. In certain embodiments, a cancer recurrence score equal to the cancer recurrence threshold may result in classification as either a candidate for further cancer treatment or not a candidate for treatment. In some embodiments, the further cancer treatment includes chemotherapy or administration of a therapeutic composition.
[0390] Any such method may include a step of determining disease-free survival (DFS) for the study subjects based on a cancer recurrence score; for example, the DFS period may be one year, two years, three years, four years, five years, or ten years.
[0391] In some embodiments, the set of sequence information includes a sequence variable target region sequence, and the step of determining the cancer recurrence score may include the step of determining at least a first subscore indicating the amount of SNVs, insertions / deletions, CNVs and / or fusions present in the sequence variable target region sequence.
[0392] In some embodiments, the number of mutations in the sequence variable target region selected from 1, 2, 3, 4, or 5 is sufficient to produce a cancer recurrence score in which the first subscore is classified as positive for cancer recurrence. In some embodiments, the number of mutations is selected from 1, 2, or 3.
[0393] In some embodiments, the set of sequence information includes epigenetic target region sequences, and the step of determining the cancer recurrence score includes determining a second subscore indicating the amount of molecules (derived from the epigenetic target region sequences) that exhibit an epigenetic state different from the DNA found in the corresponding sample from a healthy subject (e.g., cfDNA found in a blood sample from a healthy subject, or DNA found in a tissue sample from a healthy subject if the tissue sample is of the same type as the tissue obtained from the test subject). These abnormal molecules (i.e., molecules having an epigenetic state different from the DNA found in the corresponding sample from a healthy subject) may correspond to cancer-related epigenetic changes, such as methylation of the hypermethylated variable target region and / or disordered fragmentation of the fragmented variable target region, where “disordered” means different from the DNA found in the corresponding sample from a healthy subject.
[0394] In some embodiments, a percentage of molecules corresponding to the hypermethylated variable target region set and / or fragmented variable target region set exhibiting hypermethylation in the hypermethylated variable target region set and / or abnormal fragmentation in the fragmented variable target region set, greater than or equal to a value in the range of 0.001% to 10%, is sufficient for the second subscore to be classified as positive for cancer recurrence. This range may be 0.001% to 1%, 0.005% to 1%, 0.01% to 5%, 0.01% to 2%, or 0.01% to 1%.
[0395] In some embodiments, any of these methods may include the step of determining a fraction of tumor DNA from a fraction of molecules in a set of sequence information exhibiting one or more features indicating a tumor cell origin. This may be performed, for example, for molecules corresponding to some or all of an epigenetic target region that includes one or both of a hypermethylated variable target region and a fragmented variable target region (hypermethylation of a hypermethylated variable target region and / or abnormal fragmentation of a fragmented variable target region may be considered to indicate a tumor cell origin). This may be performed for molecules corresponding to sequence variable target regions, e.g., molecules containing modifications consistent with cancer, e.g., SNVs, indels, CNVs and / or fusions. The fraction of tumor DNA may be determined based on a combination of molecules corresponding to epigenetic target regions and molecules corresponding to sequence variable target regions.
[0396] The determination of the cancer recurrence score may be based at least in part on the fraction of tumor DNA, 10 -11 ~1 or 10 -10 A fraction of tumor DNA greater than a threshold within the range of ~1 is sufficient for the cancer recurrence score to be classified as positive for cancer recurrence. In some embodiments, 10 -10 ~10 -9 , 10 -9 ~10 -8 , 10 -8 ~10 -7 , 10 -7 ~10 -6 , 10 -6 ~10 -5 , 10 -5 ~10-4 , 10 -4 ~10 -3 , 10 -3 ~10 -2 or 10 -2 ~10 -1 A fraction of tumor DNA greater than or equal to a threshold within the range is sufficient for the cancer recurrence score to be classified as positive for cancer recurrence. In some embodiments, at least 10 -7 A tumor DNA fraction greater than a threshold is sufficient for the cancer recurrence score to be classified as positive for cancer recurrence. The determination that the tumor DNA fraction is greater than a threshold, e.g., a threshold corresponding to any of the embodiments described above, may be made based on cumulative probability. For example, a sample was considered positive if the cumulative probability that the tumor fraction was greater than any of the thresholds described above exceeded a probability threshold of at least 0.5, 0.75, 0.9, 0.95, 0.98, 0.99, 0.995, or 0.999. In some embodiments, the probability threshold is at least 0.95, e.g., 0.99.
[0397] In some embodiments, the set of sequence information includes a sequence variable target region sequence and an epigenetic target region sequence, and the step of determining a cancer recurrence score includes determining a first subscore indicating the amount of SNVs, insertions / deletions, CNVs and / or fusions present in the sequence variable target region sequence, and a second subscore indicating the amount of abnormal molecules in the epigenetic target region sequence, and combining the first and second subscores to provide a cancer recurrence score. When the first and second subscores are combined, they may be combined by independently applying a threshold (e.g., greater than a predetermined number of mutations (e.g., >1) in the sequence variable target region, and greater than a predetermined fraction of abnormal molecules (i.e., molecules having a different epigenetic state than the DNA found in the corresponding sample from a healthy subject; e.g., tumors)) to each subscore, or by training a machine learning classifier to determine the status based on multiple positive and negative training samples.
[0398] In some embodiments, a combined score value in the range of -4 to 2 or -3 to 1 is sufficient for the cancer recurrence score to be classified as positive for cancer recurrence.
[0399] In any embodiment in which the cancer recurrence score is classified as positive for cancer recurrence, the subject's cancer recurrence status may be a risk state for cancer recurrence, and / or the subject may be classified as a candidate for subsequent cancer treatment.
[0400] In some embodiments, the cancer is one of the types of cancer described elsewhere in this specification, for example, colorectal cancer. 3. Treatment and related administration
[0401] In certain embodiments, the methods disclosed herein relate to identifying patients with nucleic acid variant statuses that are somatic or germline origin, and administering customized treatments to such patients. In some embodiments, essentially any cancer treatment (e.g., surgical treatment, radiation therapy, chemotherapy, etc.) may be included as part of these methods. Typically, the customized treatment comprises at least one immunotherapy (or immunotherapy agent). Immunotherapy generally refers to a method of enhancing the immune response to a given type of cancer. In certain embodiments, immunotherapy refers to a method of enhancing the T-cell response to a tumor or cancer.
[0402] In certain embodiments, the status of nucleic acid variants from a sample derived from a subject, such as being of somatic or germline origin, may be compared to a database of comparative results from a reference population to identify customized or targeted therapies for that subject. Typically, the reference population includes patients with the same cancer or disease type as the subject and / or patients who are receiving or have received the same treatment as the subject. Customized or targeted therapies may be identified if the nuclear variant and comparative results meet certain classification criteria (e.g., substantial or approximate match).
[0403] In certain embodiments, the customized treatments described herein are typically administered parenterally (e.g., intravenously or subcutaneously). Pharmaceutical compositions containing immunotherapeutic agents are typically administered intravenously. Certain therapeutic agents are administered orally. However, customized treatments (e.g., immunotherapeutic agents) may also be administered by methods such as buccal, sublingual, rectal, vaginal, urethral, topical, intraocular, intranasal and / or intraauricular, and such administration may include tablets, capsules, granules, aqueous suspensions, gels, sprays, suppositories, ointments, etc.
[0404] Preferred embodiments of the present invention have been shown and described herein, but it will be apparent to those skilled in the art that such embodiments are provided only as examples. The present invention is not intended to be limited by the specific examples provided herein. The present invention has been described with reference to the above specification, but the descriptions and examples of embodiments herein are not meant to be construed as limiting. Numerous variations, alterations, and substitutions can be recalled herein to those skilled in the art without departing from the present invention. Furthermore, it should be understood that all aspects of the present invention are not limited to the specific descriptions, configurations, or relative proportions shown herein, which depend on various conditions and variables. It should be understood that various alternative methods to the embodiments of this disclosure described herein may be used when carrying out the present invention. Accordingly, it is intended that this disclosure also naturally covers any such alternative methods, alterations, variations, or equivalents. The following claims define the scope of the present invention, and it is intended that the methods and structures within these claims and their equivalents are covered thereby.
[0405] While the foregoing disclosure has been described in some detail as examples and illustrations for clarity and understanding, it will be apparent to those skilled in the art, upon reading this disclosure, that various formal and detailed variations may be made without departing from the true scope of this disclosure and may be implemented within the scope of the appended claims. For example, all methods, systems, computer-readable media, and / or component features, steps, elements, or other embodiments thereof may be used in various combinations. IV. Kit
[0406] Kits comprising the compositions described herein are also provided. The kits may be useful in carrying out the methods described herein. In some embodiments, the kit includes a first reagent (e.g., any of the reagents described elsewhere herein for converting a nucleobase, e.g., cytosine or methylated cytosine) to a different nucleobase for subjecting a plurality of samples to a procedure that affects a first nucleobase in DNA to be different from a second nucleobase in DNA, where the first nucleobase is a modified or unmodified nucleobase, and the second nucleobase is a modified or unmodified nucleobase different from the first nucleobase, where the first and second nucleobases have the same base pairing specificity. In some embodiments, the kit includes a second reagent (e.g., any of the partitioning reagents described elsewhere herein) for partitioning each sample into a plurality of partial samples as described herein. In some embodiments, the reagent for partitioning each sample is an agent that recognizes the modified nucleobase in DNA. In some embodiments, the agent that recognizes the modified nucleobase in the DNA is an antibody. In some embodiments, the modified nucleobase is a modified cytosine, for example, methylcytosine. In some embodiments, the agent that recognizes the modified nucleobase in the DNA is an antibody specific to methylcytosine in the DNA. The kit may include first and second reagents and additional elements, as discussed below and / or elsewhere in this specification. In some embodiments, the kit includes instructions for use to carry out the method described herein.
[0407] Kit includes ALK, APC, BRAF, CDKN2A, EGFR, ERBB2, FBXW7, KRAS, MYC, NOTCH1, NRAS, PIK3CA, PTEN, RBI, TP53, MET, AR, ABL1, AKT1, ATM, CDH1, CSFIR, CTNNB1, ERB B4, EZH2, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, MLH1, MPL, NPM1, PDGFRA, PROC, PTPN11, RET, SMA The oligonucleotide probes may further include multiple oligonucleotide probes that selectively hybridize to at least 5, 6, 7, 8, 9, 10, 20, 30, 40, or all genes selected from the group consisting of D4, SMARCB1, SMO, SRC, STK11, VHL, TERT, CCND1, CDK4, CDKN2B, RAF1, BRCA1, CCND2, CDK6, NF1, TP53, ARID1A, BRCA2, CCNE1, ESR1, RIT1, GATA3, MAP2K1, RHEB, ROS1, ARAF, MAP2K2, NFE2L2, RHOA, and NTRK1. The number of genes that an oligonucleotide probe can selectively hybridize to may vary. For example, the number of genes may include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, or 54. The kit may include a container containing multiple oligonucleotide probes and instructions for use to carry out any of the methods described herein.
[0408] Oligonucleotide probes can selectively hybridize to the exon regions of a gene, for example, at least five genes. In some cases, oligonucleotide probes can selectively hybridize to at least 30 exons of a gene, for example, at least five genes. In some cases, multiple probes can selectively hybridize to each of at least 30 exons. Each probe hybridizing to an exon may have a sequence that overlaps with at least one other probe. In some embodiments, oligo probes can selectively hybridize to non-coding regions of the gene disclosed herein, for example, to the intron regions of the gene. Oligo probes can also selectively hybridize to regions of a gene that include both the exon and intron regions of the gene disclosed herein.
[0409] Any number of exons can be targeted by oligonucleotide probes. For example, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 400, 500, 600, 700, 800, 900, 1,000 or more exons may be targeted.
[0410] The kit may include at least 4, 5, 6, 7, or 8 different library adapters, each having a distinct molecular barcode and the same sample barcode. The library adapters do not necessarily have to be sequencing adapters. For example, a library adapter may not include a flow cell sequence or a sequence that enables the formation of a hairpin loop for sequencing. Different variations and combinations of molecular barcodes and sample barcodes are described throughout and applicable to the kit. Furthermore, in some cases, the adapter is not a sequencing adapter. Furthermore, the adapters provided in the kit may also include sequencing adapters. A sequencing adapter may include a sequence that hybridizes to one or more sequencing primers. A sequencing adapter may further include a sequence that hybridizes to a solid support, such as a flow cell sequence. For example, a sequencing adapter may be a flow cell adapter. A sequencing adapter may be bound to one or both ends of a polynucleotide fragment. In some cases, the kit may include at least 8 different library adapters, each having a distinct molecular barcode and the same sample barcode. The library adapters do not necessarily have to be sequencing adapters. The kit may further include a sequencing adapter having a first sequence that selectively hybridizes to a library adapter and a second sequence that selectively hybridizes to a flow cell sequence. In another example, the sequencing adapter may be hairpin-shaped. For example, a hairpin-shaped adapter may include a complementary double-stranded portion and a loop portion, the double-stranded portion of which may be bound to a double-stranded polynucleotide (e.g., ligated). The hairpin-shaped sequencing adapter may be bound to both ends of a polynucleotide fragment to generate a cyclic molecule that can be sequenced multiple times.The sequencing adapter can run from end to end, up to a maximum of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54 The sequence adapter may contain 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more bases. The sequence adapter may contain 20-30, 20-40, 30-50, 30-60, 40-60, 40-70, 50-60, or 50-70 bases from end to end. In certain examples, the sequence adapter may contain 20-30 bases from end to end. In another example, a sequencing adapter may contain 50-60 bases from end to end. A sequencing adapter may contain one or more barcodes. For example, a sequencing adapter may contain a sample barcode. A sample barcode may contain a given sequence. A sample barcode may be used to identify the source of polynucleotides. A sample barcode may contain at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more (or any length as described throughout) nucleic acid bases, for example, at least 8 bases. The barcode may be a continuous or discontinuous sequence, as described above.
[0411] The library adapter may be blunt-ended and Y-shaped, and its length may be less than or equal to 40 nucleic acid bases. Other variations may be found throughout and are applicable to the kit.
[0412] All patents, patent applications, websites, other publications or documents, accession numbers, etc., cited herein are incorporated by reference in whole for all purposes to the same extent as each individual item is specifically and individually indicated as being incorporated by reference in that manner. Where an array of different versions relates to a single accession number at different points in time, it means the version related to that accession number as of the effective filing date of this application. The effective filing date means, where applicable, the actual filing date or the filing date of the priority application referring to that accession number, whichever is earlier. Similarly, where different versions of a publication, website, etc., are published at different points in time, unless otherwise indicated, it means the most recently published version as of the effective filing date of this application. [Examples]
[0413] (Example 1) Analysis of cfDNA to detect the presence or absence of tumors in the subject. A set of patient samples is analyzed by a blood-based NGS assay at Guardant Health (Redwood City, CA, USA) to detect the presence or absence of cancer. cfDNA is extracted from the plasma of these patients. The cfDNA from the patient samples is then subjected to a means of differently affecting two nucleobases in the DNA that have the same but different base pairing specificity, such that the two nucleobases have different base pairing specificity after a procedure such as bisulfite conversion. The cfDNA from the patient samples is then combined with an antibody specific to methylcytosine. The antibody and the DNA bound to it are immunoprecipitated using magnetic beads conjugated with protein G, thereby separating the highly methylated DNA from the less methylated DNA. Any unmethylated or less methylated DNA is removed by washing from the beads with a buffer containing gradually increasing concentrations of salt. Finally, strongly methylated DNA is removed by washing from the methylcytosine-specific antibody using a high-salt buffer. Unbound DNA and washing them result in at least three partitions of progressively methylated cfDNA (hypomethylated, residually methylated, and highly methylated partitions). The cfDNA molecules during partitioning are purified to remove salts and concentrated in the preparation for the enzymatic step of library preparation.
[0414] After enriching the cfDNA during the distribution, a first adapter is added to the cfDNA by ligation to its 3' end. The adapter is used as a priming site for second-strand synthesis using a universal primer and DNA polymerase. The first adapter contains biotin, and the nucleic acid ligated to the first adapter is bound to a streptavidin-containing bead. The second adapter is then ligated to the 3' end of the second strand of the double-stranded molecule. These adapters contain non-unique molecular barcodes, and each distribution is ligated with an adapter that has a non-unique molecular barcode identifiable from the barcodes in the adapters used in other distributions. After ligation, the distributions are pooled together and amplified by PCR.
[0415] After PCR, the amplified DNA is washed and concentrated before enrichment. Once concentrated, the amplified DNA is combined with salt buffer and biotinylated RNA probes containing probes for sequence variable target regions and probes for epigenetic target regions, and the mixture is incubated overnight. The probes for sequence variable regions have a footprint of approximately 50 kb, and the probes for epigenetic target regions have a footprint of approximately 500 kb. The probes for sequence variable target regions contain oligonucleotides that target at least a subset of the genes identified in Tables 3-5, and the probes for epigenetic target regions contain oligonucleotides that target a selection of highly methylated variable target regions, low methylated variable target regions, CTCF-binding target regions, transcription start site target regions, localized amplification target regions, and methylation control regions.
[0416] Biotinylated RNA probes (hybridized to DNA) are captured by streptavidin magnetic beads and separated from uncaptured amplified DNA by a series of salt-based washes, thereby enriching the sample. After enrichment, aliquots of the enriched sample are sequenced using an Illumina NovaSeq sequencer. The sequence reads generated by the sequencer are then analyzed using bioinformatics tools / algorithms. Molecular barcodes are used to identify unique molecules and for the deconvolution of the sample into differentially distributed molecules. The methods described in this example can also provide higher-resolution information about the identity and / or location of methylated cytosines, apart from providing information about the overall level of molecular methylation (i.e., methylated cytosine residues) based on their distribution. Sequence variable target region sequences are analyzed by detecting genomic modifications, e.g., SNVs, insertions, deletions, and fusions, which can be called with sufficient support to differentiate real tumor variants from technical errors (e.g., PCR errors, sequencing errors). Epigenetic target region sequences are analyzed independently to detect methylated cfDNA molecules in regions that have been shown to be differentially methylated in cancer compared to normal cells. Finally, the results of both analyses are combined to generate a final tumor presence / absence call. (Example 2) Analysis of methylation at single-nucleotide resolution in cfDNA samples from healthy subjects and subjects with early-stage colorectal cancer.
[0417] cfDNA samples from healthy subjects and subjects with early-stage colorectal cancer are analyzed as follows. The cfDNA from the subject samples is then subjected to means that affect two nucleobases in the DNA that have different but the same base pairing specificity, so that the two nucleobases have different base pairing specificity after a procedure such as a modified EM-seq conversion procedure, thereby deaminating the unmodified cytosine rather than mC and hmC. In particular, 5mC and 5hmC are converted to 5caC using Tet2 oxidation (without treatment with β-glucosyltransferase). Treatment with APOBEC3A deaminates the unmodified cytosine to uracil, but 5caC is not a substrate of APOBEC3A. Next, the cfDNA of the target sample is partitioned using an antibody, essentially as described in Example 1, except that the antibody recognizes 5caC (a conversion product generated from the originally present 5mC and 5hmC). Immunoprecipitation is then performed using magnetic beads conjugated with protein G, thereby partitioning the highly methylated DNA (now containing 5caC) from the less methylated DNA. Any unmethylated or less methylated DNA is removed by washing from the beads with a buffer containing gradually increasing concentrations of salt. Finally, strongly methylated (i.e., 5caC-containing) DNA is removed by washing from the 5caC-specific antibody using a high-salt buffer to provide highly methylated, intermediate, and less methylated partitions. The partitioned DNA from each partition is ligated into an adapter. The partitions are prepared for sequencing and subjected to whole-genome sequencing. Each distribution is sequenced separately, but in an alternative procedure, the distributions can be differentially tagged (e.g., after EM-seq conversion and distribution, and before further preparation for sequencing), pooled, and sequenced in parallel.
[0418] Sequence data from highly methylated variable target regions are isolated by bioinformatics; however, alternative procedures allow for in vitro enrichment of the target region before sequencing. Base-by-base methylation of highly methylated variable target regions is quantified to indicate the number of methylated CpGs per molecule in the highly methylated variable target regions from highly methylated distributions. Methylation is analyzed at single-base resolution to quantify base-by-base and partial molecular methylation of the distributed material. Samples from subjects with colorectal cancer show higher overall methylation in these regions than in the corresponding regions in samples from healthy subjects.
Claims
1. 1. A method for analyzing DNA in a sample, comprising: a) subjecting the sample to a procedure that affects a first nucleobase in the DNA of the sample differently than a second nucleobase in the DNA, wherein the first nucleobase is a modified or unmodified nucleobase and the second nucleobase is a modified or unmodified nucleobase that is different from the first nucleobase, and wherein the first nucleobase and the second nucleobase have the same base pairing specificity; b) partitioning the sample into a plurality of aliquots by contacting the DNA with an agent that recognizes modified nucleobases in the DNA, the plurality comprising a first aliquot and a second aliquot, the first aliquot comprising DNA having a higher proportion of cytosine modifications than the second aliquot, the modified nucleobases recognized by the agent being modified cytosines or products of the procedure that affect the first nucleobase in the DNA differently than the second nucleobase in the DNA of the sample; and c) sequencing DNA in at least one of said first and second aliquots in a manner that distinguishes said first nucleobase from said second nucleobase. A method comprising: (i) step c) comprises sequencing DNA in at least the first subsample; and / or (ii) step c) comprises sequencing DNA in the second aliquot; The method of claim 1.
3. 1. A method for analyzing DNA in a sample, comprising: a) subjecting the sample to a procedure that affects a first nucleobase in the DNA of the sample differently than a second nucleobase in the DNA, wherein the first nucleobase is a modified or unmodified nucleobase and the second nucleobase is a modified or unmodified nucleobase that is different from the first nucleobase, and wherein the first nucleobase and the second nucleobase have the same base pairing specificity; and b) partitioning the sample into a plurality of aliquots by contacting the DNA with an agent that recognizes modified nucleobases in the DNA, the plurality comprising a first aliquot and a second aliquot, the first aliquot comprising DNA having a higher proportion of cytosine modifications than the second aliquot, the modified nucleobases recognized by the agent being modified cytosines or products of the procedure that affect the first nucleobase in the DNA differently than the second nucleobase in the DNA of the sample; c) capturing at least a set of epigenetic target regions of DNA from said first and second subsamples, thereby providing captured DNA; and d) sequencing the captured DNA in a manner that distinguishes the first nucleobase from the second nucleobase. A method comprising:
4. 1. A method for analyzing DNA in a sample, comprising: a) subjecting the sample to a procedure that affects a first nucleobase in the DNA of the sample differently than a second nucleobase in the DNA, wherein the first nucleobase is a modified or unmodified nucleobase and the second nucleobase is a modified or unmodified nucleobase that is different from the first nucleobase, and wherein the first nucleobase and the second nucleobase have the same base pairing specificity; and b) partitioning the sample into a plurality of aliquots by contacting the DNA with an agent that recognizes modified nucleobases in the DNA, the plurality comprising a first aliquot and a second aliquot, the first aliquot comprising DNA having a higher proportion of cytosine modifications than the second aliquot, the modified nucleobases recognized by the agent being modified cytosines or products of the procedure that affect the first nucleobase in the DNA differently than the second nucleobase in the DNA of the sample; c) capturing a plurality of sets of target regions of DNA from the first and second subsamples, the plurality of sets of target regions including a set of sequence variable target regions and a set of epigenetic target regions, thereby providing captured DNA; and d) sequencing the captured DNA in a manner that distinguishes the first nucleobase from the second nucleobase. A method comprising: (i) cell-free DNA (cfDNA) molecules corresponding to the set of sequence-variable target regions are captured in the sample with a higher capture yield than cfDNA molecules corresponding to the set of epigenetic target regions; and / or (ii) capturing the plurality of sets of target regions comprises contacting the DNA of the first and second aliquots with a set of target-specific probes; the set of target-specific probes comprises target binding probes specific for a sequence-variable target set and target binding probes specific for an epigenetic target set; Thereby, a complex between the target-specific probe and the cfDNA is formed; and separating the complexes from cfDNA that is not bound to the target-specific probes, thereby providing captured cfDNA corresponding to the sequence-variable target set and captured cfDNA corresponding to the epigenetic target set. The method of claim 4 , comprising:
6. The set of epigenetic target regions comprises: (i) a set of hypermethylated variable target regions, optionally comprising regions having a higher degree of methylation in at least one type of tissue than the degree of methylation in cell-free DNA from a healthy subject; (ii) a set of hypomethylated variable target regions, optionally comprising regions having a lower degree of methylation in at least one type of tissue than the degree of methylation in cell-free DNA from a healthy subject; (iii) a set of methylation control target regions; and / or (iv) a set of fragmented variable target regions, optionally comprising: (a) a transcription start site region, and / or (b) CTCF binding region A fragmented variable target region set comprising: The method according to any one of claims 3 to 5, comprising: (i) the DNA is obtained from a test subject; and / or (ii) the DNA is (a) cell-free DNA (cfDNA) obtained from a test subject; or (b) DNA obtained from a tissue sample of the test subject. Optionally, the tissue sample is a biopsy, fine needle aspirate or a formalin-fixed paraffin-embedded tissue sample.
10. The method according to the preceding claims.
8. 8. The method of claims 4 to 7, further comprising the step of ligating a barcode-containing adapter to the DNA prior to capture, optionally wherein the ligating step is performed prior to or simultaneously with amplification. (i) DNA molecules derived from the first subsample and DNA molecules derived from the second subsample are differentially tagged; (ii) DNA molecules from the first aliquot and DNA molecules from the second aliquot are sequenced in the same sequencing cell; (iii) the DNA is amplified prior to the sequencing step, or the method includes a capture step and the DNA is amplified prior to the capture step; (iv) partitioning the sample into a plurality of subsamples comprises partitioning based on methylation levels, and optionally I. The agent that recognizes modified nucleobases in the DNA is a methyl-binding agent, e.g. (a) the methyl-binding reagent is an antibody; (b) the methyl-binding reagent specifically recognizes 5-methylcytosine, and / or (c) the methyl-binding reagent is immobilized on a solid support; and / or II. The step of dividing the sample into a plurality of aliquots comprises immunoprecipitation of methylated DNA; (v) partitioning the sample into a plurality of aliquots comprises partitioning based on binding to a protein, optionally wherein the protein is a methylated protein, an acetylated protein, an unmethylated protein, an unacetylated protein; and / or optionally wherein the protein is a histone, optionally wherein the partitioning comprises contacting the DNA of the sample with a binding reagent specific for the protein and immobilized on a solid support. (vi) the method comprises differentially tagging and pooling the first aliquot and the second aliquot. (vii) the plurality of aliquots includes a third aliquot comprising DNA with a higher proportion of cytosine modifications than the second aliquot but a lower proportion than the first aliquot, and optionally the method further includes a step of differentially tagging the third aliquot, e.g., the first, second and third aliquots are combined after subjecting the first aliquot to the procedure affecting the first nucleobase in the DNA differently than the second nucleobase in the DNA of the first aliquot, and optionally the first, second and third aliquots are sequenced in the same sequencing cell. (viii) the procedure to which the sample is subjected alters the base-pairing specificity of the first nucleobase without substantially altering the base-pairing specificity of the second nucleobase; (ix) the first nucleobase is a modified or unmodified cytosine and the second nucleobase is a modified or unmodified cytosine; (x) the first nucleobase comprises an unmodified cytosine (C); (xi) the second nucleobase comprises a 5-methylcytosine (mC); and / or (xii) the procedure to which the sample is subjected comprises bisulfite conversion; 10. A method according to any one of the preceding claims.
10. 10. The method of any one of claims 1 to 9(x), wherein the first nucleobase comprises mC.
11. wherein the second nucleobase comprises 5-hydroxymethylcytosine (hmC), and optionally the procedure to which the sample is subjected comprises: (i) protection of 5hmC; (ii) Tet-assisted bisulfite conversion, or (iii) Tet-assisted conversion using substituted borane reducing agents optionally wherein the substituted borane reducing agent is 2-picoline borane, borane pyridine, tert-butylamine borane, or ammonia borane; optionally wherein the substituted borane reducing agent is 2-picoline borane or borane pyridine; 10. A method according to any one of the preceding claims.
12. 13. The method of any one of claims 10 to 11(i) or 11(iii), wherein the second nucleobase comprises a C.
13. 13. The method of any one of claims 10 to 11(i) or 12, wherein the procedure to which the sample is subjected comprises protection of hmC followed by Tet assisted conversion with a substituted borane reducing agent, optionally wherein the substituted borane reducing agent is 2-picoline borane, borane pyridine, tert-butylamine borane or ammonia borane, optionally wherein the substituted borane reducing agent is 2-picoline borane or borane pyridine.
14. 13. The method of any one of claims 9(x), 9(xi), 10 to 11(i) or 12, wherein the procedure to which the sample is subjected comprises protection of hmC followed by deamination of mC and / or C, optionally wherein the deamination of mC and / or C comprises treatment with a DNA deaminase enzyme of the AID / APOBEC family.
15. 15. The method of any one of claims 11(i) or 12-14, wherein the protection of hmC comprises glycosylation of hmC. (i) the procedure to which the sample is subjected comprises a chemically assisted conversion with a substituted borane reducing agent, optionally wherein the substituted borane reducing agent is 2-picoline borane, borane pyridine, tert-butylamine borane or ammonia borane, optionally wherein the substituted borane reducing agent is 2-picoline borane or borane pyridine; and / or (ii) the first nucleobase comprises hmC; 13. A method according to any one of claims 1 to 9(ix), 9(xi), 10 or 12.
17. the modified nucleobase recognized by the agent is (i) a modified cytosine, (ii) a methylated cytosine, and / or (iii) the converted nucleobase 2. The method of any one of the preceding claims, wherein:
